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Iron homeostasis in man is tightly regulated by a 25-amino-acide peptide hormone 
(hepcidin) that is produced in the liver in response to inflammatory stimuli and iron 
loading. Its main role is thought to be part of the innate immune system, restricting iron 
delivery to infectious microorganisms, and as a consequence, reducing iron availability 
for erythropoiesis in the host. The anaemia associated with chronic kidney disease 
(CKD) is known to be in part due to relative erythropoietin deficiency, and we also now 
know that excess hepcidin is one of the reasons that dietary iron is less well absorbed 
in these patients, necessitating the administration of intravenous iron. We know that 
haemodialysis patients in particular have elevated hepcidin levels, although the precise 
mechanisms remain unclear. 
 
Characterisation of hepcidin levels in a number of CKD cohorts, including non-dialysis 
and dialysis-CKD patients, confirm that patients receiving haemodialysis have the 
highest levels, and that a considerable degree of day-to-day variability exists that is not 
completely explained by the regular administration of intravenous iron. An approach 
designed to measure hepcidin production using HAMP gene expression levels in 
circulating peripheral blood mononuclear cells found that patients with the highest 
circulating hepcidin levels had the lowest degree of HAMP expression, suggesting the 
presence of a negative feedback mechanism. 
 
Although bacterial sepsis is an extremely powerful driver of hepcidin production, 
haemodialysis patients do not appear to be able to mount an increased hepcidin 
response under such conditions, raising the possibility that their hepcidin burden is 
maximised. It is therefore possible that the role of inflammation in this context may not 
be as significant as the role of reduced hepcidin clearance, or the role of iron loading. 
In contrast, inflammation is probably a major driver of hepcidin induction in those who 
develop an acute kidney as a result of ANCA-associated vasculitis or a crescentic 
glomerulonephritis. Hepcidin expression was suppressed following the use of 
dexamethasone in a cellular hepatocyte model, and this was partly IL-6 dependent. In 
a pilot study examining the aforementioned patient groups, hepcidin levels were 
elevated at presentation and were markedly reduced following treatment with 
intravenous methylprednisolone. The glucocorticoid-induced suppression of hepcidin in 
both in vitro and in vivo settings suggests this as a pathway for the improvement in 
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The association between kidney disease and anaemia was initially recognised by 
Richard Bright, who described characteristic features in his case reports published in 
1836 during his time working at Guy’s Hospital (Feehally, McIntyre, and Cameron 
2013). It was, however, his contemporary, the forensic chemist and physician, 
Christison, whose meticulous observations signalled the first robust link between 
advanced kidney disease and the development of anaemia (Cameron 1999). At the 
turn of the 20th century, the French scientists Carnot and Deflandre were convinced of 
the existence of a humoral factor that controlled erythropoiesis (Carnot and Deflandre 
1906), for which they coined the term hemopoietine. This factor was later renamed 
erythropoietin, although it took over a hundred years from Christison’s original 
observations before its eventual detection. It was only in 1957 that the role of the 
kidney in erythropoiesis was finally discovered (Jacobson et al. 1957), and this 
provided a possible reason to explain why patients with end-stage renal disease often 
developed profound blood transfusion-dependent anaemia. Two decades elapsed 
before human erythropoietin was purified from the urine of patients with aplastic 
anaemia (Miyake et al, 1977, Goldwasser 1977), and it took a further eight years 
before the human erythropoietin gene was cloned and expressed (Miyake, Kung, and 
Goldwasser 1977; Lin et al. 1985; Jacobs et al. 1985), leading to the first clinical use of 
recombinant human erythropoietin (rhuEpo) in anaemic dialysis patients in 1986 
(Winearls et al. 1986). The following year, Eschbach and colleagues published their 
phase I and II clinical trial, which showed that the administration of rhuEpo to another 
cohort of anaemic haemodialysis patients not only treated the anaemia (and in some 
cases abolished the need for recurrent transfusions of packed red cells), but 
subsequently exposed the patients to a state of relative iron deficiency (Eschbach et al. 
1987). Up until this point, researchers had largely been concerned with solving the 
conundrum of erythropoietin deficiency in renal failure. It only became apparent after 
the clinical trials of erythropoietin in the late-1980s, that the use of erythropoietin had to 
be combined with the use of iron replacement therapy in order to optimally treat the 
anaemia of advanced CKD (Macdougall et al. 1989; Fishbane, Frei, and Maesaka 
1995). 
 
Although it had long been known that erythropoiesis depended on the availability of 
iron for the production of red blood cells in the bone marrow, it was only in the 1970s 
that the first reports of the use of intravenous iron in haemodialysis patients emerged 
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(Edwards, Pegrum, and Curtis 1970). Reports of severe anaphylaxis in a few patients 
receiving parenteral iron undoubtedly led to its limited use over the next two decades, 
amidst these obvious safety concerns (Becker et al. 1966). At the time, there was 
perhaps less impetus to study the use of parenteral iron in end-stage renal failure, 
given the inconsistent data examining the difference between the effect of parenteral 
and oral iron on various outcomes in haemodialysis patients (Brozovich et al. 1971; 
Rossi et al. 1976; Winney et al. 1977). These data, along with the findings from studies 
that implied that gastrointestinal absorption of iron in haemodialysis patients was 
normal (Eschbach, Cook, and Finch 1970), reinforced the prevalent view that blood 
loss via dialyser connections, frequent blood sampling, and increased gastrointestinal 
losses, were the principal reasons that haemodialysis patients became iron deficient, 
and in need of iron replacement therapy (Milman and Larsen 1976). In contrast, 
experimental animal models examining iron absorption from the duodenum of uraemic 
rats showed that there was a reduction in iron absorption in the uraemic group (Delano, 
Manis, and Manis 1977). The gastrointestinal absorption of iron was not really 
examined in any great depth, until after the work of Eschbach and colleagues. 
 
Around the turn of the millennium, the discovery of the factor controlling the absorption 
of iron from the gastrointestinal tract occurred somewhat by chance, whilst scientists 
were engaged in the search for cysteine-rich peptides in the ultrafiltrate from human 
blood that had antimicrobial activity (Krause et al. 2000).  This factor, which was initially 
labelled LEAP-1 (liver expressed antimicrobial peptide-1), and we now know as 
hepcidin, was also isolated from the urine of healthy donors by a second group, and 
their findings were again presented as a novel hepatic antimicrobial peptide (Park et al. 
2001). The extent to which these discoveries would revolutionise our understanding of 
the regulation of iron metabolism only became apparent after the publication of two 
French papers, which suggested that hepcidin had a role to play in iron homeostasis 
(Nicolas et al. 2001; Pigeon et al. 2001). We now know that hepcidin is not only critical 
in this process, but is indeed the master-regulator of iron homeostasis in the body, 
exerting its action by binding to ferroportin, the sole mammalian exporter of iron 
(Nemeth, Tuttle, et al. 2004). The major consequence of increased hepcidin (thereby 
leading to a decrease in ferroportin) is a reduction in iron availability to the bone 
marrow for erythropoiesis. In recent times, it has become evident that this process is 
linked to the pathogenesis of the anaemia associated with chronic kidney disease, 
which in turn has a similitude with the anaemia of chronic disease. This has opened the 
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door to the development of treatment strategies that target hepcidin (and other 
mediators involved in the pathogenesis of renal anaemia), particularly since we now 
know that safety concerns surround the use of erythropoietin. The question of potential 
harm as a result of the liberal use of intravenous iron was addressed by the PIVOTAL 
study; there was no difference in adverse events (cardiovascular outcomes or sepsis) 
between the haemodialysis group receiving high dose iron versus the group receiving 
the lower dose (Macdougall et al. 2019). 
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1.1 Chronic Kidney Disease 
1.1.1 Definition 
Chronic kidney disease (CKD) is a progressive, irreversible, and (at least in the early 
stages of the disease) often asymptomatic condition that results from a substantial loss 
of nephron function, and is typified in its later stages by a clinical syndrome that 
includes a progressive decline in glomerular filtration, systemic hypertension, oedema, 
and proteinuria. Characteristic histological findings on renal biopsy specimens from 
patients with advanced CKD include progressive tubulointerstitial fibrosis, tubular 
atrophy, and loss of peritubular capillaries resulting from hypoxia (Eddy 2005). 
 
The diagnosis of CKD is relatively simple; in the vast majority of cases, it requires two 
blood tests (that estimate the glomerular filtration rate (GFR) to be less than 60 
ml/min/1.73 m2) separated by at least 90 days. The diagnosis can also be made in the 
presence of a structural or functional defect, if this has also been shown to persist for 
more than 90 days (Table 1.1). 
 
Decreased GFR GFR <60 ml/min/1.73 m2 
Markers of kidney damage (≥1) Albuminuria (ACR ≥ 3mg/mmol) 
Abnormal urinary sediment 
 Evidence of tubular dysfunction 
 Renal histological abnormality 
 Structural abnormality 
 History of kidney transplantation 
Table 1.1 Diagnostic criteria for CKD 
One or more of the above must be present for greater than 90 days in order to make a diagnosis of CKD 
(adapted from (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group 2013)). 
 
Once the diagnosis of CKD has been made, the severity of the condition is stratified 
according to glomerular filtration (G) and urinary protein excretion (A), and the category 
within which an individual falls, has implications for the likelihood of that person 
progressing from CKD to end-stage renal failure (Figure 1.1). There are, however, a 
number of factors other than proteinuria, which are associated with this path to end-
stage renal failure, including age, gender, ethnicity, diabetes, hypertension, 
cardiovascular comorbidities (including heart failure), body mass index, smoking, low 
socioeconomic status, and a history of one or more episodes of acute kidney injury (Lo 
et al. 2009; Collister et al. 2016). 




Figure 1.1 Classification of CKD 
Risk of progressing to end-stage renal failure according to GFR (G1 to G5) category and degree of 




1.1.2 Epidemiology in the UK 
Chronic kidney disease is a growing problem in the United Kingdom, and is thought to 
affect an estimated 1.8 million people, accounting for approximately 1.5% of the entire 
National Health Service budget (£95.6 billion for 2013/14). In addition to this colossal 
figure, there may be as many as a further one million people with undiagnosed CKD in 
the population (Kerr et al. 2012). The most recent data from the UK Renal Registry 
(UKRR) are available to the year ending 2014, and these showed that the incidence of 
adults requiring renal replacement therapy (RRT) in the UK had increased to a mean of 
115 new patients per million people of the population. The incidence rate had 
plateaued in the decade preceding this annual iteration of the report (Figure 1.2).  






































G1 Normal or high ≥90
G2 Mildly decreased 60-89
G3a Mildly to moderately decreased 45-59
G3b Moderately to severely decreased 30-44
G4 Severely decreased 15-29
G5 Kidney failure <15
Prognosis of CKD by GFR























Figure 1.2 Incidence of renal replacement therapy in the UK 
Reproduced from (Gilg, Caskey, and Fogarty 2016) outlining the number of patients commencing renal 
replacement therapy on an annual basis from 1990 to 2014, in the countries of the United Kingdom 
 
As in previous years, the leading cause of renal disease in these patients developing 
end-stage renal failure was diabetes, which accounted for over a quarter of all of the 
new cases seen. The other leading causes of renal disease in the UK included 
glomerulonephritis, and renal vascular disease (Table 1.2). Chronic kidney disease is a 
condition that mainly affects those in the latter stages of their lives, and the median age 
of patients commencing RRT in the UK in 2014 was 64.8 years, a figure that has 
remained virtually unchanged since 2007. Patients who were white had a median age 
at start of RRT of 66.4 years, whereas the median age at start of RRT for non-white 
patients was considerably lower at 58.7 years (Gilg, Caskey, and Fogarty 2016). 
 
 
Table 1.2 Primary renal diagnosis incidence rates in the UK 
Reproduced from (Gilg, Caskey, and Fogarty 2016) outlining the primary renal diagnosis in the patients 

























































PRDs are likely to be falsely low in these centres, the
breakdown into these categories has not been shown in
table 1.8 or been used in the country and UK averages.
These centres have also been excluded where PRD is
used to stratify analyses.
As in previous years, there was a lot of variability
between centres in the percentages with the specific
diagnoses (partly due to the reasons mentioned above).
For example, the percentage with diabetes as PRD varied
from about 10% to almost 43% of incident patients.
The overall UK distribution of PRDs is shown in
table 1.9. Diabetic nephropathy was the most common
renal diagnosis in both the under and over 65 year age
groups, accounting for 27% of all (non-missing) incident
diagnoses. Glomerulonephritis and autosomal dominant
polycystic kidney disease (ADPKD) made up much
higher proportions of the younger than the older incident
cohorts (18% vs. 9% and 10% vs. 4% respectively), whilst
patients with renal vascular disease comprised a much
higher percentage of the older rather than the younger
patients (11% vs. 2%). Uncertainty about the underlying
diagnosis was also much more likely in the older rather
than the younger cohort (19% vs. 12%).
For all primary re al diagnoses except ADPKD and
‘Other’, the male to female ratio was 1.4 or greater.
This gender difference may relate to factors such as
smoking, hypertension, atheroma and renal vascular
disease, which are more common in males and may
influence the rate of progression of renal failure.
Table 1.10 shows the incidence rates for each PRD per
million population for the 2014 cohort. As there were
some missing data, the rates for at least some of the
diagnoses will be underestimates.
First established treatment modality
In 2014, the first treatment recorded, irrespective of
any later change, was haemodialysis in 71.8% of patients,
peritoneal dialysis in 20.0% and pre-emptive transplant
in 8.2%. The previous year on year fall seen prior to six
years ago in the proportion of patients starting on PD
levelled off during the last six years (table 1.11). The
percentage h ving a pre- mptive transplant has con-
tinued to rise (up by 44% from 2009). Table F.1.3 in
appendix F: Additional Data Tables for 2014 New and
Existing Patients gives the treatment breakdown at start
of RRT by centre.
Many patients undergo a brief period of HD before
switches to other modalities are, or can be, considered.
Therefore, the established modality at 90 days is more
representative of the elective first modality and this
odality w s used for the remainder of this section. For
Table 1.9. Percentage distribution of primary renal diagnosis
by age in the 2014 incident RRT cohort
Percentage with diagnosis
Diagnosis Age ,65 Age 565
All
patients
Diabetes 29.1 24.6 26.9
Glomerulonephritis 17.7 9.0 13.4
Pyelonephritis 5.1 6.5 5.8
Hypertension 4.9 8.3 6.5
Polycystic kidney 9.5 4.0 6.8
Renal vascular disease 2.3 10.6 6.4
Other 19.0 17.8 18.5
Uncertain aetiology 12.4 19.2 15.7
Percentages calculated after excluding those patients with data not
available
Table 1.10. Primary renal diagnosis RRT incidence rates (2014) per million population (unadjusted)
Diagnosis England N Ireland Scotland Wales UK
Diabetes 27.4 21.2 30.1 30.4 27.6
Glomerulonephritis 13.5 7.6 15.3 19.4 13.8
Pyelonephritis 5.9 6.0 4.7 8.1 5.9
Hypertension 7.3 6.5 3.9 1.9 6.7
Polycystic kidney 6.6 9.2 9.7 8.1 7.0
Renal vascular disease 6.1 4.3 7.9 12.9 6.5
Other 19.0 17.9 20.2 16.2 19.0
Uncertain aetiology 16.7 19.0 9.5 17.8 16.2
Data not available 14.8 1.6 0.0 3.9 12.6
All 117 93 101 119 115
The overall rates per country may be slightly different to those in table 1.2 as those centres whose PRD data has not been used have been
excluded from both the numerator and the denominator here
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This difference is likely a reflection of the older age distribution of whites versus non-
whites (5.3% of non-whites were over the age of 65 years old, compared to 18.3% of 
whites, UK Census 2011), and also the differences in the disease processes 
underlying their respective paths towards end-stage kidney disease. 
 
The prevalence of adult patients receiving RRT has been increasing every year since 
the data have been collected, and in 2014, was 913 per million population of the UK 
(Figure 1.3). This is nearly 75% higher than the reported figure from the year 2000, 
when the prevalence of RRT in UK adults was 523 per million population. The general 
age of the RRT population has been increasing over time; the median age of prevalent 
patients in 2014 was 59 years, and nearly one-sixth of these patients were over the 
age of 75 years. As expected, the prevalence rate in men was greater than for women 
in all age categories. In contrast to the incident RRT population, the most common 
primary renal diagnosis in the 2014 prevalent cohort was glomerulonephritis (18.9%) 
followed by diabetes (16.1%) (MacNeill et al. 2016).  
 
 
Figure 1.3 Prevalence of renal replacement therapy in the UK 
The prevalence of patients in receipt of RRT in the UK from 1997 to 2014, categorised by modality 
(peritoneal dialysis (PD), haemodialysis (HD), or transplant) (reproduced from (MacNeill et al. 2016) 
 
As with cardiovascular disease, men are more likely to require RRT than women, 
irrespective of whichever variable is statistically corrected for (i.e. gender, ethnicity 
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days of starting RRT (which in turn is far more likely to be haemodialysis as opposed to 
peritoneal dialysis) (Gilg, Caskey, and Fogarty 2016). 
 
The most recent data for the UK population estimates a life expectancy from birth of 
79.1 years for males, and 82.8 years for females; this is a figure that has been rising by 
approximately 10 and 13 weeks per year for males and females, respectively, since 
1980 (Office for National Statistics 2014). A diagnosis of end-stage renal failure 
decidedly reduces life expectancy across all groups (Hallan et al. 2012), and is 
influenced by a number of factors including age at diagnosis, the presence of other 
comorbidities, and the choice of RRT modality (Turin et al. 2012). In 2013, the overall 
one-year (after 90 day survival) unadjusted mortality rate in the UK incident RRT 
population was approximately 12%, and 15% in the prevalent dialysis population 
(Steenkamp, Rao, and Fraser 2016). Epidemiological evidence suggests that 
cardiovascular disease is by far the largest contributor to the excess mortality seen in 
patients with chronic kidney disease, and this is inclusive of an increase in cardiac 
failure and valvular heart disease (Go et al. 2004; Thompson et al. 2015). This is 
supported by data from the 2016 UKRR report, which showed that cardiac disease was 
the primary cause of death in all groups of RRT patients that were examined, except 
for transplanted patients (malignancy, then infections) (Steenkamp, Rao, and Fraser 
2016). 
 
1.1.3 Progression of CKD 
A slow decline in excretory renal function is a natural consequence of aging (Stevens 
et al. 2006), but the trajectory is often such that a person will reach the end of his/her 
natural life, before ever progressing to end-stage renal failure. There are a number of 
risk factors that affect this trajectory, some of which are modifiable. The two risk factors 
that nephrologists seek to address before any other are proteinuria and hypertension. 
The link between (even modest amounts of) proteinuria and progression of CKD is well 
established, and inhibition of the renin-angiotensin-aldosterone system (RAAS) has 
been shown to slow the progression of CKD, independent of their effects on blood 
pressure (Collister et al. 2016). The necessity for controlling blood pressure to retard 
the progression of CKD is an essential component of all national (The National Institute 
for Health and Care Excellence 2015a) and international guidelines (Kidney Disease: 
Improving Global Outcomes (KDIGO) CKD Work Group 2013) on the treatment of 
CKD, but whether the target blood pressure should be lower than stipulated by the 
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current guidelines remains a source of discussion (Wright et al. 2015). Correction of 
metabolic acidosis (de Brito-Ashurst et al. 2009), hyperuricaemia (Goicoechea et al. 
2015), and lowering the intake of dietary protein in certain situations (Levey et al. 2006) 
have also been shown to slow the rate of progression to end-stage renal failure. 
Although there have been data suggesting that treating asymptomatic hyperuricaemia 
may be of benefit in CKD, a randomised controlled trial examining the use of 
febuxostat in stage 3 CKD showed no benefit versus placebo (Kimura et al. 2018). 
Other treatments for hyperphosphataemia, hyperparathyroidism, dyslipidaemia, and 
smoking cessation do not have the same level of evidence when it comes to slowing 
the decline in renal function, but are nonetheless utilised due to the benefits in terms of 
cardiovascular risk reduction (Agarwal, Haddad, and Hebert 2008). The non-modifiable 
elements that influence the development and progression of CKD include male gender, 
African-American ethnicity, and a genetic predisposition associated with sequence 
variants in the apolipoprotein L1 gene, as well as the various gene mutations 
associated with the cystic diseases of the kidney (Collister et al. 2016).  
 
1.1.4 Sequelae of CKD 
Other than hypertension and proteinuria, which can present in early CKD (stages 1/2), 
the major clinical manifestations of CKD tend to become apparent from stage 3a 
onwards (i.e. eGFR 45-59 ml/min/1.73m2) (Table 1.3). 
 
Hypertension Malnutrition 
Anaemia Sodium and fluid overload 
Dyslipidaemia Endocrine abnormalities 
Bone and mineral disease Immune dysregulation 
Metabolic acidosis Psychological effects 
Table 1.3 Clinical manifestations of CKD 
 
As well as being a cause of CKD, hypertension frequently develops as a result of CKD, 
and it is reported that between 50-75% of patients with CKD stage 3a onwards will 
have hypertension (defined as a systolic BP ≥140 mm Hg, or diastolic BP ≥90 mm Hg). 
As the kidney is responsible for hydroxylation of 25-hydroxycholecalciferol, CKD will 
also bring about changes in bone and mineral metabolism. The combination of a 
deficiency in 1,25-dihydroxycholecalciferol and hyperphosphataemia (brought about by 
a reduction in renal phosphate clearance) contribute to secondary 
hyperparathyroidism, and if left unchecked, eventually results in the development of 
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renal bone disease. Likewise, a relative deficiency of the renal hormone, erythropoietin, 
induces anaemia due to insufficient red cell production by the bone marrow. The 
anaemia of renal disease becomes more prevalent from CKD stage 3a onwards and 
will be discussed in greater depth later in this chapter (from page 30). Tubular 
dysregulation in the renal handling of sodium in the later stages of CKD (stages 4/5) 
eventually lead to sodium and water retention, and subsequently to increased 
intravascular volume expansion, resulting in peripheral and/or pulmonary oedema. This 
no doubt plays a significant role in the pathogenesis of hypertension in CKD. The 
tubules (via reduction in excretion of hydrogen ions +/- loss of alkali) are also 
responsible for the metabolic acidosis seen in CKD stages 4/5, although the clinical 
manifestations of acidosis are often seen late in stage 5. Chronic kidney disease is an 
inflammatory state, and this, along with anorexia, metabolic acidosis, and oxidative 
stress lead to malnourishment in its very advanced stages. Endocrine abnormalities, 
such as hypothyroidism, insulin resistance, hyperprolactinaemia, and decreased levels 
of circulating growth hormone and testosterone are also commonly seen in very 
advanced renal disease. An altered hormonal milieu in CKD increases the risk of 
infertility, but this risk can be mitigated by renal transplantation (Wheeler 2010). 
 
1.1.5 Immunity and Inflammation 
After cardiovascular disease, infection is the second most common cause of death in 
patients with end-stage renal failure. Immunity is impaired in these patients through a 
number of different mechanisms; both T-cell and neutrophil responses are defective, 
meaning that patients are often susceptible to bacterial infections. The frequent use of 
tunnelled haemodialysis and peritoneal dialysis catheters in these functionally 
immunodeficient patients present possible routes of entry for opportunistic pathogens 
(Wheeler 2010). 
 
Frequent infective episodes in dialysis patients, such as catheter-related, and access 
site infections, in addition to thrombotic episodes involving arterio-venous fistulae and 
grafts, provide a rich source of cytokines and stimuli that are amongst the factors that 
form the pro-inflammatory environment that is typical of the patient with end-stage 
renal failure. Other stimuli include a higher incidence of periodontal disease, metabolic 
acidosis, deficiency of vitamin D, and other dialysis-related factors (Figure 1.4). 
Chronic inflammation, especially in the dialysis patient, is associated with increased 
morbidity and mortality, particularly cardiovascular death. Mortality has been found to 
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be associated with a number of biomarkers such as serum albumin, C-reactive protein, 
interleukin-1 and -6, and tumour necrosis factor alpha. The strong association of 
hypoalbuminaemia with increased cardiac mortality has been shown to be a result of 
inflammation, as opposed to malnutrition (Kalantar-Zadeh et al. 2005; Akchurin and 
Kaskel 2015). Highly relevant to this thesis is the fact that inflammation in CKD is also 
one of the main contributors to the anaemia of renal disease, and is a cause of 
resistance to erythropoietin therapy (Kovesdy 2013). 
 
 
Figure 1.4 Causes and consequences of inflammation in CKD 
CKD-associated inflammation results in increased cardiovascular disease and renal anaemia (adapted 





























Chapter 1. Introduction 
 
30 
1.2 Renal Anaemia 
1.2.1 Definition of Anaemia 
Anaemia is defined as a reduction in the number of circulating red blood cells (RBCs), 
and is determined by comparing the haemoglobin concentration (Hb) against standard 
laboratory reference values, which were initially determined in the 1960s by 
researchers working for the World Health Organisation (WHO). The recommendations 
for adults residing at sea level are that males should have an Hb ≥130 g/L, non-
pregnant females should have an Hb ≥120 g/L, and pregnant females should have an 
Hb ≥110 g/L (Blanc, Finch, and Hallberg 1968). However, residential elevation above 
sea level and cigarette smoking are known to increase Hb levels, and thus adjustments 
should be made in these circumstances (World Health Organisation 2011). It should be 
noted that the original 1968 WHO study was conducted using very few data, and also 
using methods that suggest that the authors of the original paper did not intend for their 
work to be the definitive article on the subject. The WHO data has since been validated 
for Caucasian men and women in large epidemiological studies, such as the National 
Health and Nutritional Examination Survey (Hollowell et al. 2005). 
 
Men tend to have higher Hb levels than women, and this is very likely due to two 
factors; that men have higher levels of testosterone, and that women have regular 
menstrual blood losses. The link between androgens and erythropoiesis has long been 
recognised, with testosterone stimulating RBC production (Carrero et al. 2012). In 
general, the main causes of anaemia are due to blood loss, decreased production of 
RBCs, increased destruction, and shortened survival (Table 1.5). Age is another factor 
that affects Hb concentrations (Cheng et al. 2004) but it remains a matter of debate 
whether the WHO values are applicable in those who are over 65 years of age, as 
there are no currently accepted definitions of anaemia in the elderly. This is 
complicated by the difficulty in finding or even defining a “healthy” cohort of elderly 
patients in which to sample Hb levels. Beutler and colleagues have made attempts to 
address this issue by mining the NHANES III database and removing those with iron 
deficiency (defined as a serum ferritin level <10 μg/L, or a transferrin saturation (TSAT) 
<16%), inflammation (elevated C-reactive protein (CRP) or erythrocyte sedimentation 
rate (ESR)), renal impairment (creatinine > 106 μmol/L), and pregnancy, to derive Hb 
levels that are representative of those younger (age 20-59 for men; 20-49 for women), 
and older white and black adults. As can be seen in Table 1.4, the actual 5th centile Hb 
values for African-American patients are significantly lower than the corresponding cut-
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off WHO values, so it is highly probable that anaemia is more likely to be over-
diagnosed and over-investigated in the black population compared to their white 
counterparts (Beutler and Waalen 2006). 
 
Gender Age (y) Number of 
patients sampled 
Hb concentration 
(5th centile) (g/L) 
Hb cut-off (g/L) 
(WHO) 
White men 20-59 1456 138 130 
 ≥60 934 128 130 
White women 20-49 1045 122 120 
 ≥50 1495 120 120 
Black men 20-59 1253 128 130 
 ≥60 235 118 130 
Black women 20-49 904 113 120 
 ≥50 442 113 120 
Table 1.4 Reassigning normal haemoglobin values following NHANES III analysis 
Lower limits (5th centile) of normal for haemoglobin concentration (g/L) of younger (age 20-59 for men; 20-
49 for women) and older white and black adults (adapted from (Beutler and Waalen 2006)) 
 
1.2.2 Definition of Renal Anaemia 
Renal anaemia is a chronic condition that is defined as a reduction in haemoglobin 
concentration occurring primarily as a result of renal disease. A gradual decrease in 
the relative concentration of circulating erythropoietin through reduced EPO production 
by the peritubular interstitial cells in the kidney is the main causative mechanism for the 
development of the normochromic, normocytic anaemia of CKD (Shanks et al. 1996). 
There are, however, a number of other contributory factors, which will be expanded 
upon further in section 1.2.4. 
 
1.2.3 Epidemiology 
Much of the current epidemiological evidence that we possess outlining the association 
between kidney disease and anaemia comes from the Third National Health and 
Nutrition Survey (NHANES III), wherein 15419 U.S. participants’ data were examined 
(Astor et al. 2002). In contrast to the WHO recommendations, the definition of anaemia 
in this study was defined as an Hb <120g/L and <110 g/L in men and women, 
respectively. Anaemia did not tend to be a feature of CKD until the eGFR was 
approximately 30 ml/min/1.73m2. The prevalence of anaemia was 9% at the start of 
stage 4 CKD, and 33% at the start of stage 5 (Figure 1.5). The one clinical situation 
where renal anaemia is often seen earlier is diabetic kidney disease, when it is not 
uncommon to see a decline in the Hb concentration with a higher eGFR threshold of 
(below) 45/ml/min/1.73m2. There are several reasons for this that include loss of 
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endogenous EPO in those with severe proteinuria, reduced production of EPO, and 
chronic inflammation (Deray et al. 2004; Loutradis et al. 2016). 
  
 
Figure 1.5 NHANES III epidemiological data – eGFR and haemoglobin levels 
Median, 5th and 95th percentiles of haemoglobin levels in men and women aged 20 and over, at different 
estimated glomerular filtration rates (reproduced from (Astor et al. 2002)) 
 
The 2016 UKRR report showed that the median Hb level in incident HD patients from 
the 2013 cohort was 97 g/L (IQR 87 – 106 g/L), and 108 g/L (IQR 100 – 117 g/L) in 
those starting on PD.  The Hb levels would have been even lower, had it not been that 
approximately 60-80% of these patients were receiving an erythropoiesis-stimulating 
agent (ESA) by the time they started dialysis. Initiation of ESA therapy in individual 
patients requires regular monitoring in order to guide Hb levels into the current target 
range of 100-120 g/L. Unsurprisingly, patients who saw a nephrologist only within 90 
days of starting dialysis (“late-presenters”) generally had lower Hb levels than those 
who had a smoother transition from CKD to RRT (Gilg, Rao, and Williams 2016). 
 
1.2.4 Pathogenesis 
Under normal circumstances, the anaemic state should produce a compensatory 
increase in circulating blood levels of EPO and therefore increase red cell production in 
the bone marrow, with a consequent increase in Hb concentration. This physiological 
adaptation occurs in healthy individuals, independent of age (de Klerk et al. 1981; Mori 
et al. 1988). Serum EPO levels in patients with CKD are actually comparable to the 
levels seen in non-anaemic healthy individuals, but the inability of the kidney to boost 
EPO production in response to a decreased Hb concentration is the main reason that 
renal anaemia develops in advanced CKD (Figure 1.6). Renal anaemia as a result of 
kidney disease is not absolute; patients with benign or malignant cystic kidney disease, 
or renal artery stenosis, may not suffer the same degree of anaemia, and might even 
see an increase in Hb concentrations (Chandra et al. 1985). 
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The possibility that renal anaemia is actually a protective mechanism in end-stage 
renal failure is lent some credence with the observation that patients with kidney 
disease possess the ability to boost EPO production under conditions of hypoxic 
stress. Blumberg and colleagues examined the effect of altitude on 6 HD patients and 
showed that plasma EPO levels were significantly increased, although not at the same 
level as in healthy controls (Blumberg, Keller, and Marti 1973). Chandra and 
colleagues also showed significant upregulation of EPO levels in 6 HD patients 
suffering episodes of hypoxia (pulmonary oedema, congestive cardiac failure and 
hypotension as a result of sepsis), from baseline EPO levels of approximately 15 
i.u./mL, to levels between 50 – 600 i.u./mL (Chandra, Clemons, and McVicar 1988). 
 
 
Figure 1.6 Relationship between serum erythropoietin levels and haemoglobin 
The normal ranges of erythropoietin (EPO) and haemoglobin (Hb) levels for non-anaemic healthy 
individuals are indicated on the graph as ‘normal’. As non-renal anaemia develops, there is an exponential 
increase in serum EPO levels, whereas in renal anaemia, the serum EPO levels remain relatively 
unchanged (reproduced from (Macdougall 2011)) 
 
Bosman and colleagues undertook a similar study comparing EPO levels in two groups 
of anaemic patients (early diabetic nephropathy versus non-dialysis stage 5 CKD) 
whilst exposing them to 6 hours of hypoxia (inspired oxygen concentration 11.6-
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patients had a greater EPO response, comparable to the rise in EPO levels seen in 
hypoxic healthy controls (Bosman et al. 2002). 
 
Following the discovery of the hypoxia-inducible factors (HIF) by Semenza and 
colleagues, it is now accepted that hypoxia is the most important element in the 
regulation of the HIF transcriptional cascade and consequently of the EPO gene. The 
discovery of this group of transcription factors further advanced the science of EPO 
from the foundations laid by Miyake, Lin, Jacobs and their colleagues (see page 19), 
using the availability of the then newly-cloned EPO gene, and hepatoma-derived cells 
that produced EPO in an oxygen-sensitive manner under laboratory conditions 
(Semenza and Wang 1992). We now know that there are three HIF-α subunits; HIF-1α 
and HIF-2α appear to be the principal elements in regulating cellular hypoxic 
responses. In the presence of oxygen, prolyl hydroxylation of HIF-α in the cytoplasm 
eventually results in its degradation by the von Hippel-Lindau (VHL)-E3 ubiquitin ligase 
complex, thereby halting its effect. The degradation of HIF-α does not occur in the 
hypoxic state, however, and the transcription factor subsequently translocates to the 
nucleus and binds to specific regulatory elements within the EPO gene (Figure 1.7). 
 
 
Figure 1.7 Regulation of HIF in normoxia and hypoxia 
Abbreviations: 2OG, 2-oxoglutarate; PHD, prolyl-4-hydroxylase domain; ARNT, aryl hydrocarbon receptor 
nuclear translocator; Pro-OH, proline residue hydroxylation; VHL, von Hippel-Lindau; HNF-4, hepatocyte 
nuclear factor 4 (reproduced from (Koury and Haase 2015)) 
 
In normoxia, HIF-α is degraded and therefore unable to upregulate EPO gene 
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hydroxylase enzymes. However, this feature of EPO gene regulatory function is not 
sufficient to explain the low-level physiological expression of the EPO promoter that is 
also witnessed in normoxic conditions. Tsuchiya and colleagues demonstrated that in 
this scenario, GATA-2 functioned as a concomitant negative regulator of the EPO gene 
in order to prevent erythrocytosis, and act as a protective mechanism (Tsuchiya et al. 
1997). 
 
More recently, processes have been described that occur independent of HIF (and 
precede the effects of hypoxia on subsequent transcriptional events) by inducing 
histone hypermethylation of key enzymes (methyl transferases), and these processes 
require neither a change in enzymes that modify histones or increases in the 
physiological inhibitors of dioxygenases (Batie et al. 2019; Chakraborty et al. 2019).  
 
In much the same way that serum EPO levels are inappropriately low for the level of 
anaemia seen in CKD, the same phenomenon is also witnessed in patients with 
chronic inflammatory conditions such as in persistently active inflammatory bowel 
disease or rheumatoid arthritis. The pro-inflammatory cytokines, IL-1 and TNF-α have 
been implicated in the pathogenesis of the anaemia of chronic disease, as both directly 
downregulate EPO gene expression under experimental conditions (Jelkmann 1998). A 
blunted response to the action of rHuEpo is also seen in inflamed patients; ex vivo data 
appears to show IFN-γ, IL-10 and IL-13 as the responsible cytokines (Cooper et al. 
2003). Other regulators of EPO include angiotensin II, which increases EPO levels via 
the action of the angiotensin II subtype I receptor (Gossmann et al. 2001). It remains 
unknown whether this is a direct effect or not. 
 
There are other factors that contribute to the anaemia of CKD, and these include 
inflammation and iron deficiency, and their respective interactions with hepcidin, 
disorders of MBD (which can also be tangentially linked with iron metabolism, and 
therefore hepcidin), decreased RBC survival in CKD, and the so-called uraemic 
inhibitors of erythropoiesis. 
 
The normal life-span of RBCs is in the region of 120 days, but increased osmotic 
fragility markedly reduces this to 60-90 days in advanced renal disease. Even with the 
advent of treatments for anaemia in well-dialysed patients, the RBC life-span remains 
shortened (Ly, Marticorena, and Donnelly 2004). The exact mechanism is yet to be 
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elucidated, although we know that blood transfusions from uraemic patients into the 
bloodstream of healthy individuals lead to the normalisation of RBC survival. 
Conversely, when blood was transfused from normal donors into the uraemic milieu, 
RBC survival is again shortened (Joske, McAlister, and Prankerd 1956; Loge, Lange, 
and Moore 1958). It therefore seems likely that factors within the uraemic environment 
are responsible for reduced RBC survival. 
 
There has been great interest in the accumulation (and removal) of small and middle 
molecules (delineated by a cut-off around a molecular weight of 500 Da), and protein-
bound compounds in renal failure, and the possible effects of these uraemic toxins in 
exacerbating renal anaemia. It is thought that some of these factors create an 
environment such that the erythroid precursors become relatively insensitive to the 
effects of EPO. The polyamines, parathyroid hormone and cytokines have all been 
postulated as candidate toxins (Macdougall 2001). The European Uremic Toxin Work 
Group has now created a database of more than 140 uraemic toxins, but no 
outstanding contender has emerged (European Work Group on Uremic toxins (EUTox) 
2016). 
 
There are a number of other factors that play a role in the pathogenesis of renal 
anaemia such as functional iron deficiency related to high hepcidin levels, and the 
effects of inflammation/cytokines and hyperparathyroidism that will be covered in 1.4 - 
Hepcidin And Its Uses In CKD. 
 
1.2.5 Clinical Features 
The presence of anaemia in CKD is associated with a number of co-morbidities. There 
are a host of subjective clinical features associated with chronic anaemia, including 
lassitude, dyspnoea, angina, palpitations, reduced attention span, poor memory, 
reduced libido, and depression. Objectively, anaemia is associated with reduced 
maximum oxygen consumption and anaerobic threshold (Mayer, Thum, and Graf 
1989). Severe anaemia can affect the cardiovascular system, and is associated with 
high-output cardiac failure subsequent to an increase in stroke volume and heart rate. 
Inflammation is likely to be the unifying precursor that explains the complex interplay 
between heart failure, CKD, and anaemia (O'Meara et al. 2014). Anaemia is also an   
independent risk factor for the development of left ventricular hypertrophy (LVH). Levin 
and colleagues found that even a small decrement in Hb concentration of just 5 g/L in 
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the context of renal disease conferred a 32% increase in risk of developing LVH (Levin 
et al. 1999). Despite the abundance of observational data detailing the existence of a 
link between anaemia and LVH, it is still uncertain whether anaemia causes an 
increase in cardiac mortality. In one example of a large observational trial in this field, 
Foley and colleagues followed 432 dialysis patients, and showed that the presence of 
anaemia in this patient cohort was independently associated with an 14% increased 
mortality risk for every 10 g/L decrement in Hb concentration (Foley et al. 1996). 
Whether or not causality is eventually proven, it is clear that anaemia in the context of 
kidney disease confers a poor prognosis. 
1.2.6 Evaluation 
The evaluation of renal anaemia relies on a diagnosis of CKD (see 1.1.1), and 
elimination of all other possible causes of anaemia. It is therefore a diagnosis of 
exclusion. In CKD, the mean cell volume (MCV) is typically within the normal range, 
and therefore, MCV values that are outside of the normal range should increase the 
suspicion for other contributory causes. Microcytosis is suggestive of iron deficiency or 
a haemoglobinopathy such as alpha thalassaemia, whereas macrocytosis is 
suggestive of vitamin B12 or folate deficiency, or hypothyroidism. Several drugs such 
as azathioprine or mycophenolate may also induce a macrocytosis. 
  
Much of the literature concerned with the evaluation of anaemia in CKD and dialysis 
has focussed on the accurate assessment of iron stores using serum ferritin and/or 
transferrin saturation (TSAT), which are the favoured biomarkers in the most recent 
KDIGO anaemia guidelines (Kidney Disease: Improving Global Outcomes (KDIGO) 
CKD Work Group 2012). Both ferritin and TSAT, however, are heavily influenced by 
the inflammatory state, which is highly prevalent in the end-stage renal failure 
population (see 1.1.5.). Ferritin, an iron storage protein, is a positive acute phase 
reactant, whereas transferrin, the main iron transport protein, is a negative acute phase 
reactant (Gabay and Kushner 1999). Aside from the influence of inflammation, both of 
these biomarkers are subject to external factors that may affect their levels, including 
gender difference, but not circadian variation (Ridefelt et al. 2010). Despite their 
widespread use, ferritin and TSAT do not perform particularly well in detecting iron 
insufficiency in dialysis patients. TSAT performs better than ferritin, with sensitivities for 
iron insufficiency that range from 59% to 88% (Fishbane et al. 1996; Kalantar-Zadeh et 
al. 1995; Tessitore et al. 2001). Multiple studies have shown that the sensitivity of 
serum ferritin is less than 50%, irrespective of whether a cut-off value of 100 μg/L or 
Chapter 1. Introduction 
 
38 
200 μg/L is used (Fishbane et al. 1996; Tessitore et al. 2001). The one clinical scenario 
where absolute iron insufficiency (reduction in total body iron stores) can definitively be 
diagnosed occurs when the serum ferritin level is <20 ng/mL (Macdougall 1994). In 
contrast to absolute iron deficiency, functional iron deficiency is a condition in which 
total body iron stores are normal (or increased), but the iron cannot be mobilised 
effectively for the purposes of erythropoiesis. This occurs either as a result of 
inflammation (this will be covered in greater detail in the chapter on hepcidin 
physiology (1.3)), or the use of ESA therapy in ‘over-driving’ the bone marrow so that 
the demand for iron outstrips the ability of circulating transferrin to provide an adequate 
amount of iron for erythropoiesis. In this situation, the TSAT will often be low (<20%), 
as iron will be rapidly shifted from transferrin for RBC production, but not replenished in 
a timely fashion from the iron stores. As a consequence, serum ferritin levels may be 
normal or high. 
 
At the other end of the spectrum, the utility of serum ferritin as a marker of iron 
overload in dialysis patients is also uncertain. The significant threat of iron overload 
exists in the dialysis population, given the systematic use of intravenous iron in virtually 
all HD patients. According to the guidance issued by KDIGO, a serum ferritin level of 
500 ng/mL is considered the threshold above which intravenous iron should not be 
administered to dialysis patients due to the risk of inadvertently causing systemic iron 
overload (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group 
2012). Rostoker and colleagues illustrated this by using magnetic resonance imaging 
(MRI) to examine the liver iron content of 119 HD patients, and found that 100 from the 
119 had excessive hepatic iron content. The mean serum ferritin level across the entire 
patient cohort was less than 500 ng/mL, and this was the case even in the group that 
was designated as having “severe” iron overload (Rostoker et al. 2012). However, it 
should be noted that the measurement of hepatic iron content by MRI to identify 
patients with iron overload remains a matter of debate (Sarigianni et al. 2015) since 
this technique cannot differentiate between iron accumulation in Kupffer cells (which 
are physiologically designed to store iron), and hepatocytes (where iron accumulation 
could be toxic). 
 
Despite the reservations surrounding the use of serum ferritin and TSAT, both KDIGO 
and the European Renal Best Practice Working Group continue to endorse both 
laboratory measures as the biomarkers of choice for managing anaemia in CKD 
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(Locatelli et al. 2013). This is juxtaposed against the most recent guidance on the 
treatment of anaemia in CKD published by NICE in 2015, which recommended the use 
of percentage hypochromic red blood cells (%HRC) as the biomarker of choice in 
managing anaemia, referencing the results of an Italian study published 14 years 
earlier (Tessitore et al. 2001). This change in biomarker affiliation, as well as the other 
salient points from the NICE guideline are summarised as follows: 
• An Hb concentration of ≤110 g/L is the trigger for investigating and treating 
anaemia when the eGFR <60 ml/min/1.73m2 
• The target Hb should be 100-120 g/L, but treatment should be individualised 
• The tests for investigating anaemia in CKD: 
Ø Percentage of hypochromic red blood cells (%HRC) >6% 
Ø Reticulocyte Hb content (CHr) <29 pg, or equivalent tests 
Ø TSAT < 20% and serum ferritin <100 μg/L 
• The assessment of iron status should not rely solely on TSAT or serum ferritin 
measurements alone, nor should erythropoietin levels be measured (The 
National Institute for Health and Care Excellence 2015b) 
 
1.2.7 Treatment 
The first step is to ensure that alternative causes for anaemia are excluded (Table 1.5). 
The mainstay of current treatment usually involves the use of iron replacement therapy 
in the first instance, followed by the use of ESAs once the patient is deemed iron-
replete. Blood transfusions are now used to support the Hb only if the above measures 
prove unsuccessful and the patient remains anaemic, or in an emergency situation 
such as acute blood loss. 
 















- drug-induced, autoimmune, 
mechanical 
Table 1.5 Causes of anaemia by mechanism 
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1.2.7.1 Red Cell Transfusions 
Prior to the widespread use of recombinant human erythropoietin in the early 1990s, 
the only option available to treat anaemia in the dialysis patient was the regular 
transfusion of red cells (as well as the use of androgen therapy (Eschbach and 
Adamson 1985)). This led to a significant proportion of patients suffering with iron 
overload, and also exposed patients to the risks of blood-borne viruses as well as the 
increased likelihood of allosensitisation. There are also rare side effects such as 
transfusion-related acute lung injury (TRALI). Blood transfusions are also more costly 
than ESAs or iron therapy. One of the many impacts of rHuEpo was to significantly 
decrease the transfusion requirements of patients with end-stage renal failure 
(Popovsky and Ransil 1996). 
 
1.2.7.2 Erythropoiesis-Stimulating Agents 
Recombinant human erythropoietin revolutionised the treatment of anaemia in patients 
with CKD and has been widely available for over 25 years. The principal cause of renal 
anaemia is a relative lack of EPO, and therefore ESAs treat the underlying 
pathophysiology, and often reverse the clinical manifestations of the condition. Several 
publications have outlined the truly magnificent work that has taken us from 
Christison’s observation connecting anaemia to kidney disease in 1839, through to 
Erslev and Jacobson’s discovery in the 1950s that the kidney is the main repository of 
EPO production, concluding with the purification of erythropoietin (Miyake, Kung, and 
Goldwasser 1977) and cloning and expression  of the erythropoietin gene (Lin et al. 
1985) – a wonderful account of the essence of “bench-to-bedside” medicine (Jelkmann 
1986; Fisher 2010).  
 
Erythropoietin is glycoprotein containing a backbone of 165 amino acids (34 KDa) and 
the recombinant human form is available in a number of different preparations (Table 
1.6). Modifications in the glycosylation pattern account for differences between the 
endogenous hormone and the various preparations; they are orally inactive and thus 
have to be administered parenterally (often intravenously in the haemodialysis 
population, and subcutaneously in non-haemodialysis patients), with the 1st generation 
ESAs (the epoetins) having a half-life in the region of 6-8 hours, which is longer if given 
subcutaneously. The 1st generation ESAs are administered 2-3 times per week, in 
contrast to the 2nd generation ESA (darbepoetin alfa), which has a longer half-life and 
is given weekly/fortnightly. The 3rd generation ESA (CERA) has an even longer half-life 
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(approximately 130 hours) due to the integration of a large pegylated side-chain, and 
this ESA can be administered fortnightly/monthly.  Following expiration of the patents 
of the first-generation ESAs, a number of biosimilar epoetins have been developed, 
which are often less costly than the reference products. These biosimilars have an 
almost identical structure to the originator epoetin and show pharmacological 
bioequivalence, being tightly regulated by the medicines regulatory agencies in 
Europe, the US, and elsewhere. The theoretical risks of increased immunogenicity 
highlighted a few years ago (Covic et al. 2008) do not appear to have been borne out 
in reality. 
 
The EPO mimetic peginesatide, on the other hand, has no structural similarity with 
epoetin, but has comparable pharmacological activity, and this was demonstrated in 
two parallel trials that confirmed its non-inferiority versus epoetin in non-dialysis CKD 
patients, and in haemodialysis patients, respectively (Macdougall et al. 2013; Fishbane 
et al. 2013). Since there is no cross-reactivity between this drug and anti-erythropoietin 
antibodies, peginesatide has also successfully been used as a rescue therapy in some 
patients who developed antibody-mediated pure-red cell aplasia (Macdougall et al. 
2009). However, the drug was withdrawn from the market in February 2013 following 
reports of fatal hypersensitivity reactions in some recipients.  
 
Generic erythropoiesis-stimulating agent Trade names 
epoetin alfa Epogen®, Eprex®  
epoetin beta NeoRecormon® 
epoetin zeta Retacrit®, Silapo® 
epoetin alfa (biosimilar) Binocrit®, Abseamed®, Hexal® 
epoetin theta Eporatio® 
darbepoetin alfa Aranesp® 
methoxypolyethylene glycol epoetin beta (CERA) Mircera® 
peginesatide Omontys® (Hematide®) 
Table 1.6 Preparations of erythropoiesis-stimulating agents 
CERA; continuous erythropoietin receptor activator 
 
In 1998, Besarab and colleagues published the first major randomised controlled trial 
evaluating whether correction of the haematocrit into the normal range (42%), with the 
use of an ESA (Epogen®) in haemodialysis patients, could reduce mortality and the 
risk of heart attacks in this patient population. 
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All-cause death was significantly higher in the normal haematocrit group (Figure 1.8), 
but the topic of optimal haematocrit (later to become Hb) targets in CKD and dialysis 
patients remained a matter of considerable debate for nearly a decade until the 
publication of the TREAT trial. Pfeffer and colleagues then showed similar negative 
findings to those of Besarab et al, with full correction of renal anaemia increasing the 
risk of cardiovascular morbidity compared to partial correction (Pfeffer et al. 2009). 
More specifically, the TREAT study showed an increased risk of stroke and venous 
thromboembolism, as well as an increased risk of cancer-related mortality (in those 




Figure 1.8 Death and cardiac morbidity in the Normal Hematocrit Trial 
Probability of death or non-fatal myocardial infarction was higher in the normal haematocrit group 
(reproduced from (Besarab et al. 1998)) 
 
ESAs are usually very well tolerated with the main side effect being related to 
hypertension. A rare and serious complication is PRCA, which arises as a 
consequence of anti-erythropoietin antibodies that are formed following treatment with 
exogenous EPO. The white cell and platelet cell lines are unaffected, differentiating this 
condition from aplastic anaemia. Immunosuppression is the mainstay of treatment for 
PRCA, although peginesatide can be used in lieu of the offending ESA to rescue these 
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ESAs are not universally successful in raising the Hb concentration in the desired 
manner, as some patients are resistant to their effects. The current UK NICE guidance 
defines ESA-resistance as being unable to achieve an Hb concentration in the 
aspirational range despite treatment with ≥300 i.u./kg/week epoetin (subcutaneously), 
≥450 i.u./kg/week epoetin (intravenously) or ≥1.5 μg/kg/week darbepoetin (The 
National Institute for Health and Care Excellence 2015b). ESA-resistance can occur as 
a result of iron deficiency, inflammation, severe hyperparathyroidism, folate deficiency, 
or PRCA. 
1.2.7.3 Iron Therapies  
Iron deficiency is common in patients with CKD for a variety of reasons including poor 
dietary intake, increased gastrointestinal losses, regular phlebotomy, and decreased 
absorption as a result of hepcidin upregulation (Table 1.7). Iron deficiency in the 
haemodialysis population was recognised over 50 years ago and 2g/year of iron 
replacement was the suggested regimen at that time (Edwards, Pegrum, and Curtis 
1970). Although we now know that gastrointestinal iron absorption is impaired in CKD, 
studies undertaken in the 1970s concluded that iron absorption was in fact normal, and 
that oral iron supplementation was likely to be as effective as intravenous preparations 
(Eschbach, Cook, and Finch 1970; Baker et al. 1975; Milman and Larsen 1976). The 
use of ESA and iron therapy is synergistic, as iron deficiency can be caused by the use 
of ESAs, and ESA resistance is caused by iron deficiency. Therefore the use of iron 
will reduce the amount of ESA therapy required to correct anaemia in CKD (Fishbane, 
Frei, and Maesaka 1995) and intravenous iron is superior in this regard to oral iron in 
both the dialysis (Macdougall et al. 1996) and CKD populations (Macdougall et al. 
2014). 
 
Both routes of administration are associated with significant side effects; the oral 
preparations lead to gastrointestinal disturbance in approximately 30-40% of patients 
due to the Fenton reaction, but are generally considered to be safe, whereas the 
intravenous preparations can occasionally cause hypersensitivity reactions (Bailie et al. 
2005). A large retrospective analysis of a Medicare database containing 688,183 non-
dialysis patients between 2003 and 2013 was analysed to examine the risk of 
anaphylaxis in incident users of iron dextran, gluconate, sucrose and ferumoxytol. 
Wang and colleagues concluded that the risk of anaphylaxis was highest for those 
initially exposed to high molecular weight iron dextran, whilst it was lowest for iron 
sucrose  (Wang et al. 2015). The authors included the administration of 
Chapter 1. Introduction 
 
44 
diphenhydramine as one of the ways to define anaphylaxis, and this flawed analysis 
led to the probable overestimate of fatal events. After the supplementary data were re-
analysed, it was found that deaths were actually higher in those receiving non-dextran 
irons (DeLoughery and Auerbach 2016; Kalra and Bhandari 2016). 
 
Systemic reactions to intravenous iron occur, as unbound circulating iron is highly 
volatile and potentially toxic due to its tendency to induce reactive oxygen species. In 
order to circumvent this problem, all iron preparations consist of a carbohydrate shell 
that shields elemental iron from its environs, allowing its slow release and subsequent 
uptake by either transferrin or ferritin, hence limiting exposure and reducing the risk of 
hypersensitivity reactions. 
 
Route of administration Iron preparation 
Oral Ferrous sulphate 
Ferrous fumarate 
Ferrous gluconate 






Table 1.7 Preparations of iron replacement therapies 
 
Iron is a critical element for both host and pathogen and as a result, iron therapy has 
traditionally been withheld from renal patients suffering from an acute bacterial 
infection. Although there are few clinical data to support this stance at the present time 
(Avni et al. 2015), there is a surfeit of pre-clinical data demonstrating that excess iron 
may cause microbial proliferation and simultaneously depress T-cell and B-cell function 
(Marx 2002).  
 
1.2.7.4 Novel Treatments 
The mainstay of renal anaemia management over the past 25 years has been ESA 
therapy and iron supplementation, consequently giving us the significant benefit of 
long-term efficacy data. As previously mentioned, both these classes of therapeutic 
agents have question marks against their long-term safety. In the event of resistance to 
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ESAs and/or iron therapies, there are few treatments in the armoury left, and clinicians 
have no recourse other than to utilise red cell transfusions in order to treat ESA-
resistant anaemia. The scientific advances in the molecular biology underpinning the 
regulation of EPO and iron metabolism over the last decade have led to the emergence 
of a number of potential therapeutic targets and investigational drugs, with the HIF-
stabilisers furthest along in their development. 
 
1.2.7.5 Strategies That Indirectly Stimulate Erythropoiesis 
The HIF-stabilisers inhibit prolyl hydroxylase (and compete with 2-oxoglutarate), with 
their primary function being to prevent the degradation of HIF-α, in effect mimicking the 
hypoxia-driven expression of endogenous erythropoietin in the kidney. The main 
advantage of the HIF-stabilisers, in contrast to the ESAs, is that they are orally active, 
making them a much more attractive proposition. The drawback of these therapeutic 
agents is that HIF transcription factors are not limited to the pathway mentioned above 
(Figure 1.7), but are also involved in the regulation of a number of other biological 
processes. Manipulation of HIF thus possesses the clear potential for a number of off-
target effects, the most worrying of which is the promotion of angiogenesis, and 
potentially tumour growth (Ratcliffe 2013). There are now at least 6 prolyl hydroxylase 
inhibitors under clinical development, some of which are in phase 3 trials (Malyszko 
and Malyszko 2016). 
 
The activin traps, like HIF-stabilisers, have the objective of treating renal anaemia by 
indirectly targeting the EPO receptor. Activins belong to the transforming growth factor 
β (TGFβ) superfamily, and regulate erythropoiesis by their action on erythroid 
progenitor, precursor, and/or the bone marrow accessory cells (Maguer-Satta et al. 
2003; Jelkmann 2015). Enhanced erythropoiesis as a result of the sequestration of 
activin was a surprise finding in a phase 1 trial investigating the effect of ACE-011 on 
bone biomarkers in post-menopausal women (Ruckle et al. 2009), paving the way for 
the current trials exploring their use in renal anaemia. However, their exact mechanism 
of action is yet to be determined, given that these molecules have been shown to both 
stimulate erythropoiesis and inhibit erythroid differentiation (Bonomini et al. 2016). 
 
1.2.7.6 Strategies That Directly Stimulate Erythropoiesis 
Novel second generation ESAs, using the addition of polysialic acid (PSA) instead of 
polyethylene glycol (PEG) polymer chains to EPO, considerably extend the half-life of 
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EPO and are currently in phase 2-3 trials. The PSA-EPO construct is an attractive 
biological alternative, given that the PSA moiety is completely biodegradable (Smirnov 
et al. 2015). EPO fusion molecules, which are created by the synthesis of EPO mimetic 
peptides onto human IgG-based constructs, are currently under evaluation in a phase 
2 trial (Bonomini et al. 2016). It is unclear whether these two strategies provide 
pharmacological advantages over the more established ESAs. 
 
Synthetic EPO mimetic peptides, which have no structural homology with the 
endogenous hormone, have the ability to directly activate the EPO receptor. As 
previously mentioned, peginesatide has now been withdrawn, but there are newer 
strategies under phase 1 development, such as pegolsihematide (Yu 2016). 
Other strategies that have pre-clinical data but are not yet in clinical development 
include antibodies that are agonists to the EPO receptor, and inducers of dimerisation 
of the EPO receptor intracellular domain (Bonomini et al. 2016).  
 
1.2.7.7 Novel Iron Strategies 
Soluble ferric pyrophosphate is a compound that was first studied in 1999 in 
comparison with intravenous iron dextran (Gupta et al. 1999), and is currently the 
subject of a number of phase 2 and 3 trials. Oral ferric citrate hydrate, originally studied 
as an iron-containing phosphate binder, presented investigators with an unintended, 
but positive outcome in terms of enhanced iron supplementation, thereby reducing the 
need for intravenous iron (Umanath et al. 2015). Despite the theoretical risks of 
aluminium toxicity (Gupta 2014), further studies are required to test its efficacy and 
safety profile. Other iron products under recent investigation include ferric maltol, which 
is not affected by gastric pH, and therefore has superior bioavailability compared to 
ferrous iron, and possibly a better side-effect profile (Kelsey et al. 1991; Reffitt et al. 
2000; Barrand et al. 1991; Stallmach and Buning 2015). Strategies that target hepcidin 
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1.3 Hepcidin Physiology 
1.3.1 Background 
Iron is a critical trace element that is required by all living organisms but is nevertheless 
toxic in its non-bound form and thus, its uptake, transport, storage, and export are very 
tightly regulated. It was only in the year 2000, when hepcidin was isolated from human 
sera, that the elusive iron regulatory peptide was finally discovered (Krause et al. 
2000). There have been some fortunate occurrences along the way that have led us to 
our current model of iron regulation; Nicolas and colleagues were attempting to 
investigate glucose dependent gene regulation in the liver, and during the course of 
their work, they created a Usf-/- murine knockout model. They subsequently noted that 
the knockout mice displayed features consistent with severe iron overload, and it 
transpired that the Usf2 gene was contiguous with the gene responsible for hepcidin 
production (HAMP) (Nicolas et al. 2001). Now called hepcidin, the peptide was initially 
known as liver expressed antimicrobial peptide-1 (LEAP-1), and was considered an 
anti-microbial (Park et al. 2001). However, there now appears to be an overall 
consensus that hepcidin-25 has a much more important role and is considered the 
master regulator of iron homeostasis. 
 
1.3.2 Iron Homeostasis 
Iron is the essential ingredient of haem, facilitating the transport of oxygen in the blood 
to all distal cellular components in biological systems. In healthy adult humans, total 
body iron amounts to approximately 55mg/kg body weight, which is equivalent to 4g in 
the typical adult male (Andrews 1999). The daily requirement of iron in healthy 
individuals is in the region of 25mg/day, of which 20mg is reserved for erythropoiesis. 
The circulating plasma pool of iron consists of approximately 3mg, and the remainder 
is recovered from senescent red blood cells. Iron excretion occurs in a completely 
unregulated fashion via the gastrointestinal (GI) tract. GI losses of iron in healthy 
individuals are in the order of 1mg/day, but their counterparts on haemodialysis can 
lose up to 5 times that amount, providing one explanation for why dialysis patients are 
comparatively deficient in total body iron (Zumbrennen-Bullough and Babitt 2014). 
Since there is no excretory mechanism for iron, the rate at which iron absorption 
occurs is tightly regulated. Dietary iron is absorbed in the duodenum, and can either be 
bound to haem, or not, in which case it is known as non-haem bound iron (NHB). The 
acidic milieu of the stomach allows NHB iron to be dissociated from food; NHB iron is 
maintained in the ferric (Fe3+) state, and is reduced to ferrous iron (Fe2+) by 
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ferrireductases, such as duodenal cytochrome B (DCYTB), which are located on the 
apical brush border of the duodenal enterocytes (Figure 1.9). Ferric reduction in man 
occurs with the assistance of ascorbic acid, which is only available via the diet (McKie 
et al. 2001). 
 
 
Figure 1.9 Schematic representation of dietary iron absorption via duodenal 
enterocyte 
(DCYTB – duodenal cytochrome B; DMT1 – divalent metal transporter 1; HO1 – haem oxygenase 1; FPN 
– ferroportin; Heph – hephaestin; aTf – apotransferrin; Tf – transferrin) 
 
The symporter, divalent metal transporter 1 (DMT1), which is located on the apical 
surface of the enterocyte, transports ferrous iron in association with ionised hydrogen, 
and the iron is then retained within the cellular storage system (ferritin) or allowed to 
exit the cell on the basolateral surface into the portal circulation via the membrane-
bound protein, ferroportin (McKie et al. 2000). Haem-bound iron is transported across 
the apical membrane via a haem transporter, known as haem carrier protein 1, which is 
now known to also transport folate (Nakai et al. 2007). Once in the intracellular space, 
haem-bound iron subsequently interacts with haem oxygenase 1, which releases 
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iron is in the plasma pool, it is oxidised back to its original ferric form via the 
membrane-bound ferroxidases, hephaestin and ceruloplasmin, and is then loaded onto 
apotransferrin, which is the iron-free form of transferrin, for distribution to distal cells 
including the bone marrow (for erythropoiesis) (Roeser et al. 1970; Vulpe et al. 1999). 
 
Cellular uptake of iron is dependent upon the presence of the transferrin receptors 
(TfR), which are expressed at the cell surface allowing the entry of the iron-transferrin 
complex via endocytosis. TfR1 is ubiquitously expressed, with the exception of mature 
erythrocytes, whereas TfR2 is confined to the liver. During endocytosis, the 
intravesicular acidic environment allows the decoupling of ferric iron from transferrin, 
and whilst iron is then utilised for intracellular functions (or simply stored in the liver), 
the transferrin receptor is then recycled into the plasma (as soluble transferrin 
receptor), to return to the enterocytes and continue its endless cycle of iron 
transportation (Hentze et al. 2010). The average 70kg man has approximately 5-6L of 
blood; given that each litre of blood contains approximately 150g of haemoglobin, and 
that each gram of haemoglobin contains approximately 2.5mg of iron, it can be 
estimated that mature erythrocytes contain nearly 70% of total body iron stores. 
However, this iron is not wasted; there is a highly efficient system designed to recover 
this iron, which is enabled by macrophages that phagocytose and digest old 
erythrocytes, known as erythrophagocyosis. Haem oxygenase 1 degrades 
haemoglobin thereby releasing iron, which is then exported out of the phagosome by 




1.3.3 The Ferroportin-Hepcidin Axis 
The only iron cellular export protein currently identified is ferroportin, and the 
concentration of functional membrane-associated ferroportin is controlled by its ligand, 
hepcidin. Three groups independently discovered ferroportin (also known in the 
scientific literature as SLC40A1, MTP1 and IREG1) and its role in iron export. 
Interestingly, ferroportin appears to be unrelated to any other mammalian transporter 
proteins and is well conserved with orthologs in plants and worms (Abboud and Haile 
2000; Donovan et al. 2000; McKie et al. 2000). Ferroportin is highly expressed by 
hepatocytes, duodenal enterocytes, and macrophages, which are all associated with 
the trafficking of iron. Donovan and colleagues inactivated the FPN gene in mice, both 
globally and selectively, and found that FPN-/- mice did not survive the embryonic 
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stage. The selective deletion of intestinal FPN in adult mice resulted in the mice 
developing anaemia, showing that FPN was essential for the intestinal absorption of 
iron. However, the parenteral administration of iron was able to override this process 
and abrogate the anaemia (Donovan et al. 2005). 
 
Cellular ferroportin expression is not static and is dependent on intracellular 
concentrations of iron. In iron deplete conditions, there is downregulation of ferroportin 
mRNA that is mediated by the 5′ iron response element (IRE) binding to iron-regulatory 
proteins (IRP) (Lymboussaki et al. 2003). In the circumstance of elevated levels of 
intracellular iron, the presence of haem leads to the increase in both haem oxygenase 
1 and ferroportin expression (Delaby et al. 2008). Despite our understanding of 
ferroportin regulation, the molecular mechanism by which intracellular iron is delivered 
to ferroportin, or the manner in which ferroportin actually transports intracellular iron is 
less well understood (Drakesmith, Nemeth, and Ganz 2015). 
 
As has been well documented, Nemeth and colleagues demonstrated that the external 
regulation of ferroportin was controlled by hepcidin, which, as its ligand, was able to 
bind to its receptor, resulting in the endocytosis and proteolysis of ferroportin. This 
interaction has the net result of restricting iron to the intracellular compartment of 
hepatocytes or macrophages (Nemeth, Tuttle, et al. 2004). The importance of the 
hepcidin-ferroportin axis can be highlighted by the clinical conditions that are 
characterised by hepcidin excess or deficiency. Iron-refractory iron deficiency anaemia 
(IRIDA) is an autosomal recessive disorder that results from mutations in the gene 
encoding for TMPRSS6, leading to elevated hepcidin levels. As the name of the 
disease implies, patients remain extremely anaemic despite attempts to correct it with 
iron therapy (Finberg et al. 2008). In contrast, mutations causing a profound reduction 
in hepcidin levels have been localised to the HAMP gene (although many other genes 
have also been implicated), and these can lead to conditions characterised by iron 
overload, such as juvenile haemochromatosis (Rideau et al. 2007). 
  
1.3.4 Structure and Kinetics of Hepcidin 
Bioactive hepcidin is a 25 amino acid polypeptide hormone that is principally 
synthesised by hepatocytes, but macrophages and other cell types (including 
adipocytes) are also able to generate small amounts. The HAMP gene is located on 
chromosome 19q13.1 and encodes an initial prepropeptide that consists of 84 amino 
Chapter 1. Introduction 
 
51 
acids that then undergoes a series of enzymatic cleavages to produce prohepcidin (60-
64 amino acids) (Figure 1.10). Prohepcidin undergoes further post-translational 
modifications, resulting in the establishment of the bioactive form (hepcidin-25) and 
other forms (hepcidin-20, hepcidin-22) whose role remains uncertain (Valore and Ganz 
2008). Recent work from within our institution has shed light on the existence of 
another isoform, hepcidin-24 but again, its role remains unclear (Handley et al. 2017).  
 
 
Figure 1.10 Amino acid sequence of prohepcidin, hepcidin-25, -24, -22, and -20 
Cysteine residues indicated in yellow with 4 disulphide bonds (dashed lines). Hepcidin-25 indicated in 
blue. Other hepcidin isoforms are indicated in green. Adapted from (Kulaksiz et al. 2004) 
 
Circulating hepcidin can be bound to carrier proteins such as α2-macroglobulin, and to 
a lesser degree, albumin, preventing its glomerular clearance under these conditions. 
When hepcidin attaches to its receptor (ferroportin), a proteolytic process occurs, and it 
is thought that this contributes to the clearance of hepcidin, with terminal excretion via 
the kidneys. However, the extent to which hepcidin is protein bound appears to be 
relatively small, and is estimated to be between 3 and 11% (Peslova et al. 2009; 
Itkonen et al. 2012). Given its size, unbound hepcidin is freely filtered at the glomerulus 
and mechanisms exist in the proximal tubular apparatus to facilitate its reabsorption. 
Thus, there is a relatively low fractional excretion of hepcidin, which has been 
estimated to be in the region of 5% (Peters et al. 2013; Kroot et al. 2011).  
 
Multiple studies have been undertaken to determine the utility of urinary hepcidin as a 
biomarker in a variety of clinical settings (various haematological conditions and AKI 
following cardiac surgery) but as yet, there is little prospect of this particular biomarker 
being adopted in the day-to-day practice of clinicians. Probably the most promising 
study to date was conducted by Prowle and colleagues, who showed that urinary 
hepcidin was associated with the development of AKI in the first 5 days following 
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cardiopulmonary bypass surgery, although the source of the urinary hepcidin is not well 
understood (Prowle et al. 2012). A possible mechanism that might contribute to the AKI 
seen in relation to cardiac surgery may be explained by increased haemolysis and the 
subsequent increased intravascular consumption of nitric oxide (Vermeulen Windsant 
et al. 2014). Van Swelm and colleagues showed that hepcidin was broken down in the 
kidney and reabsorbed via megalin, and that administered hepcidin was protective 
against early haemoglobin-mediated injury in mice (van Swelm et al. 2016). 
Administered hepcidin has also been used in pre-clinical models of renal ischaemia 
reperfusion injury (IRI). IRI induces changes in renal iron homeostasis, and hepcidin-
deficient mice sustain a more severe renal injury. Scindia and colleagues 
demonstrated that a murine intra-peritoneal injection of hepcidin 24 hours prior to IRI 
was protective against renal injury (lower plasma creatinine levels) and this was 
strongly corroborated by histological evidence, which showed far fewer tubular injuries 
(Scindia et al. 2015). 
 
When it comes to the other truncated forms of hepcidin (hepcidin-20, -22, and -24), 
little is known about their protein binding, plasma levels or excretion. These isoforms 
do not appear to have any activity towards ferroportin and are therefore unlikely to play 
a significant role in iron metabolism (Laarakkers et al. 2013; Nemeth et al. 2006). 
 
1.3.5 Regulation of Hepcidin 1: Iron and Inflammation 
A wide range of external and internal stimuli regulates hepcidin expression in the liver. 
The two most potent upregulators of hepcidin are body iron status (Figure 1.11) and 
acute inflammation, whereas iron deficiency (anaemia), hypoxia and erythropoiesis 
tend to downregulate hepcidin.  




Figure 1.11 Schematic overview of the iron cycle and hepcidin regulation 
The hormone hepcidin regulates plasma iron concentrations by controlling ferroportin concentrations on 
iron-exporting cells, including duodenal enterocytes, macrophages, and hepatocytes. Fpn – ferroportin; Tf 
– transferrin. Reproduced from (Sangkhae and Nemeth 2017) 
 
As has been mentioned previously, hepcidin excretion occurs via the kidney, and there 
is a body of evidence supporting the relationship between chronic kidney disease and 
elevated hepcidin levels. Other factors, such as vitamin D, the sex steroids, and 
heparin, have also been shown to influence hepcidin. The following sections will be 
devoted to reviewing the various stimuli and signalling pathways that are involved in 
the regulation of hepcidin (Figure 1.12 Intracellular regulation of hepcidin). 
 
1.3.5.1 Iron 
Hepcidin, being the hormone responsible for iron homeostasis, is exquisitely 
responsive to iron loading, and increases the expression of hepcidin via the BMP-HJV-
SMAD pathway in order to limit the amount of iron that is available to the circulation 
(Pigeon et al. 2001; Nicolas et al. 2002). In the iron-deficient state, hepcidin production 
is minimised in order to maximise the amount of iron available to the circulation, which 
is ultimately reserved for erythropoiesis (Hentze et al. 2010). 




Figure 1.12 Intracellular regulation of hepcidin 
The positive regulators of hepcidin are sited at the top of the figure (yellow boxes), whereas the negative 
regulators are situated in yellow boxes at the bottom of the figure. Abbreviations: BMP6 – bone 
morphogenetic protein 6; BMPR – bone morphogenetic protein receptor; C/EBPα – CCAAT enhancer 
binding protein α; CREB/H – cAMP response-element binding protein/H; EPO – erythropoietin; EPOR – 
erythropoietin receptor; ERFE – erythroferrone; ERK – extracellular signal–regulated kinases; GDF15 – 
growth differentiation factor 15; HFE – hemochromatosis protein; HIF – hypoxia-inducible factor; HJV – 
hemojuvelin (membrane and soluble); IL6 – interleukin 6; IL-6R – interleukin 6 receptor; JAK2 – Janus 
kinase; PDGF-BB – platelet-derived growth factor-BB; PDGFR – platelet-derived growth factor receptor; 
SMAD – sma and mothers against decapentaplegic homologue 1/5/8 complex; STAT3 – signal transducer 
and activator of transcription 3; TFR – transferrin receptor 1 or 2; TGFβ – transforming growth factor β; 
TGFβR – transforming growth factor β receptor; TWSG1 – twisted gastrulation BMP signalling modulator 
1; OES – oestrogen; TES – testosterone; VIT D – vitamin D [diagram adapted from (Rishi, Wallace, and 
Subramaniam 2015; Ueda and Takasawa 2017)] 
 
The bone morphogenetic proteins play a pivotal role in the pathways of iron-regulated 
hepcidin, which are part of the TGF-β superfamily of ligands. As the name would imply, 
they were originally found to have a role in the development of bone and cartilage, but 
we now know that their functions are far more widespread and they appear to be 
involved in an extensive array of biological functions ranging from embryological 
development to the formation of teeth. At the last count, there were approximately 20 
BMPs related to human biological activity (Carreira et al. 2015). In the specific arena of 
iron regulation, a number of these BMPs have been found to possess the capacity to 
stimulate hepcidin transcription in vitro, including BMP-2, BMP-4 to BMP-7, and BMP-9 
(Truksa et al. 2006; Babitt et al. 2007). Of the aforementioned bone morphogenetic 
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proteins, BMP-6 appears to be the most important ligand involved in the regulation of 
hepcidin (Andriopoulos et al. 2009). 
 
There is ample evidence in the literature in both in vivo and in vitro studies to show that 
iron loading leads to an increase in BMP-6 mRNA and protein levels, and this 
ultimately leads to an upregulation in HAMP transcription and the production of 
hepcidin in the liver (the liver is comprised of parenchymal cells, or hepatocytes (70%), 
and non-parenchymal cells, such as Kuppfer cells (stellate macrophages), hepatic 
stellate cells (involved in liver fibrosis), and liver sinusoidal epithelial cells (act as the 
interface between blood cells and hepatocytes/hepatic stellate cells)). The mechanism 
by which iron leads to an increase in BMP-6 remains largely unknown, but it has been 
shown that both parenchymal and non-parenchymal hepatic cells are able to produce 
BMP-6, albeit under different conditions, and that both canonical and non-canonical 
pathways may be involved (Enns et al. 2013; Arndt et al. 2010; Kautz et al. 2009; 
Kautz et al. 2011). 
 
The current understanding is that high levels of iron are sensed by hepatocytes, and 
this then stimulates the production of BMP-6.  The BMP-6 ligand then binds to BMP 
receptors 1 and 2, and the co-receptor hemojuvelin (HJV) stimulates phosphorylation 
of the SMAD 1/5/8 intracellular signalling proteins, which subsequently activate the 
SMAD4 downstream signalling cascade. The phosphorylated SMAD1/5/8/4 complex 
then induces hepcidin transcription by binding to the hepcidin promotor on the target 
gene (Babitt et al. 2006; Wang et al. 2005).  
 
Our understanding of the downstream mechanisms of BMP signalling is relatively well 
known, but the same cannot be said of the upstream mechanisms. It is still not entirely 
clear how iron leads to activation of the BMP-SMAD signalling system (Figure 1.13). 
There is a growing body of evidence suggesting that rather complex mechanisms exist 
in this area of iron regulation, and a number of means of ‘iron-sensing’ have been 
postulated, from the presence of intracellular or tissue iron sensors, detection of 
transferrin saturation, through to activation of transferrin receptor 2, and activation of 
hypoxia-inducible factor (HIF). It is highly likely that the sensing of iron is due to a 
number of factors and is not confined to a single governing mechanism (Ramos et al. 
2011). 
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The transferrin receptors and HFE may play a key role here; it has been suggested 
that in response to a low transferrin saturation, TfR1, which is upregulated in iron 
deficiency, may lead to its association with the HFE protein, and it is this complex that 
ultimately leads to a net downregulation of hepcidin expression. The biology of the 
TfR1 system has been well characterised, but TfR2 biology remains less so. 
 
Unlike TfR1, which is ubiquitous, TfR2 is restricted to the hepatocytes and some 
erythroid cells and is able to bind iron-loaded transferrin (holotransferrin). The HFE 
protein possesses the ability to shuttle between the two TfR homologues, and the 
activated TfR2 receptor associates with HFE, leading to activation of furin, with a net 
increase in BMP-SMAD signalling. Rishi and colleagues reviewed this subject matter 
and proposed that TfR2 initiated the BMP signalling cascade that resulted in the 
formation of BMP-6, but the BMP-6 protein could only bind with its receptor (BMPR 
type 1), which was allowed to localise to the cell surface with the aid of HFE (Rishi, 
Wallace, and Subramaniam 2015). 
 
Probably the area of BMP-SMAD signalling that has the most evidence to support it is 
hemojuvelin, which is also known in the scientific literature as HFE2. Hemojuvelin is of 
great clinical significance, as genetic mutations in the gene encoding hemojuvelin lead 
to a severe juvenile onset form of hereditary haemochromatosis (an iron overload 
condition that is a heterogeneous genetic disorder, and can be caused by mutations in 
several genes including those that encode for hepcidin, ferroportin, hemojuvelin, HFE, 
TfR2) and the phenotype is similar to that seen in mutations of hepcidin itself (Roetto et 
al. 2003; Papanikolaou et al. 2004; Babitt and Lin 2011). 
 
The action of hemojuvelin greatly depends on whether it is bound to the cellular 
membrane, or in its soluble form. TMPRSS6 (also known as matriptase-2) is activated 
in part by iron-loaded transferrin and cleaves cell-associated hemojuvelin to form a 
soluble form. Membrane-bound hemojuvelin is critical to the BMP-SMAD signalling 
cascade, as it acts as a co-receptor for the BMP-receptor-BMP-6 complex and 
ultimately upregulates hepcidin expression, whereas the soluble form actually inhibits 
its activity (Babitt et al. 2006; Lin, Goldberg, and Ganz 2005). TMPRSS6 is not the only 
protein that can cleave hemojuvelin; furin is also thought to be able to do this, and if 
hemojuvelin interacts with neogenin, then it is perhaps even more susceptible to 
cleavage (Silvestri et al. 2008; Zhang et al. 2009). 




Figure 1.13 Putative mechanisms of iron deficiency leading to reduced hepcidin 
expression  
Abbreviations: BMP6 – bone morphogenetic protein 6; TSAT – transferrin saturation; HFE – 
hemochromatosis protein; HJV – hemojuvelin; TfR – transferrin receptor 1 or 2; SMAD – sma and mothers 
against decapentaplegic homologue 
 
Although there are still some gaps in our understanding of basic hepcidin biology, there 
is a fairly robust relationship between iron and hepcidin in the clinical setting. There are 
ample studies showing that iron loading, in both the oral and intravenous forms, leads 
to a rise in hepcidin levels. A secondary analysis of the randomised FIND-CKD trial 
showed that both oral and intravenous iron led to a rise in patient hepcidin levels, but 
that the patients’ baseline hepcidin levels did not allow the extent of the rise to be 
predicted (Gaillard et al. 2016). In contrast, hepcidin levels in iron deficient cohorts tend 
to have low hepcidin levels. As a result of monthly iron losses of between 10 and 
40mg, pre-menopausal females have been found to have lower hepcidin levels than 
males, but this gender difference is negated once the females become menopausal 
(Galesloot et al. 2011). 
 
1.3.5.2 Inflammation 
In contrast to the preceding section, our understanding of the relationship between 
acute inflammatory stimuli and hepcidin upregulation is clearer, and our knowledge in 
this area has less uncertainty compared to iron regulation and hepcidin (Figure 1.15). 
Chapter 1. Introduction 
 
58 
The role of hepcidin in inflammation resulting from infectious stimuli is perhaps 
unsurprising, since it was originally called Liver-Expressed Antimicrobial Peptide 1 
(LEAP-1) prior to the identification of its pivotal role in iron regulation (Park et al. 2001; 
Krause et al. 2000). 
 
Iron is crucial for the function of all biological systems including microbes, and under 
normal conditions is extremely tightly regulated. In acute infection, hepcidin 
upregulation not only restricts iron availability to the host, but also diminishes the 
invading organisms’ access to iron, thereby creating one of the first lines of defence of 
the innate immune system, and consequently resulting in the hypoferraemia of 
infection, which was described over 80 years ago (Cartwright et al. 1946). There is 
evidence that hepcidin is an ancient defence mechanism, as its structure and 
transcriptional machinery appears to be conserved amongst vertebrate mammals and 
fish (Figure 1.14). There is even homology with a protein found in drosophila species, 
since there is a striking resemblance between hepcidin and drosomyin, which is a 4-
disulfide defensin (like hepcidin) that is synthesised in response to infections (Krause 
et al. 2000; Lombardi et al. 2015). 
 
Figure 1.14 Sequences of mammalian and fish hepcidins 
The yellow boxes indicate the cysteine residues that are conserved across the species (reproduced from 
(Ganz 2005)) 
 
There is a veritable body of evidence supporting cytokine-induced hyperhepcidinaemia 
that was initiated by Nemeth and colleagues, who described both the direct and 
indirect impact of IL-6 on hepcidin levels. Serum iron levels fell in wild-type mice that 
were injected with turpentine, but this effect was not seen in IL-6 knockout mice. They 
went on to infuse recombinant IL-6 into healthy human subjects, and saw that these 
patients’ urinary hepcidin excretion peaked 2 hours after the end of the infusion with a 
concomitant fall in their serum iron levels (Nemeth, Rivera, et al. 2004). Other 
researchers, perhaps spurred on by this study, gained ethical approval to infuse 
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lipopolysaccharide into healthy human subjects (medical students) in order to examine 
the impact of an inflammatory activator that was upstream of IL-6; similar results were 
obtained (Kemna et al. 2005). 
 
Interleukin-6 is typically considered to be pro-inflammatory but like some other 
cytokines, it has a degree of functional pleiotropy meaning that under certain 
conditions, it can actually act in an anti-inflammatory manner. Cells that are responsive 
to the classical signalling system require those cells to express both the membrane-
bound IL-6 receptor (IL-6R) and gp130, before binding to the IL-6 ligand, thereby 
forming the IL-6R complex with ensuing downstream activation of the JAK-STAT, ERK 
and PI3K transduction pathways. It has been shown that the corollary of STAT-3 
activation in this manner leads to a net reduction in inflammation. In the context of cells 
that express gp130 alone, they can be activated by the circulating IL-6/IL-6R complex 
that requires IL-6 to associate with soluble IL-6R (trans-signalling). This eventually 
leads to activation of the immune system and a pro-inflammatory environment 
(Scheller et al. 2011).  
 
Hepcidin induction occurs with inflammatory stimuli regardless of the type of infectious 
organism. Armitage and colleagues showed that bacterial, viral, and fungal toll-like 
receptor agonists were able to induce hepcidin transcription in human PBMCs in an IL-
6 dependent manner. However, they discovered that hepcidin upregulation by candida 
albicans occurred independent of IL-6, instead relying on TGF-β, suggesting that the 
type of organism encountered by the innate immune system influenced the pathway 
that was involved in the downstream activation of hepcidin (Armitage et al. 2011). The 
same group of researchers have been very prolific in the area of infection-induced 
hepcidin induction, going on to show that HIV-1 infection, but not hepatitis B or C 
induce hepcidin, and that typhoid strongly induces hepcidin in the early phase of 
infection (Armitage et al. 2011; Armitage et al. 2014). 
 
The signalling pathway that mediates IL-6 induction of hepcidin is shown in Figure 
1.15. IL-6 activates the IL-6 receptor (which interacts with gp130) that causes 
activation of Janus Kinase (JAK), which leads to the phosphorylation of the STAT3 
protein, and this translocates to the nucleus and binds to the HAMP gene promotor and 
ultimately leads to hepcidin transcription (Verga Falzacappa et al. 2007; Wrighting and 
Andrews 2006). 
Chapter 1. Introduction 
 
60 
There remain some areas, however, that do not fit neatly into the paradigm described 
above and suggest that there is interaction between the BMP-SMAD system, and the 
JAK-STAT signalling pathways. Examples of these include SMAD4-/- mice treated with 
IL-6 that did not induce hepcidin, and LPS-treated mice increased phosphorylated 
SMAD in both wild-type and BMP6-/- mice, suggesting that upregulation of SMAD can 
occur independently of the usual BMP signalling pathways, possibly at the level of the 
hepcidin promotor (Wang et al. 2005; Besson-Fournier et al. 2012). Another example 
of crosstalk between the “iron-side” and the “inflammation-side” of the hepcidin divide 
can be seen by the influence of inflammation on TMPRSS6, causing its downregulation 
and this in turn leads to increased hepcidin expression (Meynard et al. 2013). 
 
Figure 1.15 Mechanism of hepcidin upregulation in acute inflammation 
Abbreviations: IL – interleukin; STAT – signal transducer and activator of transcription 
 
There is a distinction to be drawn between acute inflammation (or anaemia of critical 
illness), such as mediated by an infectious stimulus, and chronic inflammation, seen in 
some non-infectious conditions such as rheumatoid arthritis and inflammatory bowel 
diseases. Both acute and chronic inflammation lead to disorders of iron processing but 
perhaps manifest in slightly different ways. Patients with an acute insult often develop 
the hypoferraemia of inflammation, which can develop within a few days of a critical 
illness, but that does not necessarily translate to a reduction in blood haemoglobin or 
mean cell volume (Cunietti et al. 2004). Patients with chronic inflammatory states, 
including the anaemia of CKD, tend to exhibit anaemia with a normocytic picture and 
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EPO levels within the normal range. It is thought that this is due to a functional iron 
deficiency and a degree of EPO resistance (Barany 2001). 
 
The distinction between acute and chronic inflammation can also be inferred from data 
gathered in the pre-clinical setting. Armitage and colleagues showed that hepcidin 
production in ex vivo PBMCs were refractory to repeated stimulation by IL-6 (but not 
TGFβ) raising the possibility of a difference in the cellular handing of an acute 
inflammatory/infectious stimulus versus a persistent, chronic inflammatory stimulus. 
(Armitage et al. 2011) 
 
1.3.6 Regulation of Hepcidin 2: Other Regulators 
1.3.6.1 Erythropoiesis 
The raison d’ être of iron in vivo is the production of red blood cells, and an increase in 
erythropoietic activity, via an erythroid regulator, is therefore a potent suppressor of 
hepcidin in order to prevent polycythaemia. The search for the elusive erythroid 
regulator was a long-standing one, and was believed to be a molecule that could be 
activated by anaemia and EPO, but also allowed an increase in iron supply to the bone 
marrow (which we now know equates to the ability to suppress hepcidin production) 
(Finch 1994). Both Growth Differentiation Factor 15 (GDF15) and Twisted Gastrulation 
(TWSG1) were considered possible candidates for the role, but in recent times, the 
molecule erythroferrone has come to the fore as being able to satisfy the criteria of an 
erythroid regulator (Figure 1.12). Kautz and colleagues showed that erythroferrone was 
produced by erythroblasts in response to EPO, and it was able to suppress hepcidin 
(Kautz, Jung, Valore, et al. 2014). They were also able to show that erythroferrone 
suppressed hepcidin and thus contributed to the recovery from an induced 
inflammatory anaemia in mice (Kautz, Jung, Nemeth, et al. 2014).  
 
1.3.6.2 Hypoxia 
The link between hypoxia and erythropoiesis has been known for more than a century 
and it is this relationship that forms the basis for athletes training at altitude, in order to 
seek improved athletic performance (Berglund 1992).  Hypoxia mediates an increase in 
EPO levels that is orchestrated by the hypoxia-inducible factors (HIF) and this has 
been reviewed in great detail by Haase (Haase 2013). 
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In brief, it is the transcriptional regulator HIF that possesses an O2-sensitive α subunit, 
and under normoxic conditions, HIF is hydroxylated by prolyl dehydrogenase (PHD), 
ultimately leading to the proteasomal degradation of HIF by von Hippel-Lindau factor. 
However, in hypoxic conditions, the PHDs are inactivated thus allowing HIF to target 
the promotor of the target gene, which in the case of the EPO gene causes increased 
transcription, whereas it leads to the eventual suppression of hepcidin transcription 
probably secondary to erythropoiesis (via an interaction with C/EBPα) (Pinto et al. 
2008). Inhibition of the prolyl hydroxylases is a strategy that is currently being 
investigated in order to seek new treatments to treat CKD-anaemia (Haase 2017). 
 
It is now widely accepted that hypoxia leads to decreased hepcidin levels, and this was 
shown in a simple experiment subjecting 23 healthy volunteers to hypoxia in a 
hypobaric chamber for 6 hours, which allowed their mean pO2 to fall from 96.3 mmHg 
to 45.8 mmHg. Various parameters were longitudinally assessed, including serum EPO 
(increased), serum hepcidin (decreased), and serum platelet-derived growth factor 
(PDGF)-BB (increased). The same group also provided evidence that in murine 
models, PDGF-BB likely played a role in the hypoxia-driven inhibition of hepcidin 
(Sonnweber et al. 2014). 
 
1.3.6.3 Endocrine Suppressors of Hepcidin 
The main suppressors of hepcidin are hypoxia, anaemia, and erythropoiesis, but there 
are a range of other molecules that are capable of hepcidin suppression, including 
growth factors, steroid hormones and other endocrine factors. It has long been known 
that pituitary dysfunction can lead to anaemia resulting from a deficiency in 
testosterone, and this possibility ought to be considered amongst the differential 
diagnoses of iron-deficiency anaemia in men when more common diagnoses have 
been eliminated (Watkinson, Mc, and Evans 1947). It had been thought that 
testosterone possessed the ability to stimulate erythropoiesis via a direct effect on the 
bone marrow, but as far back as 1967, Haurani and colleagues showed that 
testosterone caused a ‘reutilisation’ of iron, and posterity has proven their work to be 
correct (Haurani and Green 1967). Through both clinical and pre-clinical work, we have 
now learnt that the most likely mechanism for testosterone’s action is by suppressing 
hepcidin through an effect on epidermal growth factor receptor signalling, thus 
increasing iron availability to the bone marrow, even in the presence of EPO-
neutralising antibodies (Guo, Bachman, et al. 2013; Bachman et al. 2010; Bachman et 
Chapter 1. Introduction 
 
63 
al. 2014; Latour et al. 2014). In separate experiments, both epidermal growth factor 
receptor and hepatocyte growth factor were shown to suppress hepcidin synthesis by 
interfering with the SMAD pathway (Goodnough et al. 2012). 
 
Hepcidin suppression is not the preserve of testosterone alone, given that the female 
sex hormones were also thought to play a role in haematopoiesis, and it has now been 
shown that 17β-oestradiol and oestrogen suppress hepcidin, albeit via a different 
mechanism (targeting the oestrogen response element in the hepcidin promotor) (Yang 
et al. 2012; Hou et al. 2012). It has also been shown that murine hepcidin levels have a 
negative correlation with bone loss and that iron levels affect osteoblastic and 
osteoclastic function, suggesting a link between the pathways regulating iron and 
mineral bone metabolism (Zhang et al. 2018). 
 
This hypothesis is further strengthened by the work of Bacchetta and colleagues, who 
were able to show that the steroid hormone, vitamin D, possessed the ability to 
downregulate hepcidin transcription in HepG2 cell culture experiments (both 25-D and 
1,25-D), as well as reducing plasma hepcidin in human experiments. Seven healthy 
human subjects were dosed with 100,000 i.u. oral vitamin D2 and their mean hepcidin 
levels fell by almost 50% within 24 hours and remained at this level for at least 72 
hours. Their mechanistic work suggested direct transcriptional suppression at the level 
of the HAMP gene (Bacchetta et al. 2014). This work has been replicated by another 
American group, who have showed similar in vitro results in THP-1 cells, and have 
produced underpowered data suggesting that vitamin D supplementation in patients 
with CKD stage 2/3 may reduce hepcidin levels (Zughaier et al. 2014). 
 
The same group, perhaps encouraged by the findings of their 2014 work, undertook a 
double-blind placebo-controlled randomised trial that strengthened the assertion that 
vitamin D suppressed hepcidin levels. Their trial included 2 groups of 14 patients who 
were well matched for age, gender, ethnicity, vitamin D deficiency and inflammatory 
status, and who were randomised to receive one dose of 250,000 i.u. of vitamin D2, or 
placebo. The patients in the study arm had approximately a 70% reduction in their 
hepcidin levels after one week, with no reduction in markers of inflammation, 
supporting the results that vitamin D directly suppresses hepcidin rather than via the 
inflammatory cellular signalling pathway(s) (Smith et al. 2017). These data do not 
appear to translate to patients with established CKD. Randomised trials in both 
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paediatric and adult CKD populations show that vitamin D does not reduce hepcidin 
levels in these groups (Atkinson et al. 2017; Panwar et al. 2018). Atkinson and 
colleagues treated two small groups (n=17) with either 400 i.u. or 4000 i.u. of vitamin 
D2 and did not show a reduction in hepcidin levels. Panwar and colleagues used 
vitamin D3 for 6 weeks and also showed no reduction in hepcidin. This may be 
explained by the fact that hepcidin elevation in moderate/severe CKD has numerous 
contributory factors and that attenuating one factor has little or no overt impact on the 
total levels. They used vitamin D3 whilst the original study by Bacchetta used vitamin 
D2. This is supported by the data generated by Zughaier and colleagues, who used 
vitamin D2 versus placebo in 19 patients with early CKD and did show a correlation 
between the change in hepcidin and change in 25(OH) vitamin D levels (Zughaier et al. 
2014).  
 
Our current knowledge of hepcidin places it directly at the centre of iron homeostasis, 
but its regulation is highly complex and influenced by a number of factors. The main 
pathways linking hepcidin to iron, inflammation, hypoxia/erythropoiesis and hormonal 
regulation have been decoded, but there are likely to be a number of other pathways 
that will be uncovered, given the pivotal role of iron in a wide range of biological 
processes. 
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1.4 Hepcidin And Its Uses In CKD 
Some of the causes of anaemia associated with renal disease, such as EPO 
dysfunction, have been covered in section 1.2.4, and the impact that both iron and 
inflammation have on hepcidin has been covered in detail in section 1.3.5. Both iron 
and inflammation are two factors that play a major role in the disordered iron regulation 
in CKD. Chronic kidney disease has long been considered a pro-inflammatory state, 
particularly marked in patients receiving chronic haemodialysis, and can be due to the 
underlying disease process leading to kidney dysfunction, reduced renal clearance of 
cytokines, susceptibility to bloodstream infections (e.g. endocarditis or discitis), sub-
clinical infections (e.g. periodontal disease), and/or dialysis-related factors (Jofre et al. 
2006; Lukaszyk et al. 2015; Malyszko et al. 2012). 
 
Patients with CKD can be in net negative iron balance leading to reduced total body 
iron stores (true iron deficiency), as they may absorb less iron via the duodenal 
enterocytes, due to excess circulating hepcidin, and suffer increased losses of iron 
from the gastrointestinal tract as a result of uraemic dysfunction. The near-ubiquitous 
use of phosphate binders in the CKD-HD patient population may cause binding of 
dietary iron in addition to their intended target, and antacids and drugs intended to 
suppress the production of gastric acid may also reduce the absorption of iron. Another 
factor that may lead to iron deficiency is frequent phlebotomy, and those on 
haemodialysis may also suffer blood losses in the haemodialysis circuit. Counter-
intuitively, the administration of ESAs themselves lead to the rapid utilisation of 
available iron stores and contribute to a relative iron deficiency (Babitt and Lin 2010). 
In contrast to true iron deficiency, functional iron deficiency is characterised by the 
presence of adequate total body iron stores, but the depleted plasma iron pool is 
denied access to the iron as it is detained in the iron-storage cells (hepatocytes and 
splenic macrophages) by hepcidin. Many groups have shown that the renal clearance 
of hepcidin declines as the eGFR declines, including some of the work contained within 
this thesis, and this is one of the main contributory factors to elevated hepcidin levels in 
CKD (Tomosugi et al. 2006; Zaritsky et al. 2009; Ashby et al. 2009; Weiss et al. 2009). 
 




Figure 1.16 Regulation of iron homeostasis by hepcidin in CKD 
(Abbreviations: FPN – ferroportin; ESA – erythropoiesis-stimulating agent) 
 
The main factors that cause an elevation of hepcidin in CKD are reduced renal 
clearance, inflammation, and the use of intravenous iron, allowing increased hepcidin 
binding to its receptor (ferroportin) in the liver, duodenum and macrophages, 
preventing iron delivery to the bone marrow. In order to maintain red cell production, 
intravenous iron is used to bypass the problems of gastrointestinal iron absorption, and 
ESAs are administered (which causes hepcidin inhibition). Once the red cells reach the 
end of their lifespan, splenic macrophages are on hand to recover iron through 
erythrophagocytosis (Figure 1.16). 
 
Other potential factors that can influence hepcidin include obesity, vitamin D deficiency 
(see 1.3.6.3), and hyperparathyroidism. Obesity has been associated with iron-
deficiency anaemia and elevated hepcidin levels, possibly as a consequence of 
increased inflammatory cytokines, but the effect is offset in haemodialysis patients, 
where no difference is seen between obese and non-obese haemodialysis patients 
(Amato et al. 2010; Sarafidis et al. 2012).  
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Although there are data to suggest an improvement in ESA hyporesponsiveness 
following surgical parathyroidectomy for tertiary hyperparathyroidism, there is no direct 
evidence supporting hyperparathyroidism as a cause of ESA hyporesponsiveness 
(Bamgbola 2011). Currently, there is no evidence connecting hyperparathyroidism with 
hepcidin regulation. 
 
Linking small molecules such as hepcidin or fibroblast growth factor 23, and ESA 
hyporesponsiveness, is problematic due to the multifactorial nature of this condition. 
There is evidence that the CKD-MBD and iron regulatory pathways are not discrete 
entities but may actually be interdependent in a way that has not yet been fully 
elucidated. Examples of the interplay between the two pathways include vitamin D, 
which has a clear role in the CKD-MBD pathway and yet is a direct transcriptional 
suppressor of hepcidin (Bacchetta et al. 2014). Iron-induced renal phosphate wasting, 
via FGF23 induction, is another phenomenon suggesting a link between the 2 
pathways (Schouten et al. 2009). 
 
1.4.1 Measuring Hepcidin 
Despite the sterling efforts of clinical biochemists in the field to address this issue, the 
determination of hepcidin levels remains an area in which there is little standardisation, 
and the normal reference ranges vary markedly from laboratory to laboratory (Kroot et 
al. 2009). There are currently 4 main types of assays that are available for use; mass 
spectrometry, competitive ELISA, radioimmunoassays, and ligand binding assays, but 
it is the first two that have chiefly been employed in the measurement of hepcidin. 
As bioactive hepcidin is only 25 amino acids in length, generating a specific antibody 
has proved challenging, as the antibodies employed in ELISAs are often subject to 
non-specific antigen binding. Ganz and colleagues developed an ELISA with a 
biotinylated hepcidin as a tracer, which had no reported cross-reactivity with hepcidin-
20 or -22, but they nevertheless reported reference values that were nearly 7-fold 
higher than measurements with mass spectrometry assays. Levels of the non-bioactive 
hepcidin isoforms are demonstrably higher in renal failure, and it may be that antibody 
cross-reactivity particularly affects measurements in CKD (Macdougall et al. 2010; 
Ganz et al. 2008).  
 
Mass spectrometry works by determining the elemental composition and structure of 
peptides, by means of molecular fragmentation and the generation of charged species. 
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Measurement of the mass-to-charge ratio is enabled when positive ions hit a charged 
end plate and generates a signal, which can then be deciphered (Figure 1.17). 
 
 
Figure 1.17 Schematic representation of mass spectrometric analysis 
 
There are a number of mass spectrometry assays that have been deployed to detect 
hepcidin-25, including MALDI (Matrix-Assisted Laser Desorption Ionisation) and SELDI 
(Surface Enhanced Laser Desorption Ionisation), with or without the addition of TOF 
(Time-of-Flight) measurements, and Liquid Chromatography MS/MS. The differences 
between the various assays have been extensively reviewed elsewhere (Macdougall et 
al. 2010). 
 
Mass spectrometry is considered superior to ELISAs and relies on expensive 
equipment, is labour intensive, and few laboratories possess the required technical 
expertise to ensure reliable results are obtained. Laboratories measuring hepcidin 
using both mass spectrometry and ELISA participated in a ‘round-robin’ exercise 
designed to harmonise laboratory processes with the intention of agreeing methods. 
Although the individual assays were generally found to have a low within-sample 
variance, there was a high degree of non-concordance between assays, which was 
somewhat mitigated following the development of an algorithm using the results of the 
analysis. Some of the reasons cited were the difference in hepcidin internal standards 
and a lack of a reference measurement procedure (RMP) given that reference 
materials for hepcidin do not exist (Kroot et al. 2012). A more recent attempt to 
navigate this issue has led to the identification of a commutable secondary reference 
material, which is an encouraging development and will hopefully allow standardisation 
of hepcidin measurement results in the future (van der Vorm et al. 2016). 
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There are a number of factors including age, gender, and circadian rhythm that 
influence hepcidin levels and there is little doubt that these will have an impact on any 
future reference tables that are produced. Hepcidin levels are similar in childhood, with 
no difference between boys and girls, but levels vary following the transition into 
adulthood, with adult females having lower hepcidin (and ferritin) levels compared to 
adult males. The literature appears split, with Zaritsky and colleagues finding nearly 
double the hepcidin level in adults versus children, whereas Sdoguo and colleagues 
found higher levels in children (Zaritsky et al. 2009; Sdogou et al. 2015). The disparity 
may be explained by possible differences in iron handling, illustrated by the linear 
relationship between ferritin and hepcidin in virtually all the published adult literature, 
which is in stark contrast to the childhood data, where no correlation exists between 
the two biomarkers. However, there is agreement that hepcidin is subject to a diurnal 
variation, except in end-stage renal failure (Sdogou et al. 2015; Galesloot et al. 2011; 
Ashby et al. 2009). 
 
1.4.2 Hepcidin As A Biomarker 
As discussed in section 1.2.6, the current biomarkers that are at our disposal for iron 
status evaluation are limited, as they are unable to reliably estimate total body iron 
stores or predict the response to iron therapy (Coyne et al. 2007; Singh et al. 2007). 
The discovery of hepcidin led to renewed hopes of the emergence of a biomarker that 
was fit for purpose, but alas, these have not been realised. In all the published adult 
data on hepcidin levels to date, the extremely strong linear correlation with ferritin 
levels remains the only constant finding, leaving the distinct possibility that hepcidin is 
no better than ferritin as a marker of iron stores (Ashby et al. 2009; Zaritsky et al. 2009; 
Galesloot et al. 2011). Additionally, there are a number of confounding factors that 
impact on hepcidin levels (Figure 1.16), and there is also no convincing evidence that 
hepcidin can be used to reliably predict a patient’s response to iron therapy. 
 
Tessitore and colleagues examined the merits of percentage of hypochromic red cells 
(%hypo), reticulocyte haemoglobin content (CHr), hepcidin-25 (hep-25), and hepcidin-
20 (hep-20), as markers of iron responsiveness in a cohort of 56 haemodialysis 
patients receiving intravenous iron therapy, and found that the best performing 
biomarker was the percentage of hypochromic red cells (Figure 1.18). In contrast, both 
hepcidin isoforms were comparatively poor predictors of iron responsiveness, and only 
performed marginally better than the flipping of a coin (Tessitore et al. 2010). Weiss 
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and colleagues also produced data in 20 haemodialysis patients that showed 
intravenous iron did not cause a rise in hepcidin levels; both studies used mass 
spectrometry assays (Weiss et al. 2009). 
 
Figure 1.18 Diagnostic accuracy for iron responsiveness by ROC curve analysis 
Abbreviations: %Hypo – percentage of hypochromic red cells; CHr – reticulocyte haemoglobin content; 
Hep – hepcidin; AUC – area under the curve  (reproduced from (Tessitore et al. 2010)) 
 
In contrast, there are other research groups that have produced data showing that 
intravenous iron leads to a rise in hepcidin; Tomosugi and colleagues used mass 
spectrometry but only reported on the effects in 2 patients, whilst Malyszko and 
colleagues had more patients (12), but used an ELISA assay (DRG), which may have 
been a confounder (Tomosugi et al. 2006; Malyszko, Malyszko, and Mysliwiec 2009). A 
subset of non-HD CKD patients were assessed as part of the FIND-CKD trial, and the 
administration of iron elicited a positive hepcidin response, but neither the baseline 
hepcidin levels nor delta hepcidin levels were predictors of the responsiveness to iron 
therapy (Gaillard et al. 2016). 
 
In the non-renal population where hepcidin levels are not confounded by reduced 
glomerular clearance, Bregman and colleagues showed that hepcidin possessed the 
ability to predict non-responsiveness to oral iron therapy in those with iron-deficiency 
anaemia (Bregman et al. 2013). 
 
Therefore, in the arena of iron management in CKD, there is no evidence that hepcidin 
offers an advantage over the currently available biomarkers. Other markers that have 
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generated interest since the discovery of hepcidin include soluble hemojuvelin (sHJV), 
and growth differentiation factor 15 (GDF15). Soluble HJV levels have been shown to 
fall following iron therapy, and levels are increased in iron deficiency, but studies 
examining its use as a biomarker are still required (Brasse-Lagnel et al. 2010; Chen et 
al. 2013). GDF15 plays a role in the erythropoietic regulation of hepcidin (Figure 1.12) 
but like hepcidin, it is influenced by iron, inflammation and CKD, which may limit its 
usefulness as a ferric biomarker (Theurl et al. 2010). 
 
Attempting to find a biomarker that helps us refine patient care to the level being 
discussed may require a shift from cellular biology to genomics, and there has been a 
distinct shift in the U.K. towards ‘personalised medicine’, following in the wake of the 
100,000 genomes project (Turnbull et al. 2018). A gene currently attracting interest is 
TMPRSS6, which encodes matriptase-2 ultimately resulting in the decreased 
expression of hepcidin, by cleaving membrane-bound hemojuvelin. A rare, loss-of-
function germline mutation is implicated in IRIDA (see section 1.3.3), but more subtle 
genetic variants may theoretically help predict the response to iron therapy in CKD. 
  
Pelusi and colleagues evaluated polymorphisms in the TMPRSS6 (A736V) and HFE 
(C282Y, H63D) genes in 183 haemodialysis patients (compared to 188 controls) and 
sought to determine if there were any relationships with hepcidin and in markers of 
erythropoiesis and iron status. They found that patients with HFE mutations had lower 
hepcidin levels. They concluded that patients with the A736V TMPRSS6 (V/V variant) 
genotype had higher hepcidin levels and may possibly impact on anaemia 
management in haemodialysis patients. A prospective analysis will be necessary to 
see if it possesses any utility in this area (Pelusi et al. 2013). Other genome-wide 
association studies involving TMPRSS6 reveal that women suffering with menorrhagia 
who are RS855791 C homozygotes are less susceptible to iron-deficiency anaemia 
(Pei et al. 2014). Although this area of investigation is in its relative infancy, it clearly 
has the potential to revolutionise the assessment and treatment of patients with CKD-
anaemia. 
 
1.4.3 Hepcidin As A Therapeutic Target In CKD 
Hepcidin excess is thought to play a significant role in the pathogenesis of renal 
anaemia, and a number of therapeutic strategies have been pursued in order to 
antagonise hepcidin with the potential of new treatments emerging. These strategies 
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seek to block either the ligand (hepcidin) or its action on the receptor (ferroportin), or by 
interfering with the intracellular signalling pathways (Figure 1.19). 
 
1.4.3.1 Dialysis Clearance 
But perhaps the simplest method available to modulate hepcidin in the haemodialysis 
population is by increasing dialysis adequacy. It is well known that increasing 
clearance of small and medium-sized molecules leads to an ensuing reduction in ESA 
dosing, and it is possible that this is in part mediated by increased clearance of 
hepcidin (Ifudu, Feldman, and Friedman 1996). There are multiple studies confirming 
that hepcidin is cleared by dialysis, although some of them report that hepcidin levels 
rebound to pre-dialysis levels very quickly after the end of the session (Weiss et al. 
2009; Zaritsky et al. 2010; Campostrini et al. 2010; Peters et al. 2010; Kuragano et al. 
2010). The efficiency of hepcidin removal may differ according to the type of 
haemodialysis membrane used. For instance, high-volume online haemodiafiltration 
had been shown to be superior to standard low-flux bicarbonate haemodialysis 
following 6 months of treatment in both reducing hepcidin levels and improving the 
ESA resistance index (Panichi et al. 2015). 
 
1.4.3.2 Hepcidin/HAMP Antagonism 
Monoclonal antibodies raised against hepcidin have been successfully used to treat 
anaemia in mice and non-human-primates, and the molecule LY2787106 is in early-
phase trials to treat cancer-related anaemia (Sasu et al. 2010; Cooke et al. 2013; 
Vadhan-Raj et al. 2017). Other small proteins such as anticalins and spiegelmers are 
able to target and bind to specific ligands. In the sphere of direct anti-hepcidin agents, 
Pieris Pharmaceuticals have engineered PRS-080, an anticalin technology that has 
been developed to exhibit sub-nanomolar affinity for hepcidin. It has passed through a 
successful trial in primates in lowering hepcidin and raising iron levels and will next be 
tested in phase 1 human trials (Hohlbaum et al. 2018). Anticalins are based on 
naturally occurring lipocalins, whereas spiegelmers are synthetic compounds that 
potentially bind to their targets in a manner similar to antibodies. Lexaptepid pegol 
(NOX-H94) has been shown to be safe in healthy human subjects, and is currently in 
phase 2 clinical trials (Boyce et al. 2016). The company that have produced the 
spiegelmer technology (Noxxon Pharma) have another 2 candidate molecules for use 
in CLL and diabetic nephropathy. 
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Agents that inhibit HAMP transcription include vitamin D, testosterone, and oestrogen, 
and molecules involved in erythropoiesis, and have been discussed in section 1.3.6.3. 
Another molecule, K7174, was also shown to indirectly downregulate HAMP 
transcription by induction of GDF15, but does not appear to have been taken forward 
to clinical trials (Fujiwara et al. 2013). 
 
1.4.3.3 Ferroportin-Hepcidin Interference 
Ross and colleagues generated fully human anti-human antibodies against the 
ferroportin receptor in vitro with the potential for translation trials, and produced a 
thorough review of the current data (Ross et al. 2017). One other such molecule has 
already passed through the phase 2 clinical trial stage of development. LY2928057 is a 
humanized immunoglobulin (IgG4) monoclonal antibody, which binds to ferroportin and 
prevents the action of hepcidin and the degradation of ferroportin without affecting iron 
efflux. It has been shown to be safe in CKD patients, and although the expected 
changes in iron parameters were seen, this did not translate into a rise in haemoglobin 
(Barrington et al. 2016). Fursultiamine is a thiamine derivative that was shown to bind 
to ferroportin (inhibiting the action of hepcidin) in vitro, but did not perform well in in 
vivo studies (Fung et al. 2013). 
 
1.4.3.4 BMP-Hemojuvelin-SMAD Pathway Inhibitors 
Most of the strategies that have been developed to date target the BMP signalling 
system, either by disrupting the ligand (BMP) or the adjacent molecular structures 
including the BMP receptors (I,II), or by modulating the BMP co-receptors. 
 
Hemojuvelin is the main co-receptor for the BMP receptors, and it is cleaved leading to 
the formation of soluble hemojuvelin (sHJV), which is a negative regulator of BMPs. 
There was much interest in the action of sHJV, and an sHJV.Fc fusion protein was 
created by the fusion of the extracellular domain of the BMP co-receptor HJV to the Fc 
portion of human immunoglobulin G (Babitt et al. 2007). Although the fusion protein 
was successful in reducing hepcidin levels and correcting anaemia in an inflammatory 
rodent model, clinical trials of FMX-8 (Ferrumax Pharmaceuticals) have been 
discontinued due to lack of recruitment (Theurl et al. 2011; ClinicalTrials.gov. Bethesda 
(MD): National Library of Medicine (US) 2016). Another potent inhibitor of BMPs is 
heparin, but its anticoagulant properties preclude the use of high doses in man. Non-
anticoagulant heparins (SST0001/Roneparstat) have been designed to circumvent this, 
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and there are encouraging signs that this might provide a useful line of treatment in 
clinical settings (Poli, Asperti, Naggi, et al. 2014; Galli et al. 2018). There are other 
molecules that antagonise BMPs including BMPER and SOSTDC1 but as yet, have not 
been investigated in clinical settings (Patel et al. 2012; Tesfay et al. 2015). 
 
Agents that suppress hepcidin synthesis by way of BMP-receptor I inhibition include 
the dorsomorphin derivative, LDN-193189, which successfully ameliorated an 
inflammatory anaemia in a murine model, and plans are afoot to prepare the drug for 
testing in humans (Mayeur et al. 2015; National Institutes of Health Bethesda (MD) 
2017). Another molecule, TP-0184, modulates hepcidin levels in a similar manner to 
LDN-193189, and is slightly further ahead in its drug development, but recruitment to 
the first-in-man clinical trial has yet to commence (Peterson et al. 2017; 
ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US) 2018). 
 
As the main co-receptor to the BMP receptors, there has been a huge focus on 
hemojuvelin neutralisation, as it leads to a suppression of hepcidin synthesis. At least 2 
antibodies (ABT-207 and h5F9-AM8) have been raised against hemojuvelin; both have 
been efficacious in pre-clinical rodent and simian studies, and are being further 
developed by Abbvie (Boser et al. 2015; Kovac et al. 2016). 
 
Alnylam Pharmaceuticals developed gene silencing technology using small interfering 
RNAs (siRNAs), which have been used to knock down gene expression targeting a 
number of genes including HAMP, HJV, and HFE. They were shown to be effective in 
a host of animal models of inflammatory anaemia (Akinc et al. 2011). The company do 
not appear to have taken this therapeutic approach forward in CKD-anaemia but are 
working on other strategies targeting iron overload conditions. 
 
1.4.3.5 Disruption of IL-6/JAK/STAT Pathway 
The hepcidin “inflammatory pathway” appears to have garnered the most success in 
terms of therapeutics that have gained regulatory approvals. Toclizumab is a 
humanised anti-IL-6 receptor antibody that is used in patients with rheumatoid arthtitis 
and idiopathic juvenile arthritis, and it has been shown to reduce hepcidin in patients 
with Castleman disease (Song et al. 2010). Siltuximab is a murine-human chimeric 
monoclonal antibody directed against IL-6 and is approved for use in Castleman 
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disease. Retrospective data suggests that it too downregulates hepcidin levels when 
used in multiple myeloma or Castleman disease (Casper et al. 2015). 
 
Downstream of the IL-6 receptor, there are 3 molecules that inhibit the JAK-STAT 
intracellular signalling pathway. AG490 disrupts JAK, and PpYLKTL and curcumin 
disrupt STAT, respectively. AG490 has been shown to have some in vivo activity 
against hepcidin (Zhang et al. 2011). PpYLKTL has also been shown to have in vivo 
effects against hepcidin, whereas curcumin, which is a naturally occurring compound 
found in turmeric that is liberally used in South Asian cooking, reduces hepcidin in vitro, 
but conversely has also been shown to be an iron chelator (Fatih et al. 2010; Jiao et al. 
2009). Currently, none of these have progressed to clinical development. 
 
 
Figure 1.19 Overview of hepcidin antagonists 
Abbreviations: BMP6 – bone morphogenetic protein 6; BMPR – bone morphogenetic protein receptor; 
ESA – erythropoiesis-stimulating agent; GDF15 – growth differentiation factor 15; HJV – hemojuvelin 
(membrane and soluble); IL6 – interleukin 6; IL-6R – interleukin 6 receptor; JAK – Janus kinase; MT2 – 
matriptase 2; SMAD – sma and mothers against decapentaplegic; STAT – signal transducer and activator 
of transcription 
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1.5 Aims And Objectives Of Thesis 
In conclusion, this is an expanding field of knowledge and research, although there 
remain huge gaps, especially in the basic science regulation of hepcidin. It is an area 
of discovery that is highly relevant to CKD-anaemia, and hepcidin antagonism is an 
aspect that is being exploited in order to bring new potential anaemia treatments to the 
therapeutic arena. 
The aim of this thesis was initially developed from the following two primary research 
questions: is hepcidin elevated in CKD/haemodialysis patients (chapter 3) and is this a 
result of increased production of hepcidin/HAMP transcription (in PBMC monocytes) 
(chapter 4)? The main finding from chapter 4 was the downregulation of HAMP mRNA 
in PBMC monocytes in haemodialysis patients (compared to healthy controls) with 
approximately 10 times the serum hepcidin levels. In chapter 5, I set out to answer 
whether there was a circulating factor within the plasma of these dialysis patients that 
was impacting on HAMP by incubating human hepatocytes in plasma. Through the 
serendipitous use of heparin to prevent coagulation in cell culture, I realised that 
heparin was in fact a potent inhibitor of HAMP transcription. The project then evolved 
to look for ways that hepcidin could be reduced in CKD patients, and I then set out to 
examine whether it was the use of heparin in haemodialysis patients that led to the 
downregulated HAMP (from chapter 4) by measuring HAMP expression in heparin-
naïve patients following the administration of heparin (chapter 6). I sought to examine 
other ways of inhibiting hepcidin production through the use of corticosteroids (chapter 
7), given that the steroid hormone vitamin D had been shown to do this. 
The objectives were implemented by the following means: 
1. Use of a case-control design to match patients from the haemodialysis, 
transplant and CKD stage 4/5 populations. 
2. Use of PBMCs cultivated ex vivo from haemodialysis patients as a means of 
assessing hepcidin production in this patient population. 
3. Use of HepG2 cells for in vitro work to assess the effect of cytokines 
(interleukin-6). 
4. Use of dexamethasone and heparin administration on HAMP mRNA in HepG2 
cells. 
5. Use of a patient model of systemic (including renal) inflammation to study the 
effect of methylprednisolone on hepcidin levels to ascertain for the first time 
whether this corticosteroid could modulate hepcidin levels as has been shown 
for other steroid hormones.   
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2 Materials and Methods 
Dr Sukhi Bansal, Reader in Pharmaceutical Chemistry, performed the mass 
spectrometry measurements of hepcidin-25 levels in the Franklin-Wilkins Building, 
Waterloo Campus, King’s College London, and the methodology is available elsewhere 
(Bansal et al. 2010).  All other methodologies including cell culture, RNA extraction and 
reverse transcription, RT-qPCR, protein extraction and immunoblotting were performed 
by this investigator, in the Renal Laboratory at the Rayne Institute, Denmark Hill, King’s 
College London. 
 
2.1 Cell Culture 
2.1.1 HepG2 Cells 
Professor Andrew McKie (King’s College London) gifted HepG2 cells that were used 
during the experiments undertaken in this thesis. HepG2 cells are human hepatoma 
cells that were derived from a 15-year-old Caucasian male with hepatocellular 
carcinoma and have been used in many studies that have investigated the cellular 
regulation of hepcidin. 
 
The cells were incubated in a Techne incubator in a humidified atmosphere containing 
5% CO2, set to a temperature of 37°C. HepG2 cells were routinely cultured in 
Dulbecco’s modified Eagle Medium (DMEM), which was supplemented with ‘high’ 
glucose, and L-glutamine, with the further addition of two antimicrobial agents, 
penicillin and streptomycin. The common working concentration for penicillin was 100 
U/mL, and 100 μg/mL for Streptomycin (both from ThermoFisher Scientific, see Table 
2.2). Fetal bovine serum (10%, Sigma) was added to the culture medium to provide a 
rich variety of proteins in order to help the cells grow and divide. When the cell 
confluence reached 70-80%, the cells were prepared for experimental use and were 
simultaneously subcultured to extend the cell lineage. Cells that had been passaged (a 
maximum of) 5 times or fewer were used for experimental purposes. 
 
This adherent cell line was grown in 75cm2 flasks (431464, Corning, UK) and at the 
time of passaging, the cells were twice thoroughly washed with PBS (D8537, Sigma-
Aldrich) prior to the addition of 2mL trypsin EDTA (ThermoFisher Scientific) in order to 
detach the cells from the flask. The trypsin-bathed cells were incubated for a maximum 
of 5 minutes before 18mL culture medium was added to dilute the trypsin and 
inactivate it. The cells were washed with PBS and centrifuged (Heraeus Labofuge 400) 
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at 15000G for 5 minutes in order to completely remove all the trypsin in the 
supernatant. Following the removal of the supernatant, the cells were washed with 
PBS, and re-suspended in 20mL of warmed medium. The cell pellet was suspended in 
37°C medium to allow cell counts (by way of a haemocytometer), and cell viability tests 
(using trypan blue) to be performed prior to plating in experimental dishes measuring 
either 35 or 60cm in diameter (Greiner Bio-one 627 160 or 627 160, respectively).  
 
2.1.2 Peripheral Blood Mononuclear Cells 
Primary peripheral blood mononuclear cells (PBMCs) were isolated following the 
donation of blood from volunteers and patients within the Renal Unit. Donor blood was 
collected in EDTA tubes, and gently layered onto Ficoll® Paque Plus density gradient 
media (GE Healthcare) to allow a sharp delineation to form between the two media 
(Figure 2.1). The separation protocol was undertaken using either a 15mL or 50mL 
Falcon conical flask, depending on whether 10mL or 30-35mL whole blood was 
donated. The remainder was made up by Ficoll® Paque Plus. 
 
Figure 2.1 Separation of blood using density gradient media 
 
The Falcon tubes were then centrifuged (Heraeus Labofuge 400) at 1200 RPM at 4°C 
with no brake for 30 minutes, to prevent mixing and to allow separation of the various 
blood components (plasma, PBMCs, and blood cells). The plasma was siphoned off 
and aliquoted (500μL), and then the PBMCs were isolated. The PBMC layer was 
transferred to a fresh 50mL Falcon tube and the cells were washed twice with buffer 
solution (PBS and 2.5mM EDTA) by centrifugation at 1800 RPM for 8 minutes. Cell 
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counts and viability testing were then performed once the PBMCs had been re-
suspended in RPMI-1640 (ThermoFisher Scientific). 
 
The amount of blood obtained from individuals determined the number of PBMCs that 
could be isolated. On average, 2.5mL whole blood would yield in the region of 5x106 
PBMCs. The PBMCs were then immediately placed through the RNA extraction 
protocol, or re-suspended in RPMI-1640 and plated at a concentration of 5x106 
cells/mL at 37°C in 5% CO2 for work that involved cytokine stimulation. 
 
2.2 Recombinant Peptide/Drug Treatments  
Recombinant peptides were purchased from R&D Systems (USA) and Life 
Technologies (USA), and were reconstituted according to the manufacturers’ 
instructions (Table 2.1). Controls were created for all the treatments listed, depending 
on the excipient specified by the relevant manufacturer. A number of drugs were used 
in vitro and were obtained from the companies listed in Table 2.2. 
 
Recombinant peptide Company Catalogue number 
BMP-6 (20μg) R&D systems 507-BP-020 
IL-6 (10μg) Life Technologies PHC0065 
Table 2.1 List of recombinant peptides used in vitro 
 
Drug Company Catalogue number 
Dexamethasone Sigma-Aldrich D4902 
Enoxaparin (Clexane®) Sanofi-Aventis N/A 
Heparin sodium LEO Pharma N/A 
Penicillin ThermoFisher Scientific 15070-063 
Streptomycin ThermoFisher Scientific 15070-063 
Table 2.2 List of drugs used in vitro 
 
2.3 RNA Extraction 
All work surfaces were cleaned with detergents and industrial methylated spirits prior to 
RNA extraction. An RNase decontamination solution (AM9780, Invitrogen) was used 
for added security against RNases. The QIAshredder (79654, Qiagen) and RNeasy 
Mini Kits (74104, Qiagen) were the kits used in the extraction of RNA from cellular 
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material, and used according to the manufacturers’ instructions, and all the steps took 
approximately 23-30 minutes in total to complete, depending on the number of samples 
that were processed. Ethanol and beta-mercaptoethanol were not provided in the kit, 
but necessary for RNA extraction. All RNA that was obtained was aliquoted and then 
immediately stored at -80°C for reverse transcription. 
 
2.4 Reverse Transcription 
Reverse transcription from RNA to cDNA was undertaken using the High Capacity 
RNA-to-cDNA Kit (4387406, Applied Biosystems), according to the manufacturer’s 
instructions. An 8-well NanoDrop spectrophotometer (ThermoFisher Scientific) was 
utilised to determine the quantity and purity of the RNA prior to reverse transcription. 
Samples were then pipetted into 96-well reaction plates (N801-0560, Applied 
Biosystems) combined with the reagents supplied by the manufacturer, to a total 
volume of 20μL. This kit contained random octamers and oligo dT-16 primers, which 
have a high specificity for mRNA. The samples were heated in a cyclical manner (Veriti 
Thermal Cycler, Applied Biosystems) for 65 minutes, consisting of 60 minutes at 37°C 
and 5 minutes at 94°C, before being cooled to 4°C; 80μL of RNase-free water (129112, 
Qiagen) was added to each sample to bring the reaction to a complete halt. Samples 
were immediately stored at -20°C. All samples had a non-reverse transcriptase control 
created for use in qPCR. 
 
2.5 Quantitative PCR 
Real time PCR was conducted using the cDNA obtained from section 2.4. TaqMan 
Gene Expression Assays (Applied Biosystems, USA) were used for the detection of: 
1. HAMP mRNA (Hs00221783_m1) as the gene of interest 
2. GAPDH mRNA (Hs02758991_g1) as the housekeeping gene 
 
The primer-probes were combined with TaqMan Universal PCR Master Mix (4324018, 
Applied Biosystems), RNase-free water and the reverse-transcribed cDNA (from 
section 2.4). Volumes of 10μL per sample, which were tested in triplicate, were placed 
in a 384-well plate (4309849, Applied Biosystems), and a QuantStudio 7 Flex Real 
Time PCR System (Applied Biosystems) was used to perform the analysis that would 
determine the expression of the target gene relative to the housekeeping gene. For 
each experimental run, all the samples were defrosted and subsequently kept on ice. 
Each sample tested was made up to a final volume of 10μL, and this consisted of 
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Master Mix (5μL), prime probe (0.5μL), water (2.5μL), and cDNA (2μL). The total 
number of samples was calculated in advance and a mixture of all the elements listed 
above (except the cDNA) was made, and 8μL pipetted into each well along with the 
cDNA. The TaqMan assays are optimised to run as follows; 50°C for 2 minutes, 95°C 
for 10 minutes, and a final stage that cycles 40 times between 95°C (15 seconds) and 
60°C (60 seconds). 
 
 
Figure 2.2 Schematic representation of the TaqMan gene expression assay 
process 
(Abbreviations: FAM – dye; Q – non-fluorescent quencher; MGB – minor groove binder) 
 
TaqMan expression assays comprise a pair of primers, a TaqMan probe with a FAM™ 
dye label on the 5' end and a non-fluorescent quencher on the 3’ end, and TaqMan 
DNA polymerase. The initial heating allows the cDNA (Figure 2.2, A) to denature into 
single strands, and the temperature is lowered, thus allowing the primer and probe to 
anneal to their targets (Figure 2.2, B). Taq DNA polymerase allows the synthesis of 
new strands (Figure 2.2, C) and upon reaching the TaqMan probe, its endogenous 
nuclease activity cleaves the probe causing the FAMTM dye to separate from the probe 
and fluoresce (Figure 2.2, D). The fluorescence intensity is proportional to the amount 
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of amplicon synthesised, and reflective of the quantity of the target gene 
(ThermoFisher Scientific 2018). The cycling process allows the accumulation of a 
fluorescent signal during amplification. Control samples included non-template 
controls, serving as a general control for extraneous nucleic acid contamination. 
 
TaqMan assays are highly sensitive and allow the detection of differences as little as 
two-fold in gene expression. Each sample is assessed for the gene expression of the 
target gene, and the housekeeping gene, and a relative comparison is made to 
quantify the amount of the gene present. The cycle time (Ct) value is the number of 
cycles at which the fluorescence reaches a pre-determined threshold set/optimsed by 
the machine, and values are given for all the genes for a particular sample. The earlier 
a sample reaches the threshold, the lower the Ct value and the higher the amount of 
target gene. 
 
The method of calculating relative gene expression (HAMP vs GAPDH) was performed 
as follows: 
                        
 
2.6 Protein Extraction 
2.6.1 Cell Lysates 
Total cell lysates were extracted from HepG2 cells by the addition of 200μL of a 




Leupeptin 0.5 μg/ml 2μL 
Pepstatin 1.0 μg/ml 4μL 
EDTA 1.0 mM 40μL 
PMSF 0.2 mM 40μL 
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To allow for the detection of phosphorylated proteins, phosphatase inhibitors (1mM 
sodium orthovanadate, 25mM sodium fluoride) were added to 5mL of the above 
solution to create the protein extraction buffer. The cells were washed twice with ice 
cold PBS and harvested in the buffer and left for 45 minutes on ice, before the cells 
were scraped and homogenised using a 1mL syringe and a 22G needle (Terumo) to 
mechanically disrupt the cells. The homogenates were centrifuged at 4°C at 14000 
RPM for 10 minutes (Mikro 22R, Hettich), to separate cellular debris from the protein-
rich supernatant.  
 
2.6.2 Protein Quantification 
The supernatants from the samples were collected in labelled eppendorf tubes and the 
protein content determined using a spectrophotometric method detecting colorimetric 
absorbance at a wavelength of 562nm. Quantification of protein within the study 
samples was calculated using the Pierce™ BCA Protein Assay Kit (23225, 
ThermoScienific), and compared to pre-prepared protein standards with known 
concentrations of protein containing bovine serum albumin (BSA). The BSA 
concentrations were diluted to form a standard curve (0 mg/mL to 2mg/mL), against 
which the experimental samples were compared, in order that their protein 
concentrations were ascertained. 10μL of homogenate had been diluted up to 8-fold 
and pipetted into a 96-well plate. 
 
The assay is a two-component, high precision assay reagent set, and instructions were 
followed as detailed by the manufacturer. Briefly, this included the sequential addition 
of 2 separate reagents at a ratio of 40:1, resulting in a green solution. 200μL of the 
mixture of the reagents was subsequently added to each well. The presence of protein 
transformed the colour of the mixture from green to purple. The plate was then 
incubated at 37°C for 20 minutes and the optical densities of each well were then 
measured using a plate reader set to a wavelength of 562nm. The samples were 
normalised to a protein concentration of 1-2μg/μL, and 10μL of the sample was added 
to 2μL of betamercaptoethanol and 3μL of Western Sample Buffer in preparation for 
immunoblotting. These samples were heated to 100°C for 5 minutes to denature the 
proteins. 
 




2.7.1 Preparation Of Polyacrylamide Gel 
Gels were made of a stacking and running gel, to allow the proteins to cluster before 
running through the running gel that is achieved through the application of voltage 
across the gel. The stacking gel has a low concentration of acrylamide and the 
running gel a higher concentration capable of slowing the movement of the proteins. 
 
10mL stacking gels were prepared using a combination of water (6.8mL), 30% 
acrylamide mix (1.7mL), 10% SDS (0.1mL), 1.0M Tris (pH 6.8) 1.25mL, 10% 
ammonium persulphate (0.1mL), and Temed (0.01mL). 
 
20 mL running (also known as resolving gels, 12%) were prepared using a combination 
of water (6.6mL), 30% acrylamide mix (8.0mL), 10% SDS (0.2mL), 1.5M Tris (pH 8.8) 
5.0mL, 10% ammonium persulphate (0.2mL), and Temed (0.008mL). 
 
2.7.2 Gel Electrophoresis 
The Bio Rad Trans-Blot® Cell system was used according to the manufacturer’s 
instructions. The polyacrylamide gel was placed into the gel holder and electrophoresis 
buffer was added to the system. Five litres of this was prepared using the following 
ingredients: 60.4g Tris, 288g glycine, 20g SDS; q.s. as 5L with distilled deionised water 
made up to 1 litre. The protein samples were loaded onto the gel and 200 volts was 
applied for 1-2 hours in order to obtain the widest possible separation of the samples. 
 
The samples were then transferred from the gel to a nitrocellulose membrane using the 
same system as above, with Towbin transfer buffer. The expression of ferroportin, 
SMAD5, STAT3, and phosphorylated SMAD 1/5 and STAT3 proteins were determined 
by immunoblotting. The samples were prepared by adding loading buffer consisting of 
β-mercaptoethanol (βME), bromophenol blue, EDTA, glycerol, SDS, and Tris HCL (pH 
6.8). The samples were heated at 100°C in order to denature the proteins. 
 
Total cell extracts (10-20μg) were separated on 12% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gels that were made with 30% 
acrylamide, 10% ammonium persulphate, 10% SDS, TEMED, 1.5M Tris, and water, 
before being electro-blotted onto a nitrocellulose membrane. Ponceau S solution 
(Sigma Aldrich, 6226-79-5) was used to detect the successful transfer of proteins to the 
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membrane. The membrane was then washed and blocked in 5% dried skimmed milk 
with PBST at room temperature, followed by an overnight incubation with primary 
antibodies against ferroportin, SMAD5, STAT3, and phosphorylated SMAD and STAT 
proteins, in blocking solution at 4°C (Table 2.3). For phosphorylated proteins, 5% BSA 
was used as the blocking solution due to the high presence of phosphoproteins in milk. 
This was followed by 3 washes (10 minutes each) with PBST at room temperature after 
which, the membranes were incubated with HRP-conjugated secondary antibodies 
(1:1000) were applied at room temperature. A further three 10-minutes washes were 
performed, and the protein products were then visualised using the ECL Prime System 
(GE Healthcare Life Sciences) on Hyperfilm ECL (GE Healthcare). Image J software 
(NIH, USA) was used to quantify the intensities of the protein bands relative to 
GAPDH. 
 
Antibody Company Catalogue number Dilution 
Ferroportin Novus Biological 21502SS 1:1000 
Ferroportin Santa Cruz SC-49668 1:2000 
Ferroportin Abcam AB70866 1:1000 
SMAD5 Cell Signalling 9517 1:1000 
STAT3 Cell Signalling 4904 1:4000 
Phospho-SMAD1/5 Cell Signalling 9516 1:4000 
Phospho-STAT3 Cell Signalling 9134 1:6000 
GAPDH Millipore MAB374 1:5000 
Table 2.3 List of antibodies used in Western blot analysis 
(Dilutions listed after optimisation) 
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2.8 Buffers and Reagents 
The following reagents and buffers were used: 
Buffer Ingredients 
PBS (X10) 80g sodium chloride, 2g potassium chloride, 14.4g 
disodium hydrogenphosphate, 2.4g potassium 
dihydrogen phosphate. Titrate to pH 7.4 with 1M HCL 
PBST 0.1% PBS X1, 0.1% Tween 20 (Bio Rad, UK) 
PBSTDS lysis buffer PBS X1, 1% Triton-X 100, 0.5% sodium deoxycholate, 
0.1% SDS, leupeptin 0.5 μg/ml, pepstatin 1.0 μg/ml, 
EDTA 1.0 mM, PMSF 0.2 mM 
Towbin transfer buffer (1L) 200mL methanol, 14,4g glycine, 3.03g Tris base; q.s. as 
1L with deionised water 
TBS 50mM Tris-HCL, pH 7.5, 150mM NaCl 
TBST 0.1% (1L) 1L TBS, 1mL Tween 20 
Western blot 
electrophoresis buffer 
0.025M Tris, 0.192M glycine, 0.1% SDS, pH 8.3. 
For 5L, 60.4g Tris, 288g glycine, 20g SDS; q.s. as 5L 
with deionised water 
Western sample buffer (6X) 0.5M Tris, pH 6.8, 0.35M SDS, 30% glycerol, 0.6M 
dithiothreitol, 0.175M bromophenol blue (Bio Rad, UK) 
 
Reagent Company Catalogue number 
Beta-mercaptoethanol Sigma-Aldrich M7522 
Dulbecco’s modified Eagle 
Medium 
ThermoFisher Scientific 41966029 
EDTA ThermoFisher Scientific 118432500 
Ethanol Haymankimia F200236 
Fetal bovine serum Sigma-Aldrich F7524 
Ficoll-Paque GE Healthcare 17144003 
Phosphate-buffered saline Sigma-Aldrich D8537 
RPMI-1640 ThermoFisher Scientific 28175034 
Trypsin EDTA ThermoFisher Scientific 25300 
 
Standards/ladders Company, catalogue number 
Biotinylated protein ladder 
detection pack 
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2.9 Lactate Dehydrogenase Cytotoxicity Assay 
HepG2 cell viability during experimental conditions was assessed using a lactate 
dehydrogenase (LDH) calorimetric method assay (Cytotox 96 non-radioactive 
cytotoxicity, G1780, Promega, UK). LDH is a stable enzyme (t½=9 hours) found in the 
cytosol and is released when there is cellular damage. This assay uses a calorimetric 
method that relies on: 
1. The eventual conversion of released LDH into a red formazan product that uses 
lactate, NAD+, and INT as substrates in the presence of diaphorase (Figure 2.3) 
2. The amount of colour product being proportional to the number of 
damaged/lysed cells 
                                
Figure 2.3 Generation of red formazan product from LDH released by lysed cells 
in the cytotoxicity assay 
Abbreviations: LDH – lactacte dehydrogenase; INT – iodonitro-tetrazolium violet; NAD+/NADH - 
nicotinamide adenine dinucleotide, oxidised form/reduced form, respectively 
 
2.10  Statistics 
Differences between study groups were evaluated in pairs with the independent 
Student’s t test or the Mann-Whitney U test, depending of the normality of the 
distribution of the relevant variable. Frequencies of baseline categorical variables were 
calculated using Chi-squared tests. Relationships between various parameters under 
study were also looked at; simple linear coefficients (r) were calculated using the 
Pearson’s product formula, and stepwise multiple linear regression analyses were also 
performed. P values calculated to a level of <0.05 (two-tailed) were considered 
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statistically significant. Data were expressed as mean (±SD) or median (inter-quartile 
range, IQR) where appropriate. The Shapiro–Wilks test was used to test for normality 
of distribution. Data that were not normally distributed were log-transformed. 
Comparisons between groups were performed using either a paired Student’s t-test or 
Wilcoxon rank-sum test for normally and non-normally distributed variables, 
respectively. Bivariate correlation coefficients were calculated using the Pearson’s 
product formula. A P-value of <0.05 was considered statistically significant, although 
Tukey’s method (in conjunction with ANOVA) was used to correct for multiple 
comparisons. Analyses were performed using Statistical Package for Social Science 
version 17.0 for Windows XP (SPSS Inc., Chicago, IL) or version 19.0, and GraphPad 
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3 Hepcidin Levels in Chronic Kidney Disease 
3.1 Introduction and Aims 
Since the discovery of hepcidin as the principal hormone regulating iron homeostasis, 
there has been interest in investigating the potential role in the pathogenesis of renal 
anaemia, above and beyond the role of (relative) Epo deficiency. Several studies, 
using ELISA or mass spectrometry, have demonstrated that pro-hepcidin and hepcidin-
25 are both elevated in chronic haemodialysis (HD-CKD) patient (Tomosugi et al. 
2006; Kato et al. 2008; Ashby et al. 2009; Costa et al. 2009; Weiss et al. 2009; Zaritsky 
et al. 2009; Campostrini et al. 2010; Peters et al. 2010). At the time of writing, only one 
study had been conducted assessing the impact of dialysis on the variability of 
hepcidin levels, the conclusion of which precluded the routine adoption of hepcidin as 
an iron marker in the HD-CKD population (Ford et al. 2010). This study was 
undertaken using an ELISA immunoassay (La Jolla, California) with a stated intra-
assay CV1 of 5-19% and inter-assay CV1 of 0-44% (Ganz et al. 2008). Ford and 
colleagues found that using the same assay, the median 2-week intra-individual 
variability of serum hepcidin and ferritin was 19.0% [IQR 18.2-39.7] and 8.6% [5.2-
13.7], respectively. Over a 6-week period, the median CV1 was even higher; 22.9% 
[IQR 13.0-25.2] for serum hepcidin, and 11.5% [7.3-17.8] for serum ferritin. There are 
many factors that influence hepcidin levels in the typical HD-CKD setting. The regular 
administration of intravenous iron and the inflammatory milieu to which most HD-CKD 
patients are exposed will upregulate hepcidin. On the other hand, the anaemic state 
and ESA use, to name a few examples, will downregulate hepcidin (Girelli, Nemeth, 
and Swinkels 2016). Dialysis itself removes hepcidin from the circulation although the 
levels tend to rebound to pre-dialysis levels within an hour after the end of the session 
(Weiss et al. 2009; Kuragano et al. 2010). Ford and colleagues’ use of an ELISA may 
have captured total hepcidin rather than just the bioactive isoform (hepcidin-25), and 
this may have confounded the results seen. We decided to extend the observations 
using a validated liquid chromatography mass spectrometry assay and to compare 
those results to an ELISA (Bachem, UK) in order to assess the variability of hepcidin 
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The aim of the work in this chapter was two-fold: 
1. Cross-sectional study - characterise hepcidin-25 levels in three cohorts of 
patients with CKD (chronic haemodialysis, renal transplantation and non-
dialysis chronic kidney disease) within the population of kidney patients treated 
at King’s College Hospital, matched for age and gender. 
2. Longitudinal study - assess variability of hepcidin in a stable chronic 
haemodialysis cohort using a validated mass spectrometry assay and ELISA, 
and to ascertain whether hepcidin levels were influenced by the length of time 
between dialysis sessions. 
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3.2 Subjects and Methods 
3.2.1 Cross-sectional Study 
3.2.1.1 Subjects 
Subjects were drawn from various areas of the Department of Renal Medicine at King’s 
College Hospital. There were 3 cohorts of CKD patients that were selected from 
various departments from within the renal unit that were included in this study: 
1. Haemodialysis (HD-CKD) patients from the Main Haemodialysis Unit 
2. CKD (non-HD CKD) patients that attended the Renal Outpatients’ Clinic 
3. Renal transplant patients that attended the Renal Transplant Clinic 
 
3.2.1.2 Study Design 
This was an exploratory study using a case-control design. Of the 3 CKD patient 
groups that were enlisted into the study, the total numbers of HD-CKD patients at KCH 
were fewest (compared to the numbers of HD-CKD and RTx patients) and on that 
basis were the first patient cohort to be collated. Thus, for the purposes of this study, 
the HD-CKD cohort would be considered the “control group”. As this was an 
exploratory study, there were no statistical power calculations and a list of 40 HD-CKD 
patients was generated using broad pre-specified inclusion and exclusion criteria 
(Table 3.1). Compared to the satellite unit HD-CKD patients served by KCH, the Main 
KCH HD Unit, which had a capacity of approximately 120 patients, was considered to 
have the clinically less well patients (cf ‘stable on dialysis’ in the inclusion criteria 
below). For this reason, the goal of recruiting 40 patients was considered a practical 
target in the absence of any formal statistical power calculation. 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
Dialysis patient in KCH Main Unit Signs of acute/occult bleeding 
≥18 years of age Hospital admission within 4 weeks 
Stable on dialysis for ≥3 months History of haematological dyscrasia 
 History of liver disease 
 Active malignancy 
Table 3.1 Inclusion and exclusion criteria (cross-sectional study) 
 
Patients were considered to be stable according to the clinical judgement of the 
investigator. Patients were considered clinically unstable if, for example, they exhibited 
any overt signs of infection or were on antimicrobial therapy.  
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Exclusion criteria included a history of haematological dyscrasias, defined as any 
disease process that necessitated the patient having visited the Haematology 
department at any time for treatment or follow-up (except for iron-deficiency anaemia). 
A list of patients matching the criteria was generated, and patients were invited to 
participate until a group of 40 haemodialysis patients was achieved. Following the 
formation of the initial cohort, an independent researcher blinded to the initial HD-CKD 
group data was tasked with interrogating the King’s College Hospital RenalWare 
database in order to compile two further groups that comprised non-HD-CKD patients 
(with any aetiology), obtained from the general nephrology outpatient population, and 
renal transplant patients with functioning allografts. The 2 subsequent groups were 
age- and gender-matched with the HD-CKD cohort. Despite trying to apply the criteria 
listed above to these groups, it became clear that 9 HD patients could not be suitably 
matched with non-HD CKD and RTx cohorts and thus, the final patient population 
consisted of three groups of 31 patients. A single blood sample was required, and this 
would allow the measurement of hepcidin levels, and markers of inflammation including 
high-sensitivity CRP (hs-CRP), interleukin-6 (IL-6) and serum albumin. The timing of 
the HD-CKD blood draws was influenced by reports of the effect of dialysis on hepcidin 
levels (and other analytes) (Zaritsky et al. 2010). Consequently, single 10mL blood 
samples were taken prior to the commencement of dialysis. The patients in the other 
two groups had an extra 10mL of blood drawn along with the standard blood tests 
taken as part of their routine clinical care.  
 
3.2.1.3 Demographics and Baseline Laboratory Data 
A total of 93 subjects were included in this study, comprising 3 groups of 31 patients.  
1. HD-CKD patients or the “control” group.  
2. Non-HD CKD stages 2-4, irrespective of aetiology. 
3. RTx patients who had received a renal transplant at least 3 months prior to the 
commencement of the study, with stable renal function. 
 
The baseline demographic characteristics of the participants in all 3 groups are 
summarised in Table 3.2. A priori, there were no differences in the age and male-to-
female ratio across the groups. No statistically significant differences were observed in 
the primary cause of kidney disease across the three groups, and furthermore, there 
was no statistical difference in the prevalence of hypertension between cohorts. 
However, fewer patients in the non-CKD group (12.9%) had diabetes compared to the 
RTx (22.6%) and HD-CKD (32.3%) groups. There was no statistical difference between 
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the prevalence of diabetes in the HD-CKD group versus the non-HD CKD group 
(p=0.068, see discussion 3.4). The only statistically significant difference was seen in 
the renal function of the non-dialysis subjects, which was better in the transplant 
cohort; the creatinine in the non-HD CKD group was 218 ± 161 μmol/L compared to 
127 ± 55 μmol/L in the RTx group (p=0.003). The mean eGFR in the non-HD CKD 
group was 40.2 ± 24.9 ml/min compared to 54.3 ± 18.4 ml/min in the RTx group 
(p=0.014). 
 
Table 3.2 Demographics and baseline laboratory data (cross-sectional study) 
Adapted from (Rumjon et al. 2012) (PKD – polycystic kidney disease) 
 
Other baseline data included; the mean dialysis adequacy (Kt/V) of the HD-CKD group 
was calculated to be 1.14 ± 0.28; the mean level of proteinuria in the non-HD CKD 


















Age, years 55.0+/-14.8 55.3+/-14.8 53.7+/-14.9 0.939 0.714 0.658
Gender, male/female 15/16 15/16 15/16 1 1 1


































Diabetes, n 10 4 7 0.068 0.393 0.319
Hypertension, n 25 22 23 0.374 0.544 0.776
Urea, mmol/l – 13.5+/-7.9 10.4+/-3.9 – – 0.053
Creatinine, mol/l – 218+/-161 127+/-35 – – 0.003
eGFR, ml/min/1.73 m2 – 40.2+/-24.9 54.3+/-18.4 – – 0.014
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3.2.2 Longitudinal Study 
3.2.2.1 Subjects 
Subjects were patients drawn from the Main Haemodialysis Unit who consistently 
attended for their treatments three times per week.  
 
3.2.2.2 Study Design 
Patients from the King’s College Hospital Main Haemodialysis Unit who fulfilled the 
inclusion and exclusion criteria listed in Table 3.3 were invited to participate in this 
exploratory, prospective, longitudinal study. Of approximately 120 patients in the 
dialysis unit, only 20 patients fulfilled the criteria and gave their informed consent to 
participate. Blood samples (10mL) were drawn before the commencement of each 
dialysis session for 3 weeks (9 samples) for measurement of hepcidin, and high-
sensitivity C-reactive protein (hs-CRP). No alteration to the patients’ pre-existing iron 
replacement regimen or ESA dose was permitted during the duration of this short study 
unless there were patients safety concerns. Baseline blood samples were taken as part 
of the routine clinical care of the patients. The same definitions for ‘stable on dialysis’ 
and ‘haematological dyscrasia' applied to this study, as for the cross-sectional study 
(chapter 3.2.1.2, above). 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
Dialysis patient in KCH Main Unit Signs of acute/occult bleeding 
≥18 years of age Hospital admission within 4 weeks 
Stable on dialysis for ≥3 months History of haematological dyscrasia 
Intravenous iron dose stable for ≥2 weeks History of liver disease 
ESA dose stable for ≥4 weeks Active malignancy 
Regular dialysis 3 times/week  
Table 3.3 Inclusion and exclusion criteria (longitudinal study) 
 
Typical dialysis schedules involve patients attending three times per week for their 
treatments. As Sunday is the traditional rest day, dialysis schedules involve patients 
attending for their treatments on Monday, Wednesday and Fridays (MWF), or Tuesday, 
Thursday and Saturdays (TTS). The gap between sessions varies from 2 to 3 days, 
with the longer inter-dialytic gap (c, in Figure 3.1) inevitably occurring over the course 
of the weekend. 
 




Figure 3.1 Maintenance haemodialysis scheduling – time between sessions 
(a and b indicate a 2-day interval between successive dialysis sessions; c indicates a 3-day 
interval between dialysis sessions, occurring across the weekend) 
 
As has previously been discussed, up to 50% of hepcidin is removed by dialysis 
although levels normalise shortly after the end of the session (Kuragano et al. 2010; 
Zaritsky et al. 2010). The importance of the day of the week on which samples were 
drawn, and amount of dialysis that each individual received were also taken into 
consideration. It was therefore reasonable to assume that the hepcidin levels in 
samples drawn on a Monday or Tuesday (following a three-day inter-dialytic gap) may 
have differed from samples drawn on other days of the week (following a two-day inter-
dialytic gap) due to the nature of dialysis scheduling (Figure 3.1). 
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3.2.2.3 Demographics and Baseline Laboratory Data 
A total of 20 patients were recruited to this study; 10 had their haemodialysis 
treatments on the MWF schedule, and 10 that had their treatments on the TTS 
schedule. The baseline demographic characteristics and laboratory data of the 20 
participants in the longitudinal study are summarised in Table 3.4.  
 
Age, years (mean ± SD) 63.0 ± 15.9 
Males (n (%)) 
BMI (kg/m2) (mean ± SD) 
14 (70) 
26.1 ± 4.8 
Afro-Caribbean (n (%)) 
History of malignancy (n (%)) 
11 (55) 
1 (5) 
Haemoglobin (g/L) (median, IQR) 109 (98 - 118) 
ESA use (n (%)) 19 (95) 
Epoetin dose (i.u./week) (median, IQR) 6000 (4000 – 9000) 
IV iron supplementation (n (%)) 
IV iron dose (mg/week) (median, IQR) 
Serum ferritin (ng/mL) (median, IQR) 
C-reactive protein (mg/L) (median, IQR) 
AV fistula/AV graft/tunnelled dialysis catheter (n) 
Dialysis vintage (years) 
Dialysis adequacy (Kt/V) 
12 (60) 
100 (100 – 150) 
591.5 (321.9 – 861.1) 
5.4 (0.8 – 18.9) 
8/5/7 
4.1 ± 15.9 
1.07 ± 0.19 
Table 3.4 Demographics and baseline laboratory data (longitudinal study) 
(BMI – body mass index; ESA – erythropoiesis-stimulating agent; AV – arterio-venous) 
 
Twenty HD-CKD patients were randomly selected to take part in this study and had 
been receiving dialysis for a mean of 4.1 (± 4.6) years. The patients were aged 
between 35 and 85, and 14 of the 20 patients were male. All patients were receiving 
dialysis thrice weekly, and all had been stable for a period of at least 3 months. All 
patients, bar one, were dialysed in the afternoon (between midday and 4 p.m.). None 
of the patients had been in receipt of antimicrobial therapy within the month preceding 
the commencement of the study, and similarly, none of the patients had a history of 
liver disease. Of the 20 participants, 95% had been on an ESA with a stable dose for 
greater than 4 weeks. Fewer patients were receiving IV iron; only 60% of the enlisted 
participants had IV iron administered within the 4 weeks prior to the commencement of 
the study, and this position was maintained for the duration of the study. 
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3.2.3 Healthy Volunteers 
Staff working in the Renal Department were approached at random and asked to 
volunteer blood samples, which would be analysed for serum hepcidin. Twenty-three 
members of staff agreed to donate 10mL of whole blood, which was immediately 
processed. None amongst the 23 had a significant medical history and on that basis 
were assumed to be completely healthy. Thus, no other laboratory tests were 
conducted. 
 
3.2.4 Laboratory Methods 
All samples taken from arterio-venous fistulae and grafts were obtained immediately 
after the needles had been placed but before connection to the haemodialysis circuit. 
Patients with tunnelled dialysis catheters had 5mL of blood taken from each lumen 
(and discarded) before having 10mL of blood taken that was placed into Vacutainer® 
biochemistry tubes (containing silica and a serum separating gel with clot activator). 
The patients were then connected to the haemodialysis circuit. The study samples 
were allowed to rest at room temperature for 30 minutes, before being centrifuged at 
10000 RPM for 10 minutes. Serum was decanted and aliquotted into cryotubes that 
were immediately transferred into the -80° Celsius freezer. Following the completion of 
the longitudinal study, these samples were couriered to two laboratories (King's 
College London, UK (for measurement of serum hepcidin using mass spectrometry), 
and the University of Bialystok, Poland (for measurement of serum hepcidin using 
ELISA). Two different operators processed the samples in a single run in order to 
minimise intra-assay variability. The methods (serum hepcidin measurement by mass 
spectrometry) employed in this study have been described previously ((Bansal et al. 
2010)). The same samples were analysed by ELISA (Bialystok, Poland) using a 
commercially available kit (Bachem, UK). The reported normal range for this assay is 
0.02–25 ng/mL, and both the calculated intra- and inter-assay variations were below 
10%. High sensitivity CRP levels were determined using turbidemitry (P.Z. Cormay, 
Lublin, Poland). 
 
In the cross-sectional study, the sample obtained from each of the 93 patients was 
divided into two and in addition to the samples sent for assessment of hepcidin levels, 
the second sample was sent to the central laboratory at King’s College Hospital for 
measurement of standard biochemical and haematological laboratory parameters. 
Serum ferritin was measured using a two-site immunoassay using a direct 
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chemiluminometric technique (Siemens Healthcare Diagnostics Ltd, UK). C-reactive 
protein was measured with ELISA (Wako Chemicals, Germany). Interleukin-6 was also 
measured with a commercially available ELISA kit (R & D, Abingdon, UK). 
 
3.2.5 Statistical Analyses 
Differences between study groups were evaluated in pairs with the independent 
Student’s t test or the Mann-Whitney U test, depending of the normality of the 
distribution of the relevant variable. Frequencies of baseline categorical variables were 
calculated using Chi-squared tests. Relationships between various parameters under 
study were also looked at; simple linear coefficients (r) were calculated using the 
Pearson’s product formula, and stepwise multiple linear regression analyses were also 
performed. P <0.05 (two-tailed) were considered statistically significant. Data that were 
non-Gaussian were log-transformed if required for the purposes of linear correlation. 
Comparisons between 3 or more groups were undertaken using a one-way analysis of 
variance (ANOVA) with Tukey’s corrections for multiple analyses. 
 
The coefficient of variance (CV1) for every individual was calculated from all nine 
hepcidin values acquired for each patient in the longitudinal study. The CV1 was 
calculated using the standard deviation divided by the mean. Data were expressed as 
mean (±SD) or median (inter-quartile range, IQR) where appropriate. The Shapiro–
Wilks test was used to test for normality of distribution. Comparisons between groups 
were performed using either a paired Student’s t-test or Wilcoxon rank-sum test for 
normally and non-normally distributed variables, respectively. Bivariate correlation 
coefficients (r) were calculated using the Pearson’s product formula. A P-value of <0.05 
was considered statistically significant. Analyses were performed using Statistical 
Package for Social Science version 17.0 for Windows XP (SPSS Inc., Chicago, IL) and 
version 19.0 for the longitudinal study and the cross-sectional study, respectively. 
 
3.2.6 Ethics and Regulatory Approvals 
All patients gave informed consent for participation in the studies, which were 
conducted in accordance with the Declaration of Helsinki and approved by the London 
Research Ethics Committee 1 (LREC 09/H0718/034). Patient information leaflets were 
provided to all participants who gave their written informed consent. 
  




3.3.1 Hepcidin Levels in CKD Patient Groups and Healthy Volunteers 
Serum hepcidin levels in the HD-CKD group were nearly double the level (139.9 ± 48.1 
ng/mL) compared to either the non-HD CKD (62.9 ± 40.5 ng/mL) or the RTx (69.3 ± 
35.0 ng/mL) groups (p<0.001 for both comparisons). The biggest difference was seen 
between the HD-CKD group and the healthy volunteers (p<0.0001). The mean 
hepcidin level of the 23 healthy volunteers was 44 ± 22 ng/mL (no other data 
available); this was significantly different compared to the RTx cohort (p=0.004), but 
not statistically different from the non-HD CKD group (p=0.06) (Figure 3.2). 
 
 
Figure 3.2 Mean hepcidin levels in 3 patient cohorts and healthy volunteers 
(ns – not significant; * <0.05; ** <0.01; *** <0.001; **** <0.0001; black lines are comparisons within the 3 
CKD cohorts; grey lines are comparisons between healthy volunteers and the 3 CKD cohorts) 
 
There were no differences in the measured haematological indices between the non-
HD CKD and RTx patients (Table 3.5). The mean haemoglobin level was 111 ± 11 g/L 
in the HD-CKD patients, which was lower than both the non-HD CKD patients (124 ± 
14 g/L) and RTx recipients (125 ± 16 g/L) (p<0.001 for both comparisons). Serum 
ferritin levels were unsurprisingly higher in the haemodialysis group (558.8 ± 215.4 
µg/L), given the protocolised administration of intravenous iron in this cohort of 
patients, compared to the non-HD CKD (126.9 ± 96.6 µg/L) and RTx groups (181.3 ± 
147.7 µg/L) (p<0.001 for both comparisons). No significant difference was found 
ANOVA 
p=0.0051 
Chapter 3. Hepcidin Levels in CKD 
 
100 
between the CRP levels in the three groups. In contrast, IL-6 levels were significantly 
higher in the haemodialysis group (8.39 ± 6.56 pg/mL) compared to the non-HD CKD 
group (4.77 ± 5.67, p=0.027) and the RTx group (4.80 ± 6.44, p=0.039). Albumin 
levels, which are of course another marker of inflammation, were lower in the HD-CKD 
patient group (38.7 ± 2.3 g/L), in comparison to the other two groups (non-HD CKD 
(42.5 ± 5.1 g/L) and RTx (41.5 ± 2.2 g/L) (p<0.001 for both comparisons)) (Table 3.5). 
 
 
Table 3.5 Biochemical and haematological results (cross-sectional study 
Adapted from (Rumjon et al. 2012) (hepcidin measured by LS-LS tandem mass spectrometry) 
 
3.3.2 Correlates of Serum Hepcidin With Other Variables 
Simple linear regression analyses were undertaken in order to examine potential 
associations between the hepcidin level and relevant variables thought to impact on 
hepcidin levels. As eGFR levels were not required in the HD-CKD group, analyses to 
detect a correlation between renal function and hepcidin were undertaken. Serum 
hepcidin was not significantly associated with eGFR (r= -0.047, p=0.723). Total 
population analyses assessing the impact of inflammation on found no association - 
CRP (r= -0.254, p=0.175); IL-6 (r=0.132, p=0.227) (Figure 3.3). There was a significant 
inverse correlation seen with haemoglobin (r= -0.282, p=0.007), and a significant 
















Haemoglobin, g/l 111 +/-11 124 +/-14 125 +/-16 <0.001 <0.001 0.731
Hypochromia, % 4.93+/-5.43 2.45+/-3.25 2.39+/-2.74 0.033 0.023 0.930
Reticulocyte count 77.2+/-34.4 83.2+/-31.8 79.2+/-31.7 0.483 0.816 0.624
Ferritin, g/l 558.8+/-215.4 126.9+/-96.6 181.3+/-147.7 <0.001 <0.001 0.092
Hepcidin, ng/ml 139.9+/-48.1 62.9+/-40.5 69.3+/-35.0 <0.001 <0.001 0.515
CRP, mg/l 15.8+/-15.6 19.8+/-19.0 21.7+/-36.4 0.584 0.622 0.883
Interleukin-6, pg/ml 8.39+/-6.56 4.77+/-5.67 4.80+/-6.44 0.027 0.039 0.981
Albumin, g/l 38.7+/-2.3 42.5+/-5.1 41.5+/-2.2 <0.001 <0.001 0.318




Figure 3.3 Correlations between serum hepcidin levels and eGFR, haemoglobin, 
ferritin and interleukin-6 
Adapted from (Rumjon et al. 2012). Dashed lines indicate 95% confidence intervals. 
 
To identify independent predictors of hepcidin variability, stepwise multiple linear 
regression analysis was performed in the total population studied, with hepcidin as the 
dependent variable and albumin, haemoglobin, ferritin, and IL-6 as independent 
variables in the model. As shown in Table 3.7, ferritin was the only variable that dis- 
played an independent strong association with hepcidin levels.   
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Table 3.6 Pearson’s correlation coefficients between hepcidin and the main 
biochemical and haematological parameters 
(§HD-CKD patients were not included in correlational analyses of eGFR; p<0.05 emboldened) 
 
Independent variables beta P value 
Ferritin 0.691 <0.001 
Albumin -0.124 0.134 
Haemoglobin -0.012 0.887 
Interleukin-6 -0.038 0.647 
R2 0.48 <0.001 
Table 3.7 Coefficients of determination (beta) in multiple linear regression 
analysis including ferritin, albumin, haemoglobin, and IL-6 as independent 
variables and hepcidin as the dependent variable 
 
3.3.3 Intra-Individual Variability in HD-CKD 
Two assays (mass spectrometry and ELISA) were used to assess the variability of 
serum hepcidin levels in this study. Irrespective of the methodology used, both assays 
displayed a significant degree of biological variability in this patient cohort (Figure 3.4). 
The median CV1 for the mass spectrometry assay was 23.0% (16.8 – 27.9), compared 
to a median of 23.3% (17.1 – 38.9) for the ELISA assay. There appeared to be no 
correlation with the assay used and the calculated CV1. At the lower end of the range 
for calculated CV1 levels, both assays performed equally as well. 40% of the patients 
with a CV1 of less than 20% was seen in the use of both assays. A CV1 between 20-
25% was seen in 15% of patients using both assays. At greater CV1 ranges, however, 
both assays performed equally well; at a CV1 of 25-30%, the mass spectrometry assay 
accounted for 25% of the patients, compared to 10% with the ELISA. The situation was 
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reversed when examining CV1 levels of greater than 30%; the ELISA accounted for 
35% of the patients’ results, compared to 20% with mass spectrometry. There was no 
statistical difference between the median CV1 levels calculated by mass spectrometry 
compared to the ELISA assay. 
 
 
Figure 3.4 The coefficient of variance (CV1) of serum hepcidin in 20 
haemodialysis patients, using MS and ELISA 
 
3.3.4 Inter-method Difference in Hepcidin Values 
In contrast to the CV1 results listed above, there was a statistical difference seen in the 
absolute hepcidin levels according to the type of assay used. The median hepcidin 
level in this haemodialysis cohort assessed by mass spectrometry was 168.2 (127.9 – 
217.6) compared to 170.0 (107.0 – 238.8) when using the ELISA assay (p = 0.03). Two 
outlying ELISA hepcidin values of 4256.4 and 1372.1 ng/ml were obtained from a 
single patient, and these were confirmed on repeat testing (the mean hepcidin level of 
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3.3.5 The Effect of IV Iron Administration on CV1 and Hepcidin Levels 
The CV1 did not appear to be affected by the administration of IV iron. In the 12 
patients receiving IV iron, the median CV1 for hepcidin was 22.9% (19.7 – 31.5) and 
23.3% (17.4 – 56.8) using mass spectrometry and ELISA, respectively. This compared 
to a median CV1 of 25.9% (18.6 – 27.9) (MS) and 22.8% (15.4 – 34.0) (ELISA) in the 
remaining patients who did not receive IV iron. No statistically significant differences 
were observed in the CV1 results of the patients in relation to whether they received IV 





Patients not receiving 
Iron replacement p-value 
n (%) 12 (60) 8 (40)   
Median CV1 (MS) 22.9% (19.7, 31.5) 25.9% (18.6, 27.9) 0.77 
Median CV1(ELISA) 23.3% (17.4,56.8) 22.8% (15.4, 34.0) 0.29 
Table 3.8 Effect of intravenous iron on the variability of serum hepcidin levels 
 
Of the 12 patients receiving IV iron supplementation, 11 were having iron administered 
on a weekly basis across haemodialysis. This allowed hepcidin levels to be compared 
across three time-points: immediately before the administration of IV iron, and 
immediately prior to the subsequent two dialysis sessions. There was a trend towards 
slightly higher mean hepcidin levels measured at the beginning of the first subsequent 
dialysis session after the administration of IV iron, but overall there was no obvious 
impact of IV iron on serum hepcidin (Figure 3.5). The iron administration protocol in the 
dialysis unit necessitated the administration of thrice-weekly iron in those patients in 
whom serum ferritin levels were found to be below 100 ng/mL. This affected only one 
patient, and his hepcidin CV1 values were similar to those of the other patients: 25.6% 
(MS) and 20.0% (ELISA). 
 




Figure 3.5 Mean hepcidin levels taken immediately before a dialysis session 
during which 100mg of IV iron sucrose was administered, and the subsequent 
two dialysis sessions (p=0.55) 
 
3.3.6 Effect of Inflammatory Status on CV1 and Hepcidin Levels 
All samples of patient sera that had hepcidin measurements were also assessed for 
high-sensitivity CRP (hsCRP). The median hsCRP level was 6.1 (1.1 – 18.9) mg/L 
across the entire cohort over the three weeks of the study. The linear correlation 
between hepcidin (assessed by mass spectrometry) and hsCRP in this analysis was 
weak (r=0.15; p=0.04) (Figure 3.6). Mean serum hepcidin levels were assessed 
according to tertiles of hsCRP, and were slightly higher in the highest hsCRP tertile 
compared to the lowest hsCRP tertile [190.4±91.1 mg/L versus 161.1±50.7 mg/L, 
respectively (p=0.04)]. There was no correlation between the CV1 for hsCRP and the 
CV1 for hepcidin. Using the mass spectrometry assay, the Pearson’s correlation 
between CV1 hepcidin and CV1 hsCRP was r=0.18 (p=0.10). For the ELISA assay, 
there was actually an inverse correlation between the CV1 of hepcidin and hsCRP (r= -
0.18, p=0.04). 




Figure 3.6 Correlation between hepcidin (MS assay) and high sensitivity CRP 
(log-transformed) 
 
3.3.7 Effect of the Inter-dialytic Interval on Serum Hepcidin 
As described earlier, three haemodialysis sessions per week inevitably leads two 2-day 
intervals and one 3-day interval between dialysis sessions (the latter following the 
weekend) (Figure 3.1). Hepcidin levels were found to be higher following a 3-day inter-
dialytic interval compared to hepcidin levels following a 2-day inter-dialytic interval 
(Figure 3.7) (p=0.02, ANOVA). Median hepcidin levels on a Monday or Tuesday (the 
first dialysis session after the weekend/3-day inter-dialytic interval) were 182.8 (138.8 – 
235.0) and 184.1 (111.9 – 267.7) ng/mL with mass spectrometry and ELISA, 
respectively. No associations were found between serum hepcidin, haemoglobin, 
dosage of epoetin or serum ferritin. 




Figure 3.7 Mean hepcidin levels categorised by day of dialysis session 
 
Baseline dialysis adequacy was obtained but was not available for each individual 
haemodialysis session. Two of the 20 participants had haemodiafiltration (one in each 
dialysis cohort), whilst the rest had standard haemodialysis. All participants used 
standard FX dialysers (Fresenius®) but the size of the dialysers was not captured. 
There was no statistical difference between the dialysis quantity (in litres processed 
during haemodialysis) between the dialysis administered between the two groups over 
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3.4 Conclusions and Discussion 
The main findings from the studies in this chapter were as follows; 
1. Hepcidin levels were highest in the HD-CKD population, significantly higher 
than in non-dialysis CKD/transplant patients and healthy volunteers. 
2. Hepcidin levels were increased in non-HD CKD and renal transplant patients. 
The transplant patients had significantly higher hepcidin levels compared to 
healthy volunteers.  
3. In a small, clinically stable HD-CKD cohort, there appeared to be no impact of 
inflammation on hepcidin levels. 
4. There was high variability of hepcidin levels in HD-CKD patients, irrespective of 
whether measured by mass spectrometry or ELISA. 
5. In HD-CKD patients, pre-dialysis hepcidin levels were highest after the 
weekend interval. 
6. The administration of 100mg iron sucrose appeared to have no significant effect 
on hepcidin levels in HD-CKD patients 
 
In a well-matched cohort study, the highest serum hepcidin levels were found in the 
HD-CKD group (139.9±48.1 ng/mL), with a mean figure that was more than double that 
found in either the non-HD CKD or renal transplant groups. This was approximately 4 
times the level found in a group of healthy volunteers garnered from within the renal 
unit. These findings are in keeping with the current literature on the subject. A number 
of previous studies have examined the levels of serum hepcidin in their respective HD-
CKD patients, and with one exception, have results consistent with the findings from 
this cross-sectional study (Table 3.9). 




Table 3.9 Studies comparing serum hepcidin-25 levels (unless stated) between 
adult haemodialysis patients and healthy controls 
Adapted from ((Valenti et al. 2014)) 
 
Of the studies referred to in Table 3.9, Pelusi and colleagues performed the only study 
with results that contradict ours. One of the major strengths of the Pelusi study was the 
attention to detail in matching for age and gender between the control subjects and the 
HD-CKD patient cohort. Control subjects who had a serum ferritin level lower than 
30/40ng/mL (females and males, respectively) were excluded. This enabled patients 
with sub-clinical iron-deficiency (a strong upregulator of hepcidin) to be excluded from 
their study. They also included HD-CKD subjects with a median serum ferritin that was 
approximately half the levels seen in the HD-CKD patients from the cross-sectional 
cohort (265ng/mL [155-411] vs 558.8±215.4ng/mL, respectively). In using patients from 
a haemodialysis unit favouring a policy of relatively low iron supplementation, they 
included patients who were less likely to be iron overloaded. Pelusi and colleagues 
also sampled hepcidin from their haemodialysis patients after a 3-day inter-dialytic 
period in order to minimise the clearance effect of dialysis on hepcidin levels (citing the 
evidence from the longitudinal study in this chapter). They concluded that there was no 
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substantive difference in hepcidin levels between well-matched HD-CKD patients and 
healthy controls, but in essence they showed that there was no difference in iron-
replete healthy controls and relatively iron-deplete HD-CKD patients (compared to our 
HD-CKD patients) (Pelusi et al. 2013). The difference between the Pelusi study and the 
data from this study may be explained by the difference in ferritin levels alone. 
 
There was a very strong association seen in this study between ferritin and hepcidin in 
the non-HD CKD and the renal transplant patients, but this was not seen in the HD-
CKD patients (Table 3.6). Therefore, based on these data, and extrapolating the study 
methods of Pelusi and colleagues to the cross-sectional study population, exclusion of 
low-ferritin healthy controls would likely adjust the mean hepcidin levels of the healthy 
controls upwards. This would not necessarily be the case in the HD-CKD population, 
however, as the correlation between serum ferritin and hepcidin in the cross-sectional 
haemodialysis group had an r-value of 0.104 (p=0.597); thus any adjustment or 
selection of patients based on ferritin levels, should in theory, leave hepcidin levels 
unaffected. 
 
One limitation with respect to the healthy controls used in this study is that they were 
assumed to be healthy. This was a reasonable assumption in light of the fact that the 
hepcidin levels in this group were in keeping with previous control data, but a more 
robust control group would have been from healthy kidney donors.  
 
In contrast to the HD-CKD population, there have been fewer studies examining 
hepcidin levels in renal transplant recipients and in non-HD CKD patients. The 
transplant and non-HD CKD groups in the cross-sectional study had patients with a 
mean eGFR of 54.3±18.4, and 40.2±24.9 mL/min, respectively, but there was no 
statistical difference in the mean hepcidin levels between these two groups. Despite 
this, there was an interesting difference comparing hepcidin levels in the two non-HD 
cohorts against healthy volunteers. The non-HD CKD cohort had hepcidin levels that 
were comparable to healthy volunteers (p=0.06). However, the transplant group had a 
level that was higher in comparison (p=0.004). As hepcidin is largely excreted via the 
kidneys, this observation could be considered counterintuitive, but studies examining 
the relationship between eGFR and hepcidin have not conclusively proven a direct 
relationship between the two (Peters et al. 2010). What is not known is the extent to 
which hepcidin is renally excreted in chronic kidney disease. Peters and colleagues 
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showed that in healthy individuals, the fractional excretion of urinary hepcidin is in the 
region of 2% and there is a 10-15-fold increase in the hours following coronary artery 
bypass surgery. They also showed a 4-fold increase in the fractional excretion of 
urinary hepcidin in moderate kidney disease (CKD stage 3a, non-proteinuric patients 
with a mean eGFR of 57mL/min) and it is conceivable that the upregulation of urinary 
hepcidin excretion may account for the non-linear relationship between eGFR and 
hepcidin, although data examining urinary hepcidin in advanced CKD is currently 
lacking (Peters et al. 2013). 
 
A possible confounder was the difference in prevalence of diabetes in the 3 cohorts in 
the cross-sectional study. Although there was no statistically significant difference 
between the groups (a possible type 2 statistical error), the actual percentage of 
diabetic patients in the HD-CKD group was 32.3%, which was nearly 50% higher than 
the number in the RTx group. There were nearly double the number of diabetic patients 
in the RTx group (22.6%) compared to the non-HD CKD group (12.9%) and this may 
have contributed to the higher hepcidin level seen in the RTx group. The relationship 
between diabetes and hepcidin is complex, as there are conflicting reports suggesting 
both positive and negative associations between diabetes and levels of hepcidin in 
patient cohorts. It must also be considered that excessive iron loading is linked with the 
development of diabetes. Vela and colleagues have recently reviewed this and 
concluded that in type 2 diabetes mellitus, there are 2 distinct phenotypes seen; one 
subset of patients has low levels of hepcidin linked with insulin resistance, whilst the 
other subset has high levels of hepcidin, linked with chronic inflammation, morbid 
obesity, and of course, renal impairment (Vela, Sopi, and Mladenov 2018). This is a 
potentially significant confounder and in retrospect, should have been corrected for, but 
these data were not known/published at the outset of the studies in this chapter. 
Although the 3 groups were age- and gender-matched, the use of a propensity 
matching algorithm would have potentially reduced the confounding variables. 
 
The results of the longitudinal study suggest that there is significant intra-individual 
variability of serum hepcidin in chronic haemodialysis patients. This is consistent with a 
previous report by Ford and colleagues (Ford et al. 2010). One limitation of their study 
was the use of an ELISA to measure hepcidin. This is known to cross-react with 
hepcidin fragments (hepcidin-20 and hepcidin-22), and the contribution of this lack of 
specificity to their findings of hepcidin variability was impossible to ascertain. In the 
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longitudinal study, however, we utilized a mass spectrometry assay for biologically 
active hepcidin-25 and confirmed significant hepcidin variability. Our study design 
differed from that of Ford and colleague in that serum hepcidin was measured before 
every dialysis session, we also attempted to examine factors that could potentially 
influence hepcidin levels (IV iron administration and the degree of inflammation), as 
well as controlling for epoetin and iron administration. With the exception of an early 
drop-out (no data obtained) we were fortunate that no patient encountered any 
intercurrent morbid events such as infection, surgery, hospitalisation, or acute 
cardiovascular events during this 3-week period. 
 
The hepcidin results obtained using MS were generally lower than those obtained 
using the ELISA. This is likely to be due to the fact that the ELISA detects the smaller 
isomers of hepcidin as well as biologically active hepcidin-25. Nevertheless, as in 
previous studies, hepcidin levels in haemodialysis patients were consistently elevated 
compared to normal healthy individuals. Both assays showed a similar degree of 
hepcidin variability, and the median CV1 values were almost identical for MS versus 
ELISA (Table 3.8). 
 
Higher hepcidin levels were seen following a 3-day inter-dialytic interval versus a 2-day 
interval, possibly due to greater generation of hepcidin during the longer time period 
between dialysis sessions. No difference existed in the amount of dialysis (in terms of 
litres processed) each patient received, and it would appear that the time difference 
between dialysis sessions had a minor impact on variability. In order to further verify 
the impact of dialysis and the time between dialysis sessions on hepcidin levels, the 
analyses could have been strengthened by taking into account the patients’ residual 
renal function (using inter-dialytic urine collection and pre- and post-dialysis blood 
sampling) as well as the extent to which hepcidin was actually cleared by measuring 
dialysate hepcidin. Malyszko and colleagues produced data suggesting that the 
presence of residual renal function influenced hepcidin levels in both peritoneal and 
haemodialysis patients (Malyszko et al. 2009). If the patients in our cohort were uric, 
then the measurement of urinary hepcidin (excretion) may have determined whether 
residual renal function was a contributor to increased hepcidin variability.  
 
The use of a cohort of haemodialysis patients was considered on the basis that this 
group of patients were readily available thrice-weekly allowing regular blood sampling 
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as required. The use peritoneal dialysis patients may have been a better group to 
study, as they have fewer interventions, the process of dialysis is less pro-
inflammatory, and they have regular peritoneal equilibration testing (and potentially 
easier access to testing effluent hepcidin levels). In a very recent study by Lim and 
colleagues, both incident haemodialysis and peritoneal dialysis patients were 
prospectively evaluated for a period of 6 months. There were no significant differences 
between the baseline data between the 2 groups. After 6 months’ follow-up, a number 
of differences emerged between the 2 groups; in the HD group, the use of CERA and 
IV iron was higher, whilst the use of diuretics was higher in the PD group. Haemoglobin 
levels were significantly higher in the PD group (106 ± 10 g/L vs 100 ± 10 g/L, p=0.01) 
as was hepcidin (115.9 ± 26.9 vs 101.7 ± 24.4, p=0.008). Both AST and ALT were 
higher in the PD patients whilst serum albumin was higher in the HD group. Aside from 
the iron biomarkers (ferritin, TSAT) that unsurprisingly correlated well with hepcidin 
levels, urinary production in early haemodialysis patients was an independent predictor 
of hepcidin levels (Lim et al. 2019). Hepcidin levels were highest in PD patients and 
this was also observed by Zaritsky and Niikura and colleagues. Comparing hepcidin in 
the HD dialysate and PD effluent may have strengthened these studies and would 
have also added to the studies undertaken in this chapter (Zaritsky et al. 2009; Niikura 
et al. 2018). 
 
It has previously been demonstrated that inflammation (acute and chronic), IV iron, and 
epoetin administration influence hepcidin levels (Ashby et al. 2010). As in our parallel 
study by Peters and colleagues (Peters et al. 2012), we were unable to demonstrate a 
convincing association between CRP and hepcidin levels, in contrast to the findings of 
Ford and the multivariate analyses by Zaritsky (Zaritsky et al. 2009). We found only a 
very weak correlation with hsCRP in this study, excluding a major impact of 
inflammation on hepcidin variability. Interestingly, using a different mass spectrometry 
assay and a different study design, Peters and colleagues found very similar CV1 
values (26%, 17-48) to those seen in our study (24%, 17-28) (Peters et al. 2012). 
In general, the age- and gender-matching between the 3 CKD groups in the cross-
sectional study were well carried out. The longitudinal study was conducted 
prospectively, and nearly half of the patients did not receive IV iron (previously reported 
as a major confounder in this patient population). Moreover, this cohort was observed 
closely for intercurrent morbid events that could impact on variability – no overt events 
were seen. The studies were not without limitations, however. The lack of 
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characterisation of the healthy control group did not allow for matching of subjects as 
performed by Pelusi and colleagues. The small sample size (n = 20) and the relatively 
short duration of assessment (3 weeks) in the longitudinal study were its main 
limitation. Most of the subjects dialysed in the afternoon shift; it is not clear whether the 
data reported here would be applicable to patients dialysing in the morning or evening, 
although Ashby and colleagues did not find a diurnal variation of hepcidin levels in HD-
CKD patients (Ashby et al. 2010).  
 
In conclusion, and in concordance with the results by Peters and colleagues, we have 
demonstrated that there is considerable variability in serum levels of hepcidin-25 in a 
clinically stable cohort of haemodialysis patients, using a mass spectrometry assay. No 
major impact of IV iron or inflammatory status was observed, although a minor effect of 
length of intra-dialytic interval was seen. These data have implications for studies 
examining factors affecting hepcidin levels, and also for studies investigating the utility 
of serum hepcidin as a biomarker of iron status in haemodialysis patients. 
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4 HAMP mRNA in PBMCs From CKD Patients 
4.1 Introduction and Aims 
Serum hepcidin levels in CKD patients are increased compared to normal healthy 
controls and (as shown in the previous chapter) even within the spectrum of CKD, 
significant differences are seen. Thus, patients on regular haemodialysis have several-
fold higher hepcidin levels compared to non-dialysis CKD and transplant recipients. 
The regulation of hepcidin is complex with a number of factors known to increase 
hepcidin, while other factors have been shown to decrease hepcidin levels. At a 
molecular level, this is mediated through its interaction with ferroportin, the major iron 
exporter in mammalian cells (Nemeth, Tuttle, et al. 2004). The intracellular signalling 
mechanisms that regulate HAMP expression (the gene controlling hepcidin production) 
vary according to the stimulus. Iron increases BMP-6, which in turn activates the 
hepcidin promotor via SMAD 1/5/8 (Andriopoulos et al. 2009). Inflammation, and 
specifically IL-6, activate the IL-6 receptor that in turn acts on the JAK2/STAT3 
pathway to increase hepcidin expression (Nemeth, Rivera, et al. 2004). 
 
The clinical conditions known to increase hepcidin levels include administration of 
blood transfusions and iron, as well as acute and chronic inflammation. Those in which 
hepcidin levels are decreased include anaemia, and ESA therapy (mediated by 
erythroferrone), hepatic viral infections, and administration of vitamin D or testosterone 
therapy. Several of these clinical states may be applicable to chronic haemodialysis 
patients, particularly iron and ESA therapy as well as chronic inflammation (Girelli, 
Nemeth, and Swinkels 2016). 
 
Haemodialysis patients are known to be chronically inflamed. The primary disease 
process leading to kidney dysfunction may be a factor (e.g. autoimmune diseases, 
vasculitis or amyloidosis), and comorbidities such as diabetes or peripheral vascular 
disease may also act as a substrate for inflammation (Jaar et al. 2000). Other factors 
that contribute to the inflammatory milieu the haemodialysis population include reduced 
renal clearance of cytokines, susceptibility to bloodstream infections (e.g. endocarditis 
or discitis), sub-clinical infections (e.g. periodontal disease), and dialysis-related factors 
(Jofre et al. 2006). Dialysis may induce the release of pro-inflammatory cytokines 
during the treatment and reactive oxygen species/oxidative stress (Spittle et al. 2001; 
Tarakcioglu et al. 2003). The link between inflammation and hepcidin was seen when 
subjects injected with lipopolysaccharide mounted a rapid inflammatory response in 
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concert with a rise in hepcidin levels , likely mediated by interleukin 6 via STAT3 
intracellular signalling (Kemna et al. 2005; Wrighting and Andrews 2006). In the 
haemodialysis setting, researchers have previously shown that interleukin-6 is higher 
than in healthy controls, but was not necessarily influenced by hepcidin (Kuragano et 
al. 2010). 
 
The administration of iron in both oral and intravenous forms has been shown to 
increase hepcidin levels in the non-dialysis dependent CKD population, although the 
greatest response was seen in patients receiving a high dose intravenous iron 
preparation. Baseline hepcidin levels did not appear to predict the patients’ response to 
iron therapy (Gaillard et al. 2016). In the haemodialysis setting, there is an extremely 
strong positive relationship between hepcidin and ferritin levels, which has been 
demonstrated on a number of occasions as well as in the previous chapter of this 
thesis (Weiss et al. 2009).  
 
Being a small peptide, hepcidin is freely filtered via the glomerulus with greater than 
95% reabsorption by the proximal tubule (Swinkels et al. 2008). Thus, an increase in 
hepcidin levels could also be mediated via reduced clearance of the peptide as for 
other similarly sized molecules (e.g. inulin). Early studies using ELISA did indeed show 
an inverse correlation between eGFR and hepcidin (Troutt, Butterfield, and Konrad 
2013). Later studies using mass spectrometry showed that hepcidin-25 levels were 
actually independent of eGFR, although other hepcidin isoforms such as hepcidin-20 
were shown to accumulate in renal failure (Peters et al. 2010). To further explore the 
impact of GFR on hepcidin levels, it was good to study non-HD/HD CKD patients who 
have low clearance and to investigate whether it was possible to use a surrogate for 
hepatic production of HAMP mRNA. The expression of the gene (HAMP) responsible 
for hepcidin production in circulating macrophages was one mechanism that 
researchers in Oxford employed to determine that Plasmodium falciparum infected 
erythrocytes induced hepcidin production (Armitage et al. 2009). We therefore 
employed this methodology as a surrogate marker of hepcidin production in our CKD 
population.  
 
The aim of the work in this chapter was to therefore measure HAMP mRNA in PBMCs 
isolated ex vivo from CKD patients to see whether there was any correlation with 
serum hepcidin levels.  
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4.2 Subjects and Methods 
4.2.1 Subjects 
Subjects were selected from various areas of the Department of Renal Medicine at 
King’s College Hospital. These included 3 cohorts of CKD patients, as follows: 
Cohort 1 - CKD (non-HD CKD) patients who attended the Renal Outpatient Clinic 
Cohort 2 - Haemodialysis (HD-CKD) patients from the Main Haemodialysis Unit 
Cohort 3 - Septic haemodialysis patients that were emergency admissions to the ward 
In addition, a random group of healthy volunteers working within the department 
provided control samples (cohort 4). 
 
4.2.2 Study Design 
This was an exploratory study using a prospective, cross-sectional design. The data 
from cohorts 1 and 2 (CKD, both non-HD and HD, respectively) would be compared to 
data obtained from the healthy controls. Cohort 3 HD patients were assessed at 
baseline presenting with presumed sepsis and were then followed up prospectively 
with a blood sample taken after 28 days, at a time when there was a reasonable 
expectation that they had recovered from the initial septic insult (Figure 4.1). Being an 
exploratory study, there was no formal pre-specified statistical plan was employed, and 
no power calculation conducted. To obtain meaningful data a minimum of 6 patients 
were to be recruited to each arm of the study. Blood samples were analysed for serum 
hepcidin, and other standard laboratory variables, and PBMCs were extracted to allow 
measurement of HAMP mRNA. 
 
                                
Figure 4.1 Study design – time points for data collection 
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4.2.3 Cohort 1 - Non-dialysis CKD Patients 
Non-dialysis CKD patients were randomly approached prior to their routine general 
nephrology outpatients’ appointment. The laboratory inclusion criteria were identical to 
the HD-CKD patients in cohort 2, whereas the exclusion criteria differed only in respect 
of previous ESA and IV iron use (Table 4.1). Non-dialysis CKD patients had an extra 
10mL of blood taken for study purposes at the end of their routine outpatient clinic visit 
in addition to any routine blood samples that had been requested by their clinician. 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
Haemoglobin >100g/L History of ESA use 
Ferritin 200-500 ng/mL History of IV iron use 
C-reactive protein <20mg/L Signs of acute/occult bleeding 
 Hospital admission within 4 weeks 
 History of haematological dyscrasia 
 History of liver disease 
 Active history of malignancy 
Table 4.1 Inclusion and exclusion criteria for cohort 1 
 
4.2.4 Cohort 2 - Haemodialysis CKD Patients 
The KCH RenalWare database was interrogated to find patients who matched the 
inclusion criteria, and the patient notes were examined to filter out those patients who 
had a number of pre-specified exclusion criteria (Table 4.2). Patients were considered 
to be stable according to the clinical judgement of the investigator. Exclusion criteria 
included a history of haematological dyscrasias, defined as any disease process that 
necessitated the patient having visited the Haematology department at any time for 
treatment or follow-up (except for iron-deficiency anaemia). Examples of disease 
conditions commonly encountered in the typical renal patient population included 
myeloma, MGUS, and the myelodysplastic syndromes. Patients who had been 
hospitalised for any reason within 4 weeks of the commencement of the study were 
excluded, but all haemodialysis patients who participated had been stable on dialysis 
for considerably longer than 4 weeks. Potentially eligible patients were approached to 
assess their willingness to participate in the study and if so, then full written consent 
was obtained. A single extra blood sample (10mL) was then taken at the beginning of 
their dialysis session, following insertion of the dialysis needles, but prior to connection 
to the haemodialysis circuit. 
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INCLUSION CRITERIA EXCLUSION CRITERIA 
Dialysis patient in KCH Main Unit Signs of acute/occult bleeding 
Haemoglobin >100g/L Hospital admission within last 4 weeks 
Ferritin 200-500 ng/mL History of haematological dyscrasia 
C-reactive protein <20mg/L History of liver disease 
ESA and iron dosage stable for ≥1 month Active history of malignancy 
Definitive dialysis vascular access  
Table 4.2 Inclusion and exclusion criteria for cohort 2 
 
4.2.5 Cohort 3 - Septic Haemodialysis CKD Patients 
Unlike the groups outlined in 4.2.4 and 4.2.3 above, the patients included in this cohort 
were not pre-selected, but were considered eligible following an emergency admission 
to the Renal Ward with presumed bacterial sepsis. Only then were they approached for 
inclusion into the study following review of the pre-specified criteria outlined below 
(Table 4.3). Patients in this cohort were not eligible for the study if they had a medical 
history that included a chronic inflammatory state such as inflammatory bowel disease, 
or rheumatoid arthritis. 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
Dialysis vintage >3 months Blood transfusion within 1 month 
C-reactive protein >100 mg/L Other known chronic inflammatory 
condition 
Presenting fever of ≥ 37.8 °C Active hepatitis/HIV infection 
 Active liver disease 
 Active history of malignancy 
Table 4.3 Inclusion and exclusion criteria for cohort 3 
 
4.2.6 Cohort 4 – Healthy Volunteers 
Staff working in the Renal Department were approached at random and asked to 
volunteer blood samples, which would be analysed for serum hepcidin and HAMP 
mRNA. Nine members of staff agreed to donate 10mL of whole blood, which was 
immediately processed. None amongst the 9 had a significant medical history and on 
that basis were assumed to be completely healthy. Thus, no other laboratory tests 
were conducted. 
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4.2.7 Demographics and Baseline Laboratory Data 
The baseline demographic characteristics and laboratory data of cohorts 1, 2 and 4 are 
summarised in Table 4.4. 
 






Number of participants 10 7 9 
Age (years) 62.9 ±19.2 55.5 ±19.5 44.0 ± 15.0 
Males (n)(%) 6 (60.0) 5 (71.4) 5 (55.5) 
Haemoglobin (g/L)  125 ± 22 113 ± 8  
eGFR (ml/min) 32.9 ± 13.8   
CRP (mg/L) 5.3 ± 4.1 10.4 ± 5  
Albumin (g/L) 43.3 ± 1.7 39.7 ± 1.8  
Ferritin (ng/mL) 
(med/IQR) 
322 ± 359 
132 (74-430) 
367 ± 90  
Hepcidin (ng/mL) 32.9 ± 31.7 149.1 ± 27.3 26.9 ± 8.6 
Weekly IV iron dose 
(med/IQR) 
 100 (0-100)  
ESA dose (iu/kg/week) 
(med/IQR) 
 46.2 (18.9-114.6)  
Table 4.4 Baseline demographic and laboratory data for cohorts 1, 2, and 4 
(data expressed as mean ± standard deviation, unless otherwise specified. Grey boxes indicate 
that data were not available/applicable) 
 
A total of 17 patients were recruited to cohorts 1 and 2, as well as 9 healthy controls. 
Cohort 1 (non-HD CKD) were slightly older with a mean age of 62.9 ±19.2, compared 
to a mean age of 55.5 ±19.5 in cohort 2 (HD-CKD). Amongst the healthy volunteers in 
cohort 4, the youngest volunteer was 24 and the eldest was 70. Despite this wide 
range, the mean age of this cohort was lower than for the other two cohorts, at 44.0 ± 
15.0 (ANOVA, P<0.001). The representative mean eGFR for the non-HD CKD patients 
was 32.9 ± 31.7, equivalent to CKD stage 3b. The mean haemoglobin in this cohort 
was 125 ± 22 g/L – not supported by iron or ESA therapy – which could be considered 
to be within the normal range. Notwithstanding the relatively few patients in this study, 
the baseline biochemical data from cohorts 1 and 2 were largely in keeping with that 
obtained from the larger CKD cohorts, reported in chapter 3 (page 99). As had 
previously been observed, the mean haemoglobin and albumin levels were lower in the 
HD-CKD group than in the non-HD CKD group (P<0.001 for both comparisons), whilst 
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the mean CRP and hepcidin levels were higher in the HD-CKD group than in the non-
HD CKD group (P<0.001 for both comparisons) (Figure 4.2). The only observed 
difference in the baseline biochemical variables between these cohorts and the cohorts 
in chapter 3 was in the mean ferritin levels between the two CKD groups. The 
distribution of serum ferritin levels amongst the 10 non-dialysis CKD patients was non-
Gaussian and heavily influenced by the presence of 2 outliers, and hence no statistical 
difference was observed (Figure 4.2). 
 
 
Figure 4.2 Baseline serum hepcidin and ferritin levels in non-HD (cohort 1) and 
HD (cohort 2) CKD patients 
 
The baseline demographic characteristics and laboratory data of the septic HD-CKD 
participants (cohort 3) are summarised in Table 4.5. 
 
Number of participants 10 
Age (years) 61.1 ± 11.9 
Males (n)(%) 6 (60) 
Haemoglobin (g/L)  100 ± 19.5 
CRP (mg/dL) 221.5 ± 116.9 
Albumin (g/L) 34.9 ± 2.3 
Ferritin (ng/mL)  1702 ± 1271 
Hepcidin (ng/mL) 95.0 ± 55.5 
Weekly IV iron dose (med/IQR) 100 (0-100) 
ESA dose (iu/kg/week) 
(med/IQR) 
56.3 (30.4 – 76.2) 
Table 4.5 - Baseline demographic and laboratory data for septic HD patients 
(cohort 3) 
(data expressed as mean ± standard deviation, unless otherwise specified) 
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In total, 10 HD-CKD patients were admitted to the renal ward and fulfilled the broad 
inclusion and exclusion criteria outlined in Table 4.3. Of these, 6 were male and the 
mean age of the cohort was 61.1 ± 11.9 years. Being septic, the mean CRP of the 
cohort was very high and this no doubt influenced the serum ferritin levels, the mean of 
which was more than 3 times greater than that seen in the (non-septic) HD-CKD 
patients in cohort 2. This observation did not extend to hepcidin, however, which did 
not seem to be as responsive to sepsis as ferritin. The mean hepcidin level was 95.0 ± 
55.5 ng/mL and the mean albumin level was 34.9 ± 2.3 g/L (Figure 4.3). 
 
 
Figure 4.3 Baseline serum hepcidin and ferritin levels in septic HD patients 
(cohort 3) 
 
4.2.8 Laboratory Methods 
The methods of hepcidin measurement by mass spectrometry have been discussed in 
detail elsewhere (Bansal et al. 2010). Routine patient blood samples for were 
processed in the King’s College Hospital central laboratory. The method for HAMP 
mRNA measurement will be briefly revisited but is covered comprehensively on page 
79. 
 
HAMP mRNA measurement 
• 10mL blood drawn (and divided into two) and separated by Ficoll-Hypaque Plus 
(GE Healthcare) centrifugation 
• Plasma was obtained post-centrifugation and immediately stored in 500µL 
aliquots 
• Two sets of 5x106 peripheral blood mononuclear cells were isolated for each 
participant 
• Total cellular RNA was subsequently extracted (RNeasy, Qiagen) and 
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• 500ng RNA was reverse transcribed (High Capacity RNA-to-cDNA Kit, Applied 
Biosystems) 
• All cDNA samples were processed in a single run to eliminate inter-
experimental variability 
• Amplification reactions were performed using Taqman HAMP and GAPDH 
primer-probes in triplicate 
• Quantitative RT-PCR was performed using the 7900 HAT Fast Real-Time 
system (Applied Biosystems) 
 
4.2.9 Statistical Analyses 
Differences between the haemodialysis, non-dialysis CKD and healthy control groups 
were determined with the independent Student’s t test. Relationships between various 
parameters under study were also examined; simple linear coefficients (r) were 
calculated using the Pearson’s product formula. P-values <0.05 (two-tailed) were 
considered statistically significant. Analyses were performed using GraphPad Prism 
version 6.0 for Macintosh, GraphPad Software, La Jolla California USA. 
 
4.2.10 Ethics and Regulatory Approvals 
The London Research Ethics Committee 1 (LREC 09/H0718/034) granted ethical 
approval. Local R&D approval was obtained to undertake this study, which was 
conducted in accordance with the principles outlined in the Declaration of Helsinki. 
Patient information leaflets were provided to all participants prior to obtaining their 
written informed consent. 
  




4.3.1 HAMP mRNA Levels in Non-HD and HD CKD Patients 
 
Despite haemodialysis patients having markedly higher circulating hepcidin levels, 
HAMP mRNA levels were considerably lower in cohort 2 (HD-CKD patients) compared 
to cohorts 1 (non-HD CKD patients) and 4 (healthy controls). The distribution of the 
HAMP mRNA results was greatest in the non-HD cohort; this was in contrast to the HD 
cohort, where the distribution of results was much tighter. It was noted that the 
participant with the highest HAMP mRNA level in cohort 2, had a level that was lower 
than the mean HAMP mRNA in either of the other two cohorts. In contrast to what 
might have been predicted, HAMP mRNA was significantly lower in the HD patients in 
cohort 2 (p=0.026). Despite the graphical representation below (fold-change as 
opposed to absolute values), there was no difference in HAMP mRNA levels between 
the non-HD and HD cohorts of CKD patients (p=0.4) (Figure 4.4). 
 
 
Figure 4.4 HAMP mRNA levels in CKD cohorts and healthy volunteers 
(* Comparison between HD CKD cohort and healthy volunteers, p=0.026) 
 
4.3.2 Effect of Hepcidin on HAMP mRNA 
There was no correlation between the total circulating levels of hepcidin with HAMP 
mRNA levels in either the haemodialysis group or the non-HD CKD group separately 
(Figure 4.5a, Figure 4.5b) or when both were combined (Figure 4.5c). 
 




Figure 4.5 Correlations between hepcidin and HAMP mRNA 
a – cohort 1; b – cohort 2; c – cohorts 1 and 2 combined 
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4.3.3 Effect of Ferritin on HAMP mRNA 
A similar pattern was seen when examining the effect of ferritin on HAMP mRNA. No 
correlation was seen between serum ferritin levels and HAMP mRNA levels in either 
the HD-CKD group or the non-HD CKD group separately (Figure 4.6a, Figure 4.6b) or 
when both were combined (Figure 4.6c).  
 
Figure 4.6 Correlations between ferritin and HAMP mRNA 
a – cohort 1; b – cohort 2; c – cohorts 1 and 2 combined  
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4.3.4 Does Sepsis Influence Hepcidin Levels in HD-CKD Patients? 
Blood samples were taken within 12 hours of the patients’ admission to the renal ward 
and were processed immediately. A second sample was taken after 28 days, and the 
results from these two time-points can be seen in Table 4.6.  
 
 Baseline Recovery (28 days) p-value 
Haemoglobin (g/L)  100 ± 19.5 102 ± 8.6 0.80 
CRP (mg/L) 221.5 ± 116.9 32.4 ± 22.2 <0.001*** 
Albumin (g/L) 34.9 ± 2.3 36.4 ± 3.1 0.23 
Ferritin (ng/mL)  1702 ± 1271 919.3 ± 442.6 0.03* 
Hepcidin (ng/mL) 95.0 ± 55.5 76.9 ± 58.5 0.09 
Table 4.6 Laboratory results at baseline and recovery 
 
As expected in patients with bacterial sepsis, there was a dramatic fall in the CRP and 
ferritin levels (Figure 4.7 a,b), In contrast, there was no change in the mean hepcidin 
levels (Figure 4.7c) between baseline and after 28 days. Four patients appeared to 
have a fall in hepcidin levels, but 5 showed a slight increase or no change (Figure 
4.7d). There was no significant change in haemoglobin or albumin levels. 
 
Figure 4.7 CRP and hepcidin levels at baseline and recovery 
(a – mean CRP level; b – individual data; c – mean hepcidin level; d – individual data) 
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4.3.5 Correlation Between Hepcidin and CRP 
At baseline when patients were septic, there was no correlation seen between hepcidin 
and CRP levels (Figure 4.8a). In contrast, after 28 days, a correlation between hepcidin 
and CRP levels emerged (R2 0.62, p=0.01) (Figure 4.8b).  
 
Figure 4.8 Correlation between hepcidin and CRP at (a) baseline and (b) 28 days 
 
4.3.6 HAMP mRNA Levels – Septic HD Patients 
Unfortunately, due to a combination of time factors and experimental methodological 
failure, HAMP mRNA levels were available in 7 patient samples at baseline and only 4 
patient samples at 28 days. Technical failure in extracting PBMCs occurred in 3 of the 
baseline samples. At the 28-day time-point, all the patients had been relocated to their 
satellite units. For 3 of the patients, the time taken from blood sampling to PBMC 
extraction exceeded 2 hours, which is associated with unstable HAMP expression 
(5.3.1), hence the data were unreliable. Technical failure in extracting PBMCs occurred 
in 3 samples. Since only 4 HAMP mRNA levels were available at 28 days, it was 
impossible to draw meaningful comparisons with the baseline data Figure 4.9. 
 
Figure 4.9 HAMP mRNA in septic HD patients at baseline and 28 days 
(mean data (left) and individual data points (right)) 
The baseline data were compared to HAMP mRNA from HD-CKD patients and healthy 
volunteers (Figure 4.10). 




Figure 4.10 HAMP mRNA levels in HD patients (septic and stable) and healthy 
individuals 
(absolute values (left) and fold-change (right); *comparison between stable HD patients and 
healthy individuals, p=0.046; comparison between septic HD and stable HD patients, p=0.06) 
 
The mean HAMP mRNA level in the septic HD cohort was higher than the other two 
cohorts, but the comparisons did not reach statistical significance. There was a trend 
towards higher HAMP mRNA levels in the septic HD cohort at baseline compared to 
their non-septic counterparts (p=0.06) and healthy controls. 
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4.4 Conclusions and Discussion 
The main aim of the work presented in this chapter was to elucidate possible 
mechanisms of increased hepcidin levels in HD patients using a previously published 
methodology of HAMP mRNA production in PBMCs as a surrogate for increased 
hepcidin production. Ideally, hepatocytes would have been used but this was not 
possible in the clinical setting. The secondary aim was to determine whether high 
inflammatory states affected hepcidin levels in these patients, who already had a very 
high basal level of circulating hepcidin.  
 
The following conclusions can be made: 
1. Serum hepcidin levels are generally higher in HD-CKD patients compared to 
non-HD CKD patients and healthy controls. 
2. The data of HAMP mRNA do not support increased production of hepcidin. 
3. There is no correlation between HAMP mRNA and hepcidin suggesting that the 
PBMC ex vivo model may be not sensitive or robust enough to detect increased 
hepcidin. Clearly, increased HAMP mRNA production and generation in HD 
could still be present in the liver, but this would be difficult to determine in a 
human model. 
4. A trend towards higher HAMP mRNA in septic HD patients at baseline suggests 
possible upregulation of hepcidin production in PBMCs after a bacterial insult. 
5. No striking effect or a reduction in hepcidin levels after sepsis in HD patients as 
is the case for CRP and ferritin. This may be because hepcidin levels in HD 
patients are already at their maximum, and/or that hepcidin kinetics are different 
from CRP and ferritin in sepsis. In contrast, HAMP mRNA levels were 
significantly reduced compared to non-HD CKD and healthy controls. Whether 
this suggests a negative feedback mechanism on HAMP mRNA production is 
impossible to prove but remains a possibility. 
 
The finding was even more striking for the fact that this occurred in few subjects with 
markedly high levels of circulating hepcidin, suggesting a possible negative feedback 
mechanism to account for this (Figure 8.1). 
 
Chronic haemodialysis patients are continually exposed to a milieu of low-level 
inflammation and this is one of the mechanisms thought to contribute to the elevated 
levels of hepcidin in this group of patients. They are also susceptible to bacterial sepsis 
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and so it was interesting to see that despite having extremely high markers of 
inflammation, the hepcidin levels in septic haemodialysis patients were no higher than 
their basal levels once they had recovered from their respective septic episodes. This 
suggests that inflammation not playing a particularly major role in the high hepcidin 
levels seen in haemodialysis. The HAMP mRNA levels in the septic haemodialysis 
group were marginally higher than the uninflamed group that were used as a control, 
but certainly not dramatic. 
 
There are no previous studies on the effect of sepsis of hepcidin in HD-CKD, though 
there are two that examine this effect in non-CKD patients. A Dutch group studied 92 
adult patients (13 of whom had chronic kidney disease, which was not defined further) 
with bacterial sepsis. Hepcidin was highest on the day of admission, and had fallen by 
half by the third day (van Eijk et al. 2011). A neonatal study was undertaken in very low 
birth weight babies and a similar pattern was found. Hepcidin was highest at 
admission, and had fallen to normal levels (similar to non-septic neonates) after 2 
weeks (Wu et al. 2013). 
 
One possible unifying explanation for the findings in this chapter is that circulating 
hepcidin levels in haemodialysis patients are at their maximum level, and there is 
limited capacity for additional hepcidin production, even when an acute 
inflammatory/infective state supervenes. The PBMC HAMP data also support this 
hypothesis, as there is suppression at the mRNA level. Confirmation of this data would 
require a greater number of subjects, and possibly more stringent inclusion and 
exclusion criteria to eliminate as many confounders as possible e.g. the temporary 
cessation of ESA and iron therapy. 
 
The data presented here are not without limitations. The very use of haemodialysis 
patients as an experimental model introduced a number of possible confounders that 
were difficult to control for, especially with the increasing number of factors that are 
now known to positively and negatively affect hepcidin production (Langer and 
Ginzburg 2017). This was an exploratory study, and the number of patients may have 
been too small to detect certain effects, such as differences in HAMP mRNA levels in 
the septic haemodialysis group. It was also unfortunate that methodological issues 
resulted in sub-optimal numbers of samples being obtained from cohort 3 in their 
recovery phase for HAMP mRNA analysis. The use of circulating macrophages as a 
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surrogate marker for hepcidin production may be a practical approach to this issue but 
is clearly less than ideal given that the main cells producing hepcidin are hepatocytes, 
and there is no known data on PBMC HAMP mRNA in the renal setting. Obtaining 
hepatocytes from haemodialysis patients was briefly considered but the idea was 
rapidly rejected given the potential safety and ethical issues. The logic for selecting 
PBMC HAMP as a surrogate for liver HAMP was based on hepcidin upregulation being 
an integral mechanism in innate immunity and the importance of PBMCs as an 
essential component of the innate immune system’s response to infection, and so, 
assessing PBMC responses to IL-6 stimulation/inflammation was considered apposite. 
This approach is consistent with other researchers in the arena of hepcidin regulation, 
who have used also PBMC methodology as a surrogate marker for liver HAMP in the 
absence of access to primary in vivo hepatocytes. I am not aware of the existence of 
any published pre-clinical models/studies that have been produced, which prove the 
correlation between neutrophil and hepatic cellular HAMP responses to infectious/iron 
stimuli. 
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5 Cytokine Regulation of HAMP in Hepatoma Cells and 
PBMCs 
5.1 Introduction and Aims 
Mammals do not possess regulatory processes that allow iron to be excreted from the 
body, and thus, iron homeostasis is very tightly controlled via a process of absorption, 
recruitment and recycling of existing iron stores. Cellular iron flow is completely 
controlled by membrane-bound ferroportin, which in turn is under the (probably 
exclusive) control of its ligand, hepcidin. In the presence of increased hepcidin, 
ferroportin is degraded and iron transit into the plasma ceases, thus maintaining 
intracellular stores and inhibiting erythropoiesis (Nemeth, Tuttle, et al. 2004). Although 
the liver is the predominant site of hepcidin, and ferroportin is fundamentally a 
hepatocyte-expressed protein, ferroportin is also expressed in a number of other cell 
types, including enterocytes, macrophages and erythroid precursors. 
 
The import of iron via enterocytes has been well characterised, with the most important 
apical protein being divalent metal transporter 1 (DMT1) (Illing et al. 2012). However, 
the actual contribution of dietary iron to total body iron stores is very limited. 
Reticuloendothelial macrophages play a far greater role in regulating total body iron 
stores, as they are principally responsible for the recovery and recycling of iron from 
senescent red blood cells. In contrast to enterocytes, which predominantly interact with 
ferrous iron (Fe2+), splenic and hepatic (Kuppfer) macrophages are able to 
phagocytose terminal age whole red cells and extract heme and then iron from them 
(Beaumont and Delaby 2009). 
 
Studying hepcidin and ferroportin regulation has been greatly facilitated by the use of 
commercial hepatoma cell lines, which have been essential in determining many of the 
basic cellular and signalling mechanisms involved. Access to primary human 
hepatocytes is difficult, but hepatoma cell lines, such as HepG2 and HuH-7 cells, have 
been shown to be well suited to studies examining the transcriptional regulation of 
hepcidin (Jacolot, Ferec, and Mura 2008; Kanamori et al. 2014). Using these in vitro 
models, we now know that exogenous IL-6 causes increased transcription of HAMP 
(which then translates to hepcidin) via the janus kinase-2 (JAK2) STAT3 pathway 
(Wrighting and Andrews 2006; Fein et al. 2007; Verga Falzacappa et al. 2007). 
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We also know that macrophages export iron in a similar fashion to hepatocytes, using 
a series of elegant experiments demonstrating that macrophages overexpressing 
ferroportin allowed the release of greater amounts of 59Fe-labelled rat erythrocytes than 
control cells, after erythrophagocytosis. This effect was significantly diminished 
following treatment with hepcidin, confirming the parallel iron export mechanisms that 
exist between hepatocytes and macrophages (Knutson et al. 2005). 
 
The mechanisms of hepcidin regulation in monocytes and macrophages have been 
elucidated predominantly using well-characterised models such as the THP-1 
commercial monocyte cell line, which was derived from a 1-year-old patient with acute 
myeloid leukaemia. THP-1 cells are grown in suspension, and possess the ability to 
differentiate into macrophages when exposed to phorbol 12-myristate 13-acetate 
(Jacolot, Ferec, and Mura 2008). These cells have been studied independently, or in 
cross-culture with hepatoma cells in order to establish the cell-to-cell interaction that 
exists. 
The first report of the use of THP-1 cells being co-cultured with hepatoma cells 
originated from Andriopoulos and colleagues, who showed that hepcidin released from 
IL-6-stimulated HuH-7 cells significantly decreased the efflux of 59Fe from co-cultured 
THP-1 cells (Andriopoulos and Pantopoulos 2006). Although both hepatocytes and 
macrophages respond to the same stimuli, the speed of their respective responses 
differ; macrophages appear to be more sensitive and respond more acutely to hepcidin 
than intestinal epithelial cells, perhaps indicative of the macrophage’s central position 
in maintaining body iron homeostasis (Chaston et al. 2008). 
 
However, macrophages do not necessarily require liver-derived hepcidin for their 
activation and possess the ability to act in an autocrine manner (Theurl et al. 2008; 
Sasaki et al. 2014). Consequently, there is very likely great utility in measuring HAMP 
mRNA from human peripheral blood mononuclear cells (PBMCs) in order to determine 
the cells’ intrinsic production of HAMP, and therefore hepcidin (Ryan et al. 2012). Both 
THP-1 cells and PBMCs express significant amounts of HAMP mRNA (although much 
lower amounts than that expressed in hepatocytes), and are activated by IL-6 and 
BMP-6 in the same manner as hepatocytes (Armitage et al. 2011). Accordingly, 
researchers have made use of PBMC HAMP mRNA measurements in a variety of 
clinical scenarios (Table 5.1). 
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Authors, year PBMC HAMP mRNA induction agents and/or findings from 
clinical studies 
(Theurl et al. 
2008) 
Anaemia of chronic disease patients had approximately double 
the expression of PBMC HAMP mRNA than control patients 
(Armitage et al. 
2009) 
Plasmodium falciparum infected RBCs induced HAMP production 
in co-cultured PBMCs 
(Armitage et al. 
2011) 
A variety of infectious and inflammatory stimuli induced HAMP 
(Sow et al. 2011) Mycobacterium induction of HAMP 
(Ryan et al. 
2012) 
Reduction of HAMP within 12 hours of PEG-IFNα treatment in 
hepatitis C patients. Correlated with serum hepcidin 






HAMP mRNA was highest in obese diabetic and obese non-
diabetics compared to control subjects 
Table 5.1 A selection of studies utilising measurement of PBMC HAMP mRNA 
 
Over the years, nephrologists appear to have extensively utilised PBMCs as a tool with 
which to study disease processes in the haemodialysis population, with hundreds of 
citations in the literature referencing their use. They have been used in a variety of 
scientific studies, mainly as a gauge of immune function and oxidative stress, or as a 
surrogate marker of cytokine activation or production. 
 
The aim of the work presented in this chapter is to: 
1. Replicate laboratory work in the Oxford laboratory of Dr Drakesmith, in order to 
validate these techniques  
2. Verify results from within the scientific literature with reference to HAMP 
induction in HepG2 cells and peripheral blood mononuclear cells 
3. Determine the ideal concentrations of cytokines for stimulating HAMP 
upregulation in HepG2 cells and ex vivo peripheral blood mononuclear cells, for 
use in downstream experiments 
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5.2 Methods 
All the experimental work undertaken in this chapter was carried out in the Renal 
Sciences Laboratory at the Rayne Institute, Denmark Hill, King’s College London.  
 
5.2.1 Cell Culture and Reagents 
Cell culture experiments were carried out using commercial HepG2 cells (ATCC), and 
human peripheral blood mononuclear cells donated by healthy volunteers from within 
the laboratory and from the Renal Unit at King’s College Hospital. A list of the reagents 
is listed in Table 5.2. A total of 3 separate experiments were performed unless 
otherwise stated. 
 
5.2.2 Stability of Peripheral Blood Mononuclear Cells 
Peripheral blood mononuclear cells (PBMCs) are circulating cells that possess a single 
nucleus. Examples of these cells include monocytes, macrophages and lymphocytes. 
In contrast, neutrophils possess multiple nuclei, whilst red blood cells and platelets 
have no nuclei at all. In healthy individuals, monocytes typically form 20-30% of the 
PBMC population, with lymphocytes comprising the rest. Using the varying properties 
of these cell types, PBMCs can be reliably separated from the other blood cells using 
density gradient media. Prior to obtaining blood from the volunteers, 50mL Falcon® 
conical centrifuge tubes were prepared with 50μL of heparin-sodium (1000 iu/mL) in to 
which the blood, obtained via venepuncture was transferred in order to prevent 
coagulation. PBS supplemented with sterile 2.5mM EDTA solution was used to perform 
the cell washes and additional 50mL conical tubes were prepared with 15mL Ficoll 
solution. The entire protocol typically took 25-30 minutes to perform. 
 
Blood (35mL) was carefully layered onto the Ficoll to ensure a sharp separation 
between the two layers. The tubes were then centrifuged at 1200 RPM at 4°C for 30 
minutes with no brake applied. The plasma layer was aspirated and stored at -80°C. 
The PBMC layer was aspirated and transferred to a 50mL conical tube and washed 
twice with the PBS-EDTA solution. The cell pellet was re-suspended in RPMI 1640 and 
divided into two fractions, for assessment and cell seeding. A haemocytometer was 
used to count the number of cells, and trypan blue was used to assess cell viability. 
The cells were re-suspended in RPMI 1640 to a concentration of 1 x 106 PBMCs/mL, 
and 1 x 106 PBMCs were seeded into 12-well plates (665180, Greiner Bio-one) and 
incubated at 37°C in 5% CO2 for 1 hour, prior to experimental use. 
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In preparation for the mRNA work to be undertaken during this thesis, and due to the 
possibilities of time delays between bloods samples being drawn from subjects, to 
processing of these samples in the laboratory, it was necessary to ascertain the 
stability of PBMCs ex vivo. One of the prime objectives of this exercise was to 
ascertain whether blood samples obtained from patients in satellite haemodialysis 
could be used for experimentation. 
 
In order to test this, healthy volunteers donated 35mL of blood, and the blood was 
immediately transferred into 7 heparinised 15mL conical tubes (5mL in each tube). One 
reference sample was immediately processed, and the remaining samples were rested 
at room temperature or on ice. The samples were processed on an hourly basis, for up 
to 3 hours, as this was the maximum time delay that was anticipated (Figure 5.1). 
 
 
Figure 5.1 Study schedule outlining the time of blood processing in relation to 
the initial blood draw 
(Blood samples were Ficoll® separated on a hourly basis and RNA immediately extracted) 
 
5.2.3 Laboratory Methods 
5.2.3.1 HepG2 Cells 
HepG2 cells are human hepatoma cells that were derived from a 15-year-old 
Caucasian male with hepatocellular carcinoma. Cell culture involves supplementation 
with 10% fetal bovine serum (FBS), and treatment with 100U/mL penicillin and 
100μg/mL streptomycin. The flasks were incubated in a Techne incubator at a 
temperature of 37°C, in a humidified atmosphere containing 5% CO2. When the cells 
were approximately 80% confluent, the growth medium was removed and the cells 
were twice-washed with phosphate-buffered saline (PBS) (D8537, Sigma-Aldrich) to 
remove any trace of serum-supplemented medium, which may have rendered the 
trypsinisation process ineffective. 
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Trypsin EDTA (2mL) was added to allow complete coverage of the cells, and the flasks 
were incubated for 5 minutes to allow complete detachment of the adherent cells from 
the flask. FBS-supplemented medium was then added to neutralise the trypsin. In 
order to completely remove the trypsin, the cells were centrifuged at 15000G for 5 
minutes, with subsequent removal of the supernatant; the cells were then washed with 
PBS, and 20mL of warmed medium was used to suspend the pellet. The cells were 
counted and seeded into 35mm dishes (627160, Greiner Bio-one) at a concentration of 
8 x 105 cells/dish with a total of 2mL DMEM. The cells reached 70% confluence after a 
48-hour incubation period. The cells were serum-starved overnight, for experimental 
use the following morning. 
 
Reagent Company Catalogue number 
Beta-mercaptoethanol Sigma-Aldrich M7522 
BMP-6 R&D systems 507-BP-020 
Dulbecco’s modified Eagle 
Medium 
ThermoFisher Scientific 41966029 
EDTA ThermoFisher Scientific 118432500 
Ethanol Haymankimia F200236 
Fetal bovine serum Sigma-Aldrich F7524 
Ficoll-Paque GE Healthcare 17144003 
Heparin sodium LEO Pharma N/A 
IL-6 Life Technologies PHC0065 
Penicillin ThermoFisher Scientific 15070-063 
Phosphate-buffered saline Sigma-Aldrich D8537 
RPMI-1640 ThermoFisher Scientific 28175034 
Streptomycin ThermoFisher Scientific 15070-063 
Trypsin EDTA ThermoFisher Scientific 25300 
Table 5.2 Reagents used in experimental cell culture 
 
5.2.3.2 RNA Extraction 
All work surfaces were cleaned with detergents and industrial methylated spirits prior to 
RNA extraction. An RNase decontamination solution (AM9780, Invitrogen) was used 
for added security against RNases. The QIAshredder (79654, Qiagen) and RNeasy 
Mini Kits (74104, Qiagen) were the principal kits used in the extraction of RNA from 
cellular material, and used according to the manufacturers’ instructions, and all the 
steps took approximately 25-30 minutes in total to complete, depending on the number 
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of samples that were processed. Ethanol and beta-mercaptoethanol were not provided 
in the kit, but necessary for RNA extraction. All RNA that was obtained was 
immediately stored at -80°C for reverse transcription. 
 
5.2.3.3 Reverse Transcription 
Reverse transcription from RNA to cDNA was undertaken using the High Capacity 
RNA-to-cDNA Kit (4387406, Applied Biosystems), according to the manufacturer’s 
instructions. An 8-well NanoDrop spectrophotometer (ThermoFisher Scientific) was 
utilised to determine the quantity and purity of the RNA prior to reverse transcription. 
Samples were then pipetted into 96-well reaction plates (N801-0560, Applied 
Biosystems) combined with the reagents supplied by the manufacturer, to a total 
volume of 20μL. The samples were heated in a cyclical manner (Veriti Thermal Cycler, 
Applied Biosystems) for 65 minutes, before being cooled to 4°C; 80μL of RNase-free 
water (129112, Qiagen) was added to each sample to bring the reaction to a complete 
halt. Samples were immediately stored at -20°C. 
 
5.2.3.4 Quantitative PCR 
TaqMan (Applied Biosystems) primer-probes were used for the detection of HAMP 
mRNA (Hs00221783_m1) and GAPDH mRNA (Hs02758991_g1). The primer-probes 
were combined with TaqMan Universal PCR Master Mix (4324018, Applied 
Biosystems), RNase-free water and the reverse-transcribed cDNA. Volumes of 10μL 
per sample, which were tested in triplicate, were placed in a 384-well plate (4309849, 
Applied Biosystems), and a QuantStudio 7 Flex Real Time PCR System (Applied 
Biosystems) was used to perform the analysis that would determine the expression of 
the target gene relative to the housekeeping gene. 
 
5.2.3.5 Cytokines 
IL-6 (PH C0065, Life Technologies), and BMP-6 (507-BP, R&D Systems) were 
reconstituted according to the manufacturers’ instructions. Experiments were 
performed to examine the effect of repeated IL-6 stimulation on PBMCs and HepG2 
cells. Treatments were applied at baseline (0 hours) and after 3 hours, the cells were 
washed, and fresh medium was applied. Following this, a second treatment was 
applied, and RNA was extracted after a further one hour. 
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5.2.3.6 Human Plasma 
Frozen plasma from haemodialysis patients and healthy subjects obtained in chapter 3 
was used in the incubation medium at varying concentrations (0.5-10%) in order to 
assess the effect on HAMP mRNA expression in HepG2 cells. 
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5.3 Results 
Results are expressed as means ± standard deviations, unless otherwise specified. 
 
5.3.1 Stability of Ex Vivo PBMC HAMP and GAPDH 
Three volunteers donated blood samples for use in this experiment. There was no 
significant difference in HAMP mRNA levels between the samples that were 
immediately processed, and the samples that were rested at room temperature or on 
ice, for up to 2 hours after the initial blood draw. The standard deviation of the 
reference samples was extremely tight, as was the standard deviation for the samples 
resting for 1 hour on ice.  
After 3 hours rest, there was a marked increase in HAMP mRNA, in samples kept at 
both at room temperature (p=0.07) and on ice (p=0.009) (Figure 5.2). 
 
 
Figure 5.2 RNA extracted from PBMCs resting at room temperature or on ice 
(Black data plot indicates the reference sample; red data plots indicate samples resting at room 
temperature; blue data plots indicate samples resting on ice; comparison between reference sample and 
samples indicated with p-values) 
 
When the data were pooled together at the 3 time points, there was no difference seen 
between PBMC HAMP mRNA levels after 1 and 2 hours, compared to the reference 
time point. After 3 hours, significant HAMP/GAPDH instability was demonstrated 
(p=0.0477) (Figure 5.3); however, this could not be attributed to the instability of the 
housekeeping GAPDH gene. 
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Figure 5.3 RNA extracted from PBMCs – pooled data 
(*HAMP/GAPDH mRNA at 3 hours versus 0 hours, p=0.0477) 
 
To assess the suitability of GAPDH as the housekeeping gene, a separate experiment 
was conducted to determine the stability of GAPDH up until 24 hours post-
venepuncture. Three people donated 30mL of blood, which was separated into 6 
conical tubes. The first sample was processed immediately, and the other 5 samples 
were rested at room temperature for 1, 2, 3, 6, and 24 hours, respectively. GAPDH was 
robustly stable for 3 hours, but after this time, the ΔCt (i.e. maximum Ct – minimum Ct) 
values rose outside the bounds of acceptability (Ct ≥1) after 24 hours (Figure 5.4). 
 
Figure 5.4 GAPDH Ct values from PBMCs rested at room temperature up to 24 
hours 
(Arrow ‘a’ denotes a GAPDH difference (ΔCt) of 0.47 between the samples with the minimum and 
maximum Ct values within the first 3 hours; ‘b’ represents a ΔCt of 0.75, and ‘c’ represents a ΔCt of 1.48 
between their respective samples, and the sample with the minimum Ct value) 
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5.3.2 PBMC Stimulation Using IL-6 
Stimulation of PBMCs was performed with IL-6. Serial dilutions of stock concentrations 
of IL-6 (10ng/μL) were performed to make a range of concentrations, which were 




Figure 5.5 Dose-response curve for IL-6 stimulation of PBMCs 
(IL-6 concentrations started from 25 ng/mL diluted down to 0.39ng/mL; hyperbolic model with 95% 
confidence intervals shown – R2 = 0.9563; results from 3 independent experiments) 
 
There was a clear dose-response curve of IL-6 at the lower concentrations, which then 
reached a plateau using doses ≥12.5ng/mL (Figure 5.5). On the basis of these results, 
a dose of 12.5ng/mL of IL-6 was selected for the subsequent set of experiments, 
examining the impact of various time delays on RNA extraction. For this experiment, 
HAMP mRNA relative to the housekeeping gene was assessed at 30-minute intervals 
up to 180 minutes (Figure 5.6). 
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Figure 5.6 PBMC time-response curve using 12.5ng/mL of IL-6 
(Results from 3 independent experiments) 
 
The maximum response to this dose was witnessed at 60 minutes, and the response to 
IL-6 fell significantly after 180 minutes but was not back to baseline and would have 
taken approximately a further 30-60 minutes to do so if the data was extrapolated and 
the descent remained linear. 
 
5.3.3 HepG2 Stimulation Using IL-6 
Similar experiments were undertaken using HepG2 cells. Serial dilutions from a stock 
concentration of 10ng/μL IL-6 were undertaken resulting in the following concentrations 
being applied for 2 hours: 3.13, 6.25, 12.5, 25, 50, and 100 ng/mL. 
 
Figure 5.7 Dose-response curve for IL-6 stimulation of HepG2 cells 
(IL-6 concentrations started from 100ng/mL diluted down to 3.125ng/mL; hyperbolic model with 95% 
confidence intervals shown – R2 = 0.9267; results from 3 independent experiments) 
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Again, the dose-response relationship to IL-6 plateaued, but this time at a 
concentration of 25ng/mL (Figure 5.7). On the basis of these results, a dose of 
25ng/mL of IL-6 was selected to create a time-response curve extracting RNA at 30-
minute intervals. 
 
The response of the HepG2 cells to IL-6 differed somewhat to the PBMCs; the 
maximum attainable response of these cells occurred at 120 minutes after the initial 
treatment, with a 50% reduction in the response 60 minutes after the peak response. 
The variance in responses from 120 minutes onwards (as was judged by the standard 




Figure 5.8 HepG2 time-response curve using 25ng/mL IL-6 
(Results from 3 independent experiments) 
 
5.3.4 HepG2 Stimulation Using BMP-6 
Stimulation of HepG2 cells was performed with BMP-6. Serial dilutions of stock 
concentrations of BMP-6 (20ng/μL) were performed to create a range of 
concentrations, which were applied for 2 hours. The doses used were 1.56, 3.13, 6.25, 
12.5, 25, 50, and 100 ng/mL. 
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Figure 5.9 Dose-response curve for BMP-6 stimulation of HepG2 cells 
(BMP-6 concentrations started from 100ng/mL diluted down to 1.5625ng/mL; hyperbolic model with 95% 
confidence intervals shown – R2 = 0.9507; results from 3 independent experiments) 
 
The maximal attainable response elicited with BMP-6 was much higher than the 
responses seen with IL-6. IL-6 stimulation elicited a maximal HAMP/GAPDH fold-
change rise in the region of 10-15, whereas 30- to 40-fold-change rises were witnessed 
with BMP-6. The HAMP/GAPDH mRNA level plateaued after a dose of 25ng/mL, with 
no additional responses seen, even with doses as high as 100ng/mL (Figure 5.9). 
 
5.3.5 Are PBMCs and HepG2 Cells Refractory to Repeated IL-6 Stimuli? 
These data from this set of experiments suggest that PBMCs and HepG2 cells behave 
differently to repeated stimulation of IL-6. The same experiment was undertaken in 
both cell types, with treatments applied at 0 hours and again at 2 hours. The cells were 
washed prior to the second treatment. RNA was extracted 1 hour later, a total of 3 
hours after the initial treatment. 
 
When PBMCs were treated with 12.5ng/mL of IL-6 followed by vehicle, there was no 
difference seen to PBMCs that were treated twice with IL-6 (Figure 5.10). 
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Figure 5.10 Repeated treatments of IL-6 or vehicle applied to PBMCs 
(Treatments 1 and 2 indicated above; IL-6 dose was 12.5ng/mL; cells treated twice with IL-6 showed the 
same response compared to cells treated with IL-6 followed by a vehicle treatment; results from 3 
independent experiments) 
 
In contrast, HepG2 cells treated with 25ng/mL of IL-6 had a greater HAMP mRNA 
response with a second IL-6 treatment, compared to cells that had only had a baseline 
IL-6 treatment (Figure 5.11).  
 
Figure 5.11 Repeated treatments of IL-6 or vehicle applied to HepG2 cells 
(Treatments 1 and 2 indicated above; IL-6 dose was 25ng/mL; two treatments with IL-6 produced a 
significantly increased response compared to IL-6 treatment followed by vehicle, p=0.009; results from 3 
independent experiments) 
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5.3.6 Is HepG2 HAMP Expression Induced By Human Plasma? 
As was shown earlier in this thesis, PBMC HAMP expression was lower in clinically 
stable and relatively uninflamed haemodialysis patients compared to healthy controls 
(4.3.1). In order to assess whether a circulating factor was possibly responsible for this, 
plasma from 6 haemodialysis patients and from 4 healthy individuals was incubated 
with HepG2 cells. A plasma concentration of 10% was used initially, followed in 
successive experiments by 5%, 2.5%, 1%, and 0.5% plasma, and these cells were 
incubated for 24 hours prior to RNA extraction. Irrespective of the plasma 
concentration used to incubate the cells, coagulation of the culture medium was 
witnessed, even with a plasma concentration as low as 0.5%. To circumvent this 
problem, heparin-sodium (10μL of 1000 iu/mL), as an anticoagulant, was added to the 
culture medium. No difference was seen in HAMP mRNA expression between HepG2 
cells that had been incubated with patient plasma, and cells incubated with plasma 
from healthy individuals. 
 
The experiment was repeated with plasma-free HepG2 cells, and plasma-free cells 
with heparin alone; rather unexpectedly, this showed considerable (>95%) 
downregulation of HAMP expression in the plasma-free cells treated with heparin, 
compared to the treated cells treated with heparin (p<0.0001) (Figure 5.12). 
 
 
Figure 5.12 HepG2 cells incubated with plasma and treated with heparin 
represented as (a) absolute mRNA values, and (b) fold-change values 
(Control plasma indicated by open circles; black squares indicate plasma from HD patients; crosses 
indicate that cells were free of plasma; heparin dose equivalent to 10 i.u.; plasma-free, heparin treated 
cells v plasma-free, heparin-free cells, p<0.0001;***p=0.0009; **p=0.0018) 
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There was no difference in HAMP expression between the cells treated with patient 
plasma, and the cells treated with control plasma from healthy individuals. HAMP 
expression was on average 90-92% lower in the plasma-treated cells, when compared 
to the cells that were treated with neither plasma nor heparin (Figure 5.12b). 
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5.4 Conclusions and Discussion 
The main findings from the work undertaken in this chapter were as follows; 
 
1. HAMP expression was upregulated in both PBMCs and HepG2 cells following 
treatment by IL-6 and BMP-6 
2. In PBMCs, HAMP expression peaked at 60 minutes following treatment with IL-
6; in HepG2 cells it peaked at 120 minutes 
3. HAMP induction in HepG2 cells was considerably more pronounced with BMP-
6 than with IL-6 
4. PBMCs that were treated with an initial dose of IL-6 appeared to be refractory to 
a second IL-6 treatment, whereas in HepG2 cells, a second dose of IL-6 
produced an additional effect  
5. The addition of heparin to the culture medium caused >90% HAMP 
downregulation in HepG2 cells 
 
The mechanism by which IL-6 upregulates HAMP expression in PBMC and HepG2 
cells occurs via activation of the IL-6 receptor with downstream JAK-STAT signalling 
causing increased HAMP transcription. In this model, STAT3 signalling only fully works 
in the presence of a functional SMAD pathway (Verga Falzacappa et al. 2007; Wang et 
al. 2005). The suppressive action of heparin on HAMP occurs via a completely 
separate pathway to IL-6; HepG2 cells express endogenous BMPs, which (in an 
autocrine fashion) eventually leads to HAMP transcription via the SMAD intracellular 
signalling system, and heparin is an enormously potent BMP binder (Poli et al. 2011). 
 
The HepG2 cell line was selected to study HAMP regulation in this chapter of work as it 
had been used by many researchers previously, including some of those that published 
seminal works in field of hepcidin regulation. The results, in terms of IL-6 stimulation, 
have been robustly consistent throughout the literature. The other human hepatic cell 
lines that have been used to study cellular hepcidin regulation are the Hep3B and Huh-
7 cell lines, which were all originally derived from patients with a form of hepatocellular 
carcinoma. Cancer is a well-known cause of anaemia affecting up to one-third of 
patients who are not on anti-neoplastic therapy (Gascon and Barrett-Lee 2006). There  
has been some interest in the possible role of cancer in hepcidin regulation. Vela and 
Vela-Gaxha produced an extensive review of the known mechanisms of hepcidin 
regulation in cancer, which appears to be mainly driven by the bone morphogenetic 
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proteins. Although BMP-6 is of primacy in iron/hepcidin regulation, some of the other 
BMPs are linked with hepcidin upregulation and are specifically linked with different 
tumour types e.g. BMP-7 in prostate and breast cancer, and BMP-2 in lung cancer. 
The expression of interleukin-6 is frequently increased in cancer and thus related to 
elevated hepcidin levels. Local hepcidin expression appears to be increased in most 
tumour types (except colon and hepatocellular carcinoma). Tumour hepcidin 
overexpression may be part of a tumour’s strategy to increase cellular iron (i.e. prevent 
its export from the cell) and this might represent an adaptive process to increase 
tumourigenesis. It is interesting that local hepatocellular carcinoma hepcidin levels are 
lower compared to controls given that the liver is the principal reservoir of hepcidin, and 
that relatively low hepcidin allows hepatocytes to become the preferential site of iron 
storage allowing the uninterrupted inward flow of iron (cf. enterocytes, macrophages) in 
order to increase cellular iron levels (Vela and Vela-Gaxha 2018). 
 
The results from the work in this chapter replicated some of the results published by 
Armitage and colleagues, both validating their work and confirming the ability of this 
investigator to replicate the methodology (Armitage et al. 2011). In the experiments to 
determine whether PBMCs were refractory to successive IL-6 stimulation, there was a 
slight difference in methodology used. Armitage and colleagues did not change the 
PBMC culture medium or wash the cells prior to the second treatment; nonetheless, 
both sets of results indicated that PBMCs were refractory to repeated IL-6 stimulation, 
thought to be a result of feedback inhibition on IL-6 signalling by SOCS3. Inhibition of 
IL-6 signalling is not a phenomenon witnessed in HepG2 cells, suggesting that the 
intra-cellular signalling mechanisms differ between the two cells types, perhaps 
underlining the difference that they play in innate immunity (Bode et al. 1999; Armitage 
et al. 2011). 
 
The most striking finding in this chapter was the profound suppression of HAMP 
expression, seen with heparin. This was a chance finding, arising from an attempt to 
investigate the effect of circulating factors in the plasma of haemodialysis patients upon 
HepG2 cells. Heparin has been shown to inhibit BMP-6, and an Italian group have 
previously demonstrated the suppressive effect of heparin on HAMP mRNA that it is 
mediated via the BMP-SMAD signalling system (Zhao et al. 2006; Poli et al. 2011). 
 
Chapter 5. Cytokine Regulation of HAMP in Hepatoma Cells and PBMCs 
152 
Unfractionated heparin-sodium is part of the standard anticoagulation regimen 
administered to haemodialysis patients at King’s College Hospital, and given its 
apparent substantial effect in vitro, the question then arose as to whether it was in fact 
administered heparin that caused the reduction in PBMC HAMP expression rather than 
a feedback inhibitor. This will be further explored in the next chapter of work. 
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6 Heparin and Hepcidin 
6.1 Introduction and Aims 
For decades, heparin has been used as a therapeutic anticoagulant in the 
management and thromboprophylaxis of conditions such as atrial fibrillation and 
venous thromboembolism. Interestingly, this glycosaminoglycan was originally 
discovered by a 2nd year medical student following extraction and purification from 
canine livers (McLean 1916; Howell and Holt 1918). Specifically, in the field of 
nephrology, heparin has, and still is used as an anticoagulant in the extracorporeal 
blood circuits of patients undergoing chronic haemodialysis. Under normal 
physiological conditions, heparin is produced by mast cells and since it is found in only 
trace amounts in the body, possesses no appreciable anticoagulant properties. 
However, when manufactured heparin is administered via the intravenous or 
subcutaneous route, it exerts a potent anticoagulant effect by combining with and 
increasing the activity of circulating antithrombin III causing neutralisation of thrombin 
and other factors found within the coagulation cascade (Guyton 1991). 
 
Although the initial discovery and work on heparin was undertaken by McLean, it was 
Howell who deduced that heparin was a carbohydrate and contained no phosphate 
residues (Howell 1928). Jorpes and others continued working on determining the 
structure of heparin and discovered that it contained a high degree of sulfate and 
carboxyl groups, rendering heparin both highly acidic and giving it possibly the highest 
negative charge of any known biological macromolecule (Capila and Linhardt 2002). It 
is these qualities that permit the promiscuous interaction of heparin with a number of 
positively charged endothelial and plasma-bound proteins (Table 6.1). 
 
Table 6.1 Selection of proteins that bind to heparin 
(Adapted from (Tyrell, Kilfeather, and Page 1995)) 
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While heparin is in widespread use as an anticoagulant and is generally considered 
safe, it has a wide range of biological activity that is responsible for the varied side-
effect profile that is witnessed outside the sphere of the coagulation systems. Up to 5% 
of those receiving long-term unfractionated heparin are in danger of developing 
osteoporosis, but hepatotoxicity, heparin-induced skin lesions, and hypoaldosteronism 
have also been associated with its use (Hirsh et al. 2001). At least 18 bone 
morphogenetic proteins (BMP) have been identified, which are part of the transforming 
growth factor-β superfamily of proteins, and the BMP signalling pathway is implicated 
in many of the body’s biological functions (Figure 6.1); the interaction between heparin 
and BMP-2 is thought to be one of the factors that contributes to the risk of 
osteoporosis (Simann et al. 2015). 
 
Figure 6.1 Representative members of the BMP signalling pathway that have 
been demonstrated to cause or be associated with human diseases 
Abbreviations: BMP(R) – bone morphogenetic protein (receptor); LOF, loss-of-function; GOF: gain-of-
function; CAKUT, congenital anomalies of the kidney and urinary tract; CKD, chronic kidney disease; FOP, 
fibrodysplasia ossificans progressiva; OI, osteogenesis imperfecta; OA, osteoarthritis; A–M, 
anophthalmia–microphthalmia; PAH, pulmonary arterial hypertension; HHT, hereditary haemorrhagic 
telangiectasia; BO, Barrett’s oesophagus; JP, juvenile polyposis (reproduced from (Wang et al. 2014)) 
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Contained within the list of BMP-mediated biological functions is iron metabolism and 
the control of the main iron regulatory hormone, hepcidin. Babitt and colleagues 
established the importance of the BMP signalling system in the regulation of hepcidin, 
and furthermore showed that hemojuvelin (HJV) was an important co-receptor in the 
signalling pathway (Babitt et al. 2006). Both circulating and hepatic iron regulate the 
activity of hepcidin by modulating the BMP-6-SMAD signalling system, although these 
occur through different mechanisms (Ramos et al. 2011; Corradini et al. 2011). 
 
As far as can be ascertained, until Poli and colleagues showed that heparin was a 
potent inhibitor of hepcidin both in vitro and in vivo, there had been only one other 
(German) study that examined the use of heparin and demonstrated derangements in 
iron metabolism and availability (Braunsteiner, Sailer, and Weippl 1959). Poli et al used 
cultured hepatocyte (HepG2) cells to show that concentrations of unfractionated 
heparin of 4μg/mL and above were sufficient to reduce HAMP expression to <5% of 
basal levels, and that this was enacted through a reduction in phosphorylated SMAD 
1/5/8 proteins via BMP-6 (Poli et al. 2011). Other research groups have also confirmed 
that heparin strongly binds BMP-6 (Brkljacic et al. 2013). Similar effects were 
witnessed with low-molecular weight heparin and a synthetic selective factor Xa 
inhibitor, although the inhibition of HAMP expression was less marked than that 
achieved with unfractionated heparin. The reduction of hepcidin and subsequent 
increase in serum iron concentrations were confirmed in murine models, cementing the 
relationship between heparin and hepcidin. The conclusion from their patient data was 
weaker, however, with the authors tentatively suggesting that heparin may induce an 
increase in serum iron concentrations as well as a reduction in CRP levels in 5 
inflamed patients (Poli et al. 2011).  
 
There have been recent attempts to capitalise on heparin’s powerful negative 
regulatory effect on hepcidin and harness it as a potential therapeutic. Poli and 
colleagues have investigated the non-anticoagulant heparins and found that glycol-split 
non-anticoagulant heparins as well as over-sulfated low molecular weight heparins 
inhibit hepcidin both in vitro and in vivo (Poli, Asperti, Naggi, et al. 2014; Poli, Asperti, 
Ruzzenenti, et al. 2014). Heparins that are able to maximally antagonise hepcidin are 
both highly sulfated and possess an N-acetylation degree of approximately 14% 
(Asperti et al. 2015). 
 
Chapter 6. Heparin and Hepcidin 
156 
To date, there has been one published clinical study examining the impact of low-
molecular weight heparin on hepcidin levels in a paediatric cohort presenting with 
acute ischaemic strokes, in which the authors showed that use of subcutaneous 
enoxaparin sodium (Sanofi-Aventis) was associated with a fall in serum hepcidin levels 
(Azab et al. 2016). 
 
As was shown in 4.3.1, monocyte HAMP expression is reduced in chronic 
haemodialysis patient in spite of having very high plasma hepcidin levels. It is possible 
that this may be a result of feedback inhibition, but dialysis patients also receive 
intravenous heparin with each dialysis session. Given the potent negative effect of 
heparin on HAMP expression, it was important to determine whether administered 
heparin was responsible for reduced PBMC HAMP expression. 
 
The aim of the work presented in this chapter is to: 
1. Examine the effect of unfractionated heparin and low-molecular weight heparin 
on in vitro HAMP expression 
2. Investigate whether human PBMC HAMP is affected by the administration of 
unfractionated heparin to renal patients that are new to haemodialysis and are 
heparin-naïve 
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6.2 Methods 
6.2.1 In Vitro Experiments 
The in vitro experiments presented in this chapter of work were undertaken using 
HepG2 cells that were gifted by Professor Andrew McKie (King’s College London). All 
experiments were carried out in the Renal Sciences Laboratory at the Rayne Institute, 
Denmark Hill, King’s College London. 
 
6.2.1.1 Cell Culture and Reagents 
HepG2 cells are an adherent human hepatoma cell line that are commonly used in 
studies investigating hepcidin regulation, and were used by Poli and colleagues to 
examine the effect of heparin on HAMP expression (Poli et al. 2011). The standard 
culture medium included Dulbecco’s modified Eagle medium (DMEM) (11965092, 
Gibco, ThermoFisher Scientific, Paisley, UK) supplemented with 10% fetal bovine 
serum (FBS) (F7524, Sigma-Aldrich), which was then treated with 100U/mL penicillin 
and 100μg/mL streptomycin (15070-063, ThermoFisher Scientific). The cells were 
routinely grown and passaged in rectangular 75cm2 flasks (431464, Corning, UK) and 
incubated in a Techne incubator at a temperature of 37°C, in a humidified atmosphere 
containing 5% CO2. Passaging of the cells was permitted by the use of phosphate-
buffered saline (PBS) (D8537, Sigma-Aldrich) to wash the cells, and trypsin-EDTA 
(25300, ThermoFisher Scientific) to separate the cells from the flask. The cells were 
centrifuged (Heraeus Labofuge 400) at 15000G for 5 minutes; following the removal of 
the supernatant, the cells were washed with PBS, and re-suspended in 20mL of 
warmed medium. The cells were seeded into 35mm dishes (627 160, Greiner Bio-one) 
at a concentration of 8 x 105 cells/dish with a total of 2mL DMEM. After the cells 
reached 70% confluence, usually after a 48-hour incubation period, they were serum-
starved overnight, for experimental use the following morning. 
 
Heparin sodium and enoxaparin was obtained from the Renal Ward supply and were 
applied for 18 hours, after which time RNA was extracted. The concentrations of 
heparin sodium (i.u./mL) that were applied were as follows: 
0.48, 0.98, 1.95, 3.90, 7.81, 12.50, 15.63, 25.00, 31.25, 50.00, 62.50, 100.00 
 
The concentrations that are underlined were serial dilutions made with DMEM culture 
medium from an initial stock concentration of 1000 i.u./mL. The other (non-underlined) 
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concentrations were made from an initial stock concentration of 100 i.u./mL, again 
using DMEM culture mediums to make the dilutions 
 
The concentrations of enoxaparin (μg/mL) that were applied were as follows: 
0.32, 1.60, 8.00, 40.00, 200.00, 400.00 
 
Serial dilutions were made from an initial stock concentration of 400 μg/mL, again 
using DMEM culture medium. All the reagents used during the in vitro experiments are 
listed in Table 6.2. 
 
Reagent Company Catalogue number 
Dulbecco’s modified Eagle 
Medium 
ThermoFisher Scientific 41966029 
Enoxaparin (Clexane®) Sanofi-Aventis N/A 
Ethanol Haymankimia F200236 
Fetal bovine serum Sigma-Aldrich F7524 
Heparin sodium LEO Pharma N/A 
Penicillin ThermoFisher Scientific 15070-063 
Phosphate-buffered saline Sigma-Aldrich D8537 
Streptomycin ThermoFisher Scientific 15070-063 
Trypsin EDTA ThermoFisher Scientific 25300 
Table 6.2 Reagents used in experimental cell culture 
 
6.2.1.2 RNA Extraction 
All work surfaces were cleaned with detergents and industrial methylated spirits prior to 
RNA extraction. An RNase decontamination solution (AM9780, Invitrogen) was used 
for added security against RNases. The QIAshredder (79654, Qiagen) and RNeasy 
Mini Kits (74104, Qiagen) were the principal kits used in the extraction of RNA from 
cellular material and used according to the manufacturers’ instructions. All RNA that 
was obtained was immediately stored at -80°C for reverse transcription on a future 
occasion. 
 
6.2.1.3 Reverse Transcription 
Reverse transcription from RNA to cDNA was undertaken using the High Capacity 
RNA-to-cDNA Kit (4387406, Applied Biosystems), according to the manufacturer’s 
instructions. An 8-well NanoDrop spectrophotometer (ThermoFisher Scientific) was 
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utilised to determine the quantity and purity of the RNA prior to reverse transcription. 
Samples were then pipetted into 96-well reaction plates (N801-0560, Applied 
Biosystems) combined with the reagents supplied by the manufacturer, to a total 
volume of 20μL. The samples were heated in a cyclical manner (Veriti Thermal Cycler, 
Applied Biosystems) for 65 minutes, before being cooled to 4°C; 80μL of RNase-free 
water (129112, Qiagen) was added to each sample to bring the reaction to a complete 
halt. Samples were immediately stored at -20°C. 
 
6.2.1.4 Quantitative PCR 
Quantitative PCR is used to measure the amplification of DNA, and this methodology 
can detect even minor changes in gene expression. TaqMan (Applied Biosystems) 
primer-probes were used for the detection of HAMP mRNA (Hs00221783_m1) and 
GAPDH mRNA (Hs02758991_g1). The primer-probes were combined with TaqMan 
Universal PCR Master Mix (4324018, Applied Biosystems), RNase-free water and the 
reverse-transcribed cDNA. Volumes of 10μL per sample, which were tested in 
triplicate, were placed in a 384-well plate (4309849, Applied Biosystems), and a 
QuantStudio 7 Flex Real Time PCR System (Applied Biosystems) was used to perform 
the analysis that would determine the expression of the target gene relative to the 
housekeeping gene. 
 
6.2.2 Clinical Study 
The clinical element of the work presented in this chapter was carried out using 
samples obtained from patients who were dialysed on the Main Haemodialysis Unit, 
King’s College Hospital, London. The aim of this study was to assess the response of 




Subjects were adult patients who were tracked in the Low Clearance Clinic and were 
approached by this investigator prior to their planned start to haemodialysis. The 
decision to commence dialysis was taken by the patients’ renal physician, during the 
weekly Low Clearance Results meeting, when the criteria for haemodialysis were 
considered. Biochemical data, patient symptoms, pulmonary/peripheral oedema, and 
electrolyte disturbances were the main criteria that were taken into consideration. 
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6.2.2.2 Study Design 
This was an exploratory, prospective, longitudinal cohort study. Once patients had 
been identified in the Low Clearance Clinic weekly meeting, they were approached and 
given a patient information sheet. If they agreed to participate in the study and provided 
a signed consent form, they were considered eligible for the study. It was imperative 
that the patients had been embedded within the Low Clearance service for 3 months or 
longer, and that the transition to haemodialysis was deliberately planned. Patients who 
had been consented but were admitted as an emergency to the Accident and 
Emergency department and who commenced haemodialysis in an emergency 
unplanned fashion were not included in the study. Patients who were formally 
anticoagulated with vitamin K antagonists, or who had received any form of heparin 
within the 4 previous weeks were deemed ineligible. The other inclusion and exclusion 
criteria can be seen in Table 6.3. The exclusion criteria included a history of 
haematological dyscrasias, defined as any disease process that necessitated the 
patient having visited the Haematology department at any time for treatment or follow-
up (except for iron-deficiency anaemia). 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
≥18 years of age Active malignancy 
Low Clearance patient ≥3 months Anticoagulation within 4 weeks 
Stage 5 CKD-ND Blood transfusion within 4 weeks 
 Chronic inflammatory condition 
 History of haematological dyscrasia 
 History of liver disease 
 Hospital admission within 4 weeks 
 Signs of acute/occult bleeding 
Table 6.3 Inclusion and exclusion criteria for heparin study 
 
The King’s acute haemodialysis protocol for patients newly commenced on 
haemodialysis has specific recommendations for the commencement of 
anticoagulation, and this is summarised in Figure 6.2. Only the first two haemodialysis 
sessions are undertaken without anticoagulation, with unfractionated heparin being 
administered thereafter, as a bolus of 1000 i.u. and a subsequent infusion of 1000 i.u. 
Chapter 6. Heparin and Hepcidin 
161 
 
Figure 6.2 Blood sampling schedule  
(Squares indicate haemodialysis (HD) sessions that were heparin-free; circles indicate HD sessions where 
a total of 2000 i.u. unfractionated heparin was administered) 
 
Baseline blood samples were obtained prior to the start of the first session of 
haemodialysis as part of routine clinical care. Study samples were taken prior to the 
start of the first 6 HD sessions (Figure 6.2). 
 
6.2.2.3 Demographics and Baseline Data 
A total of 8 patients, who satisfied the inclusion and exclusion criteria, were recruited 
for this study. Of the 8 patients, 6 started haemodialysis in a planned fashion and their 
data were analysed. The 2 other patients were recruited but commenced dialysis in an 
unplanned fashion and were admitted to the Renal Ward for emergency care. 
 
Age (years) 56.3±17.0 
Males (n (%)) 5 (83.3) 
Caucasian (n (%)) 4 (66.7) 
Diabetes (n (%)) 2 (33.3) 
Hypertension (n (%)) 4 (66.7) 
eGFR (mL/min/1.73m2) 8.2±1.0 
Haemoglobin (g/L) 100.2±14.7 
Ferritin (ng/mL) 207.5±62.8 
Albumin (g/L) 38.8±3.1 
Table 6.4 Demographics and baseline laboratory data 
 
The mean age of the patients who were recruited into this study was 56.3±17.0 years 
of age. The patients were anaemic, at the lower end of the acceptable range for stage 
5 CKD patients, with a mean haemoglobin of 100.2 g/L and ferritin of 207.5 ng/mL 
(Table 6.4). None of the patients had been commenced on an ESA prior to the 
commencement of dialysis. The mean eGFR at the start of dialysis was 8.2 
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mL/min/1.73m2, and the commonest reason for the commencement of haemodialysis 
was the development of uraemic symptoms, in 4 patients (Figure 6.3). 
 
Figure 6.3 Schematic representation of numbers of subjects with their (a) cause 
of end-stage renal failure (b) reasons for commencement of haemodialysis  
 
6.2.2.4 Methods 
The methods of hepcidin measurement by mass spectrometry have been discussed in 
detail previously (1.4.1). Routine patient blood samples were processed in the King’s 
College Hospital central laboratory. The method for HAMP mRNA measurement will be 
briefly revisited but is covered comprehensively on page 80. 
 
HAMP mRNA measurement 
• 10mL blood drawn (and divided into two) and separated by Ficoll-Hypaque Plus 
(GE Healthcare) centrifugation 
• Plasma was obtained post-centrifugation and immediately stored in 500µL 
aliquots 
• Two sets of 5x106 peripheral blood mononuclear cells were isolated for each 
participant 
• Total cellular RNA was subsequently extracted (RNeasy, Qiagen) and 
immediately stored at -80°C 
• 500ng RNA was reverse transcribed (High Capacity RNA-to-cDNA Kit, Applied 
Biosystems) 
• All cDNA samples were processed in a single run to eliminate inter-
experimental variability 
• Amplification reactions were performed using Taqman HAMP and GAPDH 
primer-probes in triplicate 
• Quantitative RT-PCR was performed using the 7900 HAT Fast Real-Time 
system (Applied Biosystems) 
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6.2.2.5 Statistical Analyses 
Differences between the means of normally distributed test statistics were determined 
with the independent Student’s t test. Relationships between various parameters under 
study were also examined; simple linear coefficients (r) were calculated using the 
Pearson’s product formula. P-values <0.05 (two-tailed) were considered statistically 
significant. Analyses were performed using GraphPad Prism version 6.0 for Macintosh, 
GraphPad Software, La Jolla California USA. 
 
6.2.2.6 Ethics and Regulatory Approvals 
The London Research Ethics Committee 1 (LREC 09/H0718/034) granted ethical 
approval. Local R&D approval was obtained to undertake this study, which was 
conducted in accordance with the principles outlined in the Declaration of Helsinki. 
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6.3 Results 
Results are expressed at means ± standard deviation, unless otherwise specified, of 
three separate experiments. 
 
6.3.1 Unfractionated Heparin Dose-Response 
HepG2 cells were incubated with increasing doses of unfractionated heparin from 0.48 
i.u./mL to 100 i.u./mL for 18 hours.  
 
 
Figure 6.4 Log dose-response curve relative to basal levels: unfractionated 
heparin concentrations 0.48 to 100 i.u./mL 
 
At concentrations of unfractionated heparin below 1 i.u./mL, there was no reduction in 
HAMP expression relative to basal levels. However, there was a steep dose-response 
relationship seen between 1 and 4 i.u./mL, with HAMP expression levels suppressed to 
approximately 20% of basal levels. 
 
Between 4 and 100 i.u./mL, there continued to be a dose-dependent suppression of 
HAMP expression, with levels down to 5% with suppression of HAMP expression down 
to approximately 5% of the basal level seen with the maximum concentration tested 
(100 i.u./mL) (Figure 6.4). 
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6.3.2 Low Molecular Weight Heparin Dose-Response 
HepG2 cells were incubated with increasing doses of low molecular weight heparin, 
enoxaparin, from 0.32 μg/mL to 400 μg/mL for 18 hours.  
 
 
Figure 6.5 Log dose-response curve relative to basal levels: low-molecular 
weight heparin concentrations 0.32 to 400 μg/mL 
 
In contrast to unfractionated heparin, the low molecular weight heparin appeared to 
induce HAMP expression at the lower concentrations of enoxaparin, of 1.6 μg/mL and 
8 μg/mL. At a concentration of 1.6 μg/mL, HAMP expression was approximately 30% 
higher compared to basal levels, while at 8 μg/mL, levels were 10% higher than at 
basal. 
 
However, with higher concentrations of enoxaparin, HAMP expression was significantly 
reduced. At 40 μg/mL, HAMP expression was approximately 40% of basal levels; this 
fell to approximately 25% of basal levels at 200 μg/mL, and approximately 20% of 
basal levels at 400 μg/mL (Figure 6.5). 
 
6.3.3 Hepcidin and HAMP Levels – Individual Data 
Blood samples were taken at the beginning of each haemodialysis session for 6 
patients who transitioned from the Low Clearance Service. All patients received no 
heparin during their first two haemodialysis sessions, and then went on to receive 
heparin during their subsequent sessions. All patients were prescribed intravenous iron 
Chapter 6. Heparin and Hepcidin 
166 
and were given 100mg iron sucrose weekly, thereby receiving two doses during the 
course of the study. 
 
As can be seen in Figure 6.6, Patient A received 2 doses of intravenous iron, which 
was administered during their second and fifth haemodialysis session (as indicated by 
the solid arrows in the figure). There was a rise in hepcidin in response to the first 
dose, but this was not seen following the second dose. HAMP expression appeared to 
fall consistently from the third haemodialysis session onwards, with no overt response 
to systemic iron. 
 
Figure 6.6 Hepcidin and HAMP expression in Patient A following their first 6 
haemodialysis sessions 
(Arrows indicate the HD session wherein iron sucrose was administered (100mg)) 
 
Hepcidin and HAMP data for all 6 patients (A to F) is shown in Figure 6.7. All of the 
patients had a rise in hepcidin levels following the administration of the first dose of IV 
iron. Following the second dose of iron, 3 patients had fall in hepcidin levels (patients 
A, B, and F), and 3 patients had a rise in iron (C and E), whilst patient F had a dose of 
iron at the end of the 2 weeks and the hepcidin response to this dose was not 
assessed. There was an enormous degree of variability in the hepcidin levels across 
the 2 weeks among the 6 patients, and no pattern emerged related to the timing of the 
administration of IV iron. The HAMP response to IV iron also appeared indiscriminate. 
Four of the patients (B, C, D, and E) had a rise in HAMP mRNA levels following the first 
dose of IV iron. As was seen for hepcidin, fewer patients (only 2; patients B and C) had 
a rise in HAMP mRNA levels following the second IV iron dose. Again, HAMP mRNA 
levels were highly variable and there was no pattern between the dosing of the iron 
and the subsequent measured levels (Figure 6.7, overleaf). 
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Figure 6.7 Hepcidin and HAMP expression in all six patients following their first 6 
haemodialysis sessions 
(Bold arrows indicate the HD session wherein iron sucrose was administered (100mg); upper panels 
represent hepcidin levels, and lower panels represent HAMP mRNA levels) 
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6.3.4 Hepcidin and HAMP Expression Levels – Group Data 
There was no difference in the mean hepcidin levels categorised by haemodialysis 
session (Figure 6.8). 
 
 
Figure 6.8 Mean hepcidin levels categorised per haemodialysis session 
 
Although there was a trend towards greater mean HAMP expression levels in the 
samples taken prior to the sixth haemodialysis session, this was not statistically 
different from the levels seen at any of the other time points (Figure 6.9). 
 
 
Figure 6.9 Mean HAMP levels categorised per haemodialysis session 
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There was also no correlation seen (R2=0.07) between absolute HAMP expression and 
hepcidin levels (Figure 6.10).  
 
 
Figure 6.10 Correlation between hepcidin and HAMP expression 
 
6.3.5 Does Heparin Affect Hepcidin or HAMP Expression Following Iron 
Therapy? 
 
All 6 patients received their first dose of intravenous iron therapy within the first two 
haemodialysis session; during this time, no heparin was administered. Their second 
dose of intravenous iron was administered one week after their respective first doses, 
and all the patients were receiving heparin by this point. 
 
Without heparin, there was a trend towards greater mean HAMP expression and 
hepcidin levels post-iron therapy compared to the pre-iron therapy levels, although the 
differences were not statistically significant (HAMP mRNA, p=0.13; hepcidin, p=0.2)  
(Figure 6.11). The impact of haemodialysis on the levels was negligible, given that the 
mean dialysis dose delivered during the sessions within which the first dose of 
intravenous iron was administered was 31.1±8.1 litres processed. 
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Figure 6.11 Hepcidin and HAMP expression before and after the first dose of 
intravenous iron 
(HAMP mRNA expression, comparison p=0.13; hepcidin comparison, p=0.2) 
 
In contrast, mean hepcidin levels following the second dose of intravenous iron were 
slightly lower following iron therapy, compared to the pre-iron level, but were not 
statistically different (p=0.6) (Figure 6.12). HAMP expression followed the same 
trajectory as seen in the pre-heparin comparison (p=0.6). The dialysis dose delivered 
during the sessions within which the second dose of intravenous iron was administered 
was 34.7±9.2 litres processed, which was similar to the pre-heparin group (p=0.7). 
 
 
Figure 6.12 Hepcidin and HAMP expression before and after the second dose of 
intravenous iron   
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6.4 Conclusions and Discussion 
The main findings from the work undertaken in this chapter were as follows; 
1. Unfractionated heparin suppresses HAMP expression in HepG2 cells in a dose-
dependent manner, with maximal suppression occurring above 4 i.u./mL 
2. Low molecular weight heparin also suppresses HAMP expression, but appears 
to induce HAMP at lower concentrations 
3. Patients who were heparin-naïve and started haemodialysis in a planned 
fashion had a rise in hepcidin levels following a dose of IV iron 
4. Once these patients received heparin, 50% of them had a fall in hepcidin levels 
following a second dose of IV iron 
5. No correlation was seen between hepcidin and HAMP mRNA 
 
The in vitro data presented in this chapter are consistent with the data from Poli and 
colleagues, confirming that heparin is a potent suppressor of hepcidin expression in 
hepatocytes (Poli et al. 2011). Unfractionated heparin suppressed hepcidin in a dose-
dependent fashion, with near-maximal suppression from 4 i.u./mL in this chapter, 
whereas Poli and colleagues showed maximal suppression at slightly higher 
concentrations. Interestingly, HAMP suppression was also demonstrated with the low-
molecular weight heparin, but HAMP stimulation was observed at the lower 
concentrations. The ability of low molecular weight heparins to simultaneously 
stimulate and suppression HAMP may be due to competitive inhibition with 
endogenous heparin sulfates or the interaction with BMP antagonists, although the 
exact mechanism for this remains unknown, and requires elucidation. Similar 
phenomena have been previously reported in relation to the bone morphogenetic 
proteins (Takada et al. 2003; Miyazono, Kamiya, and Morikawa 2010). 
 
This is the first attempt to examine the effect of heparin on hepcidin levels in a 
haemodialysis cohort. This exploratory study was undertaken in a small patient cohort 
and despite the small numbers, there was a suggestion that those patients who were 
new to haemodialysis and received IV iron had a rise in hepcidin levels in response to 
the IV iron. However, this observation was not replicated in patients in whom heparin 
was administered. None of the patients were on an ESA at the start of the study, but all 
of the patients were prescribed Neorecormon® 2000 i.u. thrice-weekly as part of 
routine clinical care, and had a dose administered by at least the second session of 
haemodialysis. ESAs are a potential confounder as they reduce HAMP expression, but 
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all the patients had a rise in hepcidin levels, whist 4 out of 6 patients had a rise in 
HAMP mRNA following the first dose of iron. Following administration of the second 
dose of iron, half of the patients had a fall in hepcidin levels and HAMP mRNA. 
 
The effect of dialysis on hepcidin levels has been well described, but in this study, the 
dialysis dose (in terms of litres processed) administered to each patient was less than 
half the recommended dose. Ashby and colleagues have shown that hepcidin is 
correlated with both dialysis clearance and ESA dose, although the authors’ 
interpretation of the data was that increased hepcidin clearance led to a reduced 
erythropoietin requirement, rather than ESAs leading to reduced hepcidin levels (Ashby 
et al. 2017). If this is true, then we are left with the only other significant modifier being 
the addition of heparin. However, there was no statistically significant difference 
between mean hepcidin and HAMP levels, before and after the administration of iron. 
 
The dose of heparin administered to the haemodialysis patients was 2000 i.u., which 
equates to approximately 0.35 i.u./mL in the typical patient with a circulating volume of 
5-6L. In the in vitro study, this concentration had no discernible effect, and perhaps this 
may explain the lack of effect at this dose. In light of this, it is possible that the 
reduction in hepcidin levels in heparin-naïve patients was simply a chance finding and 
would be better tested in a larger cohort of patients who are ESA-naïve. These patients 
could be split into 2 groups; one group in whom iron is administered, and a control 
group. It is theoretically possible that higher concentrations of heparin might suppress 
hepcidin to a larger degree than seen in this study, but the administration of such 
doses would not be possible in clinical practice. There are no published data on 
whether the effect of heparin on HAMP differs when cells are in plasma or serum. 
 
The obvious limitation of the study was the patient numbers, which were too small for a 
definitive effect to be seen, and the study was conducted within the constraints of 
routine clinical care, which did not allow for the correction for factors such as time 
between dialysis or dialysis dose (which were incidentally equivalent between the two 
groups), or the withholding of ESA therapy. 
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7 Glucocorticoids and Hepcidin 
7.1 Introduction and Aims 
Given the principal role that hepcidin plays in the metabolism of iron, it is perhaps not 
surprising that much of the recent renal literature concerning hepcidin has been 
devoted to its potential role either as a biomarker (to stratify the severity of anaemia or 
to guide iron therapy), or as a therapeutic target to treat anaemia. There has been less 
focus on the role that inflammation plays in the renal setting, which in part prompted 
the work presented in this chapter. As has previously been discussed, the two main 
drivers of hepcidin production are inflammation, which is largely mediated by IL-6, and 
iron, which is predominantly mediated by BMP-6 (1.3.5.1). In addition to IL-6, IL-1β and 
lipopolysaccharide have both been shown to upregulate HAMP expression via the 
JAK/STAT intracellular signalling pathway (Lee et al. 2005). There is emerging 
evidence that the two pathways are not completely separate and that there may be 
crosstalk between the two sides of the hepcidin divide. TMPRSS6 (also known as 
matriptase-2) inhibits hepcidin expression and is crucial in regulating iron homeostasis 
(Guo, Casu, et al. 2013). However, it has now been shown that inflammation is also a 
downregulator of TMPRSS6 expression, acting independently of the BMP-SMAD 
pathway, occurring instead through a reduction in STAT5 phosphorylation (Figure 7.1) 
(Meynard et al. 2013).  
 
 
Figure 7.1 Schematic representation of the role of inflammation and hepcidin in 
the anaemia of chronic disease 
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It has long been recognised that inflammatory cytokines cause functional iron 
deficiency by locking iron stores in the reticuloendothelial system, but the effector 
mechanism was not known until the discovery of hepcidin, providing increased clarity in 
the understanding of the aetiology of the anaemia of chronic disease (ACD). Hepcidin 
is crucial for maintaining iron homeostasis, but in the presence of increased hepcidin 
levels, the cellular iron export protein, ferroportin, is degraded and iron is locked within 
the reticuloendothelial system, incapable of being used for erythropoiesis (Nemeth, 
Tuttle, et al. 2004). Thus, inflammatory cytokines ostensibly lead to iron deficiency, or 
at least an inability to utilise iron efficiently, but they also instigate other effects that 
result in an anaemic state. This of course is not recent information; the link between 
inflammation, disordered iron metabolism and anaemia was reported in the 1940s by 
researchers who injected animals with bacteria and then measured their subsequent 
capacity to utilise iron (for Hb synthesis) using radioactive tracers (Wintrobe, 
Greenberg, and et al. 1947). Twenty-seven years later in the same journal, Zucker and 
colleagues added to this earlier work by describing the link between inflammation and 
the blunting of EPO responsiveness. They showed that an inflammatory anaemia could 
be overcome by the use of erythropoietin (Zucker, Friedman, and Lysik 1974). We now 
know the identity of some of the over-expressed cytokines that are involved in the 
anaemia of chronic disease, including IL-1, IL6, IL-10, LPS, TNF-α, and IFN-γ (Weiss 
and Goodnough 2005). Other factors that contribute to the anaemia of chronic disease 
include direct bone marrow suppression, and decreased survival of red blood cells. 
Their sites of action are summarised below in Table 7.1. 
 
Cytokine(s) Site of action 
IL-6, LPS Hepcidin induction 
IFN-γ FPN degradation 
IFN-γ, LPS  Increase expression of DMT-1 stimulating iron uptake 
IL-1, IL-6, IL-10, TNF-α Increase ferritin, leading to macrophage iron storage 
IL-1, TNF-α, IFN-γ Inhibit differentiation/proliferation of erythroid progenitor cells 
TNF-α, IFN-γ Decreases renal EPO production 
IL-22 Hepcidin induction (animal models) 
Table 7.1 Sites of action of cytokines in the development of anaemia 
Abbreviations: IL – interleukin; LPS – lipopolysaccharide; IFN – interferon; TNF – tumour necrosis factor; 
DMT-1 – divalent metal transporter 1; EPO – erythropoietin; FPN – ferroportin; TfR – transferrin receptor; 
TBI – transferrin bound iron 
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Many of the treatment options, available for decades prior to the discovery of hepcidin, 
are still in use, including epoetin, iron, and red cell transfusions (Weiss 2002). 
Predictably, there is a quest to develop anti-hepcidin strategies, as they provide an 
attractive addition to the ACD armamentarium, theoretically unlocking hitherto 
inaccessible iron stores for the purpose of erythropoiesis. These and other novel 
agents are at various stages in the drug development cycle. 
 
The main drivers of hepcidin production in non-renal chronic inflammatory conditions, 
such as inflammatory bowel disease or rheumatoid arthritis, are related to the 
production of monocyte-derived IL-6 and IL-1 that subsequently activate production of 
interferon β and γ (Raj 2009; Voulgari et al. 1999). To further highlight the integral part 
that IL-6 plays in inflammatory anaemias, the use of a monoclonal antibody specific for 
IL-6 (tocilizumab) has been very successful in the treatment of juvenile rheumatoid 
arthritis, significantly improving the associated anaemia (De Benedetti et al. 2012). In 
renal disease, many of the pathophysiological mechanisms described above apply to 
the pathogenesis of anaemia in CKD. The vast majority of studies to date have 
examined the role of inflammatory cytokines in CKD-anaemia. There is, however, also 
some interest in the role of IL-22, which is simultaneously implicated in AKI and also 
able to induce hepcidin in pre-clinical models (Wallace and Subramaniam 2015). The 
inflammatory milieu of renal disease has consequences aside from anaemia, including 
renal fibrosis and changes in the renal tubule that control sodium transport, thereby 
allowing sodium retention in the face of an inflammatory stimulus (Meng, Nikolic-
Paterson, and Lan 2014; Norlander and Madhur 2017). 
 
Along with autoimmune-driven disease processes, inflammation is one of the most 
important pathophysiological mechanisms in nephrology, given the fact that anti-
inflammatory drugs, in the form of glucocorticoids, play an essential role in the 
treatment of a host of renal diseases (Kidney Disease: Improving Global Outcomes 
(KDIGO) Glomerulonephritis Work Group 2012). These include many of the 
glomerulonephritides and vasculitides that are encountered during everyday practice. 
In end-stage kidney disease, corticosteroids are one of the three pillars of current 
transplant immunosuppression practice along with the anti-proliferative agents and 
calcineurin inhibitors. 
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Zucker and colleagues showed that erythropoietin could overcome an inflammatory 
anaemia without a concomitant rise in the concentration in serum iron, but this was not 
the only hormone known to have this effect. A clinical study in the 1960s showed that 
testosterone could also mobilise iron from the reticuloendothelial system, although the 
mechanism was not understood (Haurani and Green 1967). We now know that steroid 
hormones such as testosterone, oestradiol and vitamin D have negative regulatory 
effects on hepcidin, thereby providing an explanation for Zucker’s observations 
(Dhindsa et al. 2016; Yang et al. 2012; Bacchetta et al. 2014). In contrast to the sex 
steroids, there are very limited data published on the role of glucocorticoids in human 
hepcidin regulation (Table 7.2). 
 
Author, year Study/subjects Steroid – finding  
(Salas-Leiton et 
al. 2012) 
Sole (fish) Dexamethasone – HAMP1 mRNA increased 
after 48h, but fell significantly after 2 weeks 
(Nie et al. 2014) Case report Methylprednisolone – hepcidin fell with 
concomitant rise in Hb, in a patient with IRIDA 




Hepcidin inversely associated with urinary 
prednisolone excretion 
Table 7.2 Studies examining the relationship between hepcidin and 
glucocorticoids 
Abbreviations: HAMP – hepcidin antimicrobial peptide; IRIDA – iron-refractory iron deficiency 
anaemia; RTx – renal transplant 
 
There is a single case report of a glucocorticoid (methylprednisolone) being used as a 
therapeutic agent in a 10-year-old girl with IRIDA (iron-refractory iron deficiency 
anaemia, resulting from a mutation in the gene encoding for TMPRSS6). Despite 
recurrent red cell transfusions, she remained profoundly anaemic. TMPRSS6 works by 
cleaving membrane-bound HJV, with the net effect of preventing BMP-SMAD 
activation, thus preventing hepcidin upregulation (Finberg et al. 2008). 
 
In IRIDA, the TMPRSS6 mutation leads to unregulated hyperhepcidinaemia, explaining 
why this patient remained anaemic despite iron and EPO therapy. Methylprednisolone 
(0.8mg/kg/day) was administered daily for one month; her hepcidin level fell 3-fold into 
the normal range, whilst simultaneously experiencing a rise in her Hb, which more than 
doubled from 58g/L to 124g/L (Figure 7.2).  
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Figure 7.2 The effect of methylprednisolone on hepcidin and haemoglobin levels 
in a patient with IRIDA 
(Reprinted from (Nie et al. 2014)) 
 
Upon cessation of the methylprednisolone, the patient’s hepcidin levels once again 
dramatically increased and her Hb returned to its pre-treatment level. Following a re-
challenge with methylprednisolone, her hepcidin levels fell and her Hb once again 
increased (Nie et al. 2014). 
 
Given the paucity of data in the literature examining the interaction of glucocorticoids 
and hepcidin, the aim of the work presented in this chapter is to: 
1. Use an in vitro model to investigate the effect of glucocorticoids on HAMP 
mRNA in a human hepatoma cell line 
2. Explore the effect of methylprednisolone on hepcidin levels in a cohort of 
vasculitis and glomerulonephritis patients presenting acutely to the renal unit at 
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7.2 Subjects and Methods 
7.2.1 In Vitro Experiments 
The in vitro experiments presented in this chapter were undertaken using cells that 
were gifted by Professor Andrew McKie (Nutritional Sciences, King’s College London). 
All experiments were carried out in the Renal Laboratory at the Rayne Institute, 
Denmark Hill, King’s College London. Cell culture experiments were carried out using 
HepG2 cells (ATCC). The reagents used are listed in Table 7.3. 
 
7.2.1.1 Cell Culture and Reagents 
HepG2 cells are human hepatoma cells that were derived from a 15-year-old 
Caucasian male with hepatocellular carcinoma. They have been used in many studies 
investigating hepcidin regulation and are adherent in cell culture. They were routinely 
grown and passaged in rectangular 75cm2 flasks (431464, Corning, UK) containing 
Dulbecco’s modified Eagle medium (DMEM) (11965092, Gibco, ThermoFisher 
Scientific, Paisley, UK) supplemented with 10% fetal bovine serum (FBS) (F7524, 
Sigma-Aldrich). The medium was treated with 100U/mL penicillin and 100μg/mL 
streptomycin (15070-063, ThermoFisher Scientific), and the flasks were incubated in a 
Techne incubator at a temperature of 37°C, in a humidified atmosphere containing 5% 
CO2. When the cells were approximately 80% confluent, the growth medium was 
removed and the cells were twice-washed with phosphate-buffered saline (PBS) 
(D8537, Sigma-Aldrich) to remove any trace of serum-supplemented medium, which 
may have rendered the trypsinisation process ineffective. 
 
The smallest amount (2mL) of trypsin EDTA (25300, ThermoFisher Scientific) was 
added to allow complete coverage of the cells, and the flasks were placed in the 
incubator for 5 minutes to allow complete detachment of the cells from the flask. FBS-
supplemented medium was then added to neutralise the trypsin. In order to completely 
remove the trypsin, the cells were centrifuged (Heraeus Labofuge 400) at 15000G for 5 
minutes, with subsequent removal of the supernatant; the cells were then washed with 
PBS, and 20mL of warmed medium was used to suspend the pellet. The cells were 
counted and seeded into 35mm dishes (627 160, Greiner Bio-one) at a concentration 
of 8 x 105 cells/dish with a total of 2mL DMEM, reaching 70% confluence after a 48-
hour incubation period. The cells were pre-treated with dexamethasone (D4902, 
Sigma-Aldrich) for up to 18 hours, and serum-starved overnight, for experimental use 
the following morning. 
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Reagent Company Catalogue number 
BMP-6 R&D systems 507-BP-020 
Dexamethasone Sigma-Aldrich D4902 
Dulbecco’s modified Eagle 
Medium 
ThermoFisher Scientific 41966029 
Ethanol Haymankimia F200236 
Fetal bovine serum Sigma-Aldrich F7524 
IL-6 Life Technologies PHC0065 
Penicillin ThermoFisher Scientific 15070-063 
Phosphate-buffered saline Sigma-Aldrich D8537 
Streptomycin ThermoFisher Scientific 15070-063 
Trypsin EDTA ThermoFisher Scientific 25300 
Table 7.3 Reagents used in experimental cell culture 
 
Dexamethasone (10mg) was reconstituted with ethanol (F200236, Haymankimia) and 
DMEM, as per the manufacturer’s instructions, to a stock solution of 20 μg/mL, and 
serial dilutions were then made in order to achieve a final concentration of 1.22 ng/mL 
using DMEM growth medium (Table 7.4). IL-6 (PH C0065, Life Technologies) and 
BMP-6 (507-BP, R&D Systems) were also reconstituted according to the 
manufacturers’ instructions. 
 
Dilution  Concentration 
0 20 μg/mL 
1 10 μg/mL 
2 5 μg/mL 
3 2.5 μg/mL 
4 1.25 μg/mL 
5 625 ng/mL 
6 312.5 ng/mL 
7 156.25 ng/mL 
8 78.12 ng/mL 
9 39.06 ng/mL 
10 19.53 ng/mL 
11 9.77 ng/mL 
12 4.88 ng/mL 
13 2.44 ng/mL 
14 1.22 ng/mL 
Table 7.4 Serial dilutions of 20μg/mL stock solution of dexamethasone 
(Shaded concentrations used in 7.3.1) 
 
7.2.1.2 Cell Viability Assay 
HepG2 cell viability during experimental conditions was assessed using a lactate 
dehydrogenase (LDH) assay (Cytotox 96 non-radioactive cytotoxicity, G1780, 
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Promega, UK). LDH is a stable enzyme (t½=9 hours) found in the cytosol and is 
released when there is cellular damage.  
 
5 x 103 HepG2 cells were suspended in 200μL DMEM, seeded into a sterile 96-well 
plate (3596, Corning), and incubated in an environment containing 5% CO2 at 37°C. 
The experimental schema comprised cells that were untreated, cells with the addition 
of dexamethasone (a dose of 20ng/mL was selected following the dose-response 
treatment curves), and cells with vehicle alone (2% ethanol). The cells were incubated 
for 48 hours before being serum-starved overnight (DMEM) and were subsequently 
treated with dexamethasone for 18 hours. LDH activity was assessed according to the 
manufacturer’s instructions, and absorbance was read on a 96-well spectrophotometer. 
Absorbance, at a wavelength of 490nm, was measured in each well. 
 
7.2.1.3 RNA Extraction 
All work surfaces were cleaned with detergents and industrial methylated spirits prior to 
RNA extraction. An RNase decontamination solution (AM9780, Invitrogen) was used 
for added security against RNases. The QIAshredder (79654, Qiagen) and RNeasy 
Mini Kits (74104, Qiagen) were the principal apparatus used in the extraction of RNA 
from cellular material and used according to the manufacturers’ instructions. All RNA 
that was obtained was immediately stored at -80°C for reverse transcription at a future 
occasion. 
 
7.2.1.4 Reverse Transcription 
Reverse transcription from RNA to cDNA was undertaken using the High Capacity 
RNA-to-cDNA Kit (4387406, Applied Biosystems), according to the manufacturer’s 
instructions. An 8-well NanoDrop spectrophotometer (ThermoFisher Scientific) was 
utilised to determine the quantity and purity of the RNA prior to reverse transcription. 
Samples were then pipetted into 96-well reaction plates (N801-0560, Applied 
Biosystems) combined with the reagents supplied by the manufacturer, to a total 
volume of 20μL. The samples were heated in a cyclical manner (Veriti Thermal Cycler, 
Applied Biosystems) for 65 minutes, before being cooled to 4°C; 80μL of RNase-free 
water (129112, Qiagen) was added to each sample to bring the reaction to a complete 
halt. Samples were immediately stored at -20°C. 
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7.2.1.5 Quantitative PCR 
Quantitative PCR is used to measure the amplification of DNA, and this methodology 
can detect even minor changes in gene expression. TaqMan (Applied Biosystems) 
primer-probes were used for the detection of HAMP mRNA (Hs00221783_m1) and 
GAPDH mRNA (Hs02758991_g1). The primer-probes were combined with TaqMan 
Universal PCR Master Mix (4324018, Applied Biosystems), RNase-free water and the 
reverse-transcribed cDNA. Volumes of 10μL per sample, which were tested in 
triplicate, were placed in a 384-well plate (4309849, Applied Biosystems), and a 
QuantStudio 7 Flex Real Time PCR System (Applied Biosystems) was used to perform 
the analysis that would determine the expression of the target gene (HAMP) relative to 
the housekeeping gene (GAPDH). 
 
7.2.1.6 Protein Extraction 
1 x 106 HepG2 cells were plated in 60mm dishes with 5mL culture medium containing 
DMEM supplemented with 10% FBS, penicillin and streptomycin as described in 
6.2.1.1 (page 157). The dishes were incubated until the cells were approximately 70% 
confluent; cells were serum-starved prior to the application of experimental 
treatments/vehicle. The dishes were placed on ice and the cells washed thoroughly 
(twice) with PBS. Isolation of cellular protein occurred via disruption of the cell 
membranes using a PBSTDS lysis buffer with the addition of protease inhibitors (1x 
PBS, 1% Triton-X 100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate 
(SDS), leupeptin 0.5 μg/ml, pepstatin 1.0 μg/ml, EDTA 1.0 mM, PMSF 0.2 mM). To 
allow for the detection of phosphorylated proteins, phosphatase inhibitors (1mM 
sodium orthovanadate, 25mM sodium fluoride) were added. The dishes were rested on 
ice for 45 minutes and the contents were subsequently transferred to eppendorf tubes. 
A 1mL syringe and 22G needle (Terumo) was used to mechanically disrupt the cells to 
allow complete homogenisation of the samples, and the tubes were centrifuged at 4°C 
at 14000 RPM for 10 minutes (Mikro 22R, Hettich), to separate cellular debris from the 
protein-rich supernatant.  
 
7.2.1.7 Protein Quantification 
The supernatants from the samples were collected in labelled eppendorf tubes and the 
protein content determined using a spectrophotometric method detecting colorimetric 
absorbance at a wavelength of 562nm. Quantification of protein within the study 
samples was calculated using the Pierce™ BCA Protein Assay Kit (23225, 
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ThermoScienific), and compared to pre-prepared protein standards with known 
concentrations of protein containing bovine serum albumin (BSA). 
 
7.2.1.8 Protein Analysis 
Expression of ferroportin, SMAD5, STAT3, and phosphorylated SMAD 1/5 and STAT3 
proteins were determined by immunoblotting. The samples were prepared by adding 
loading buffer consisting of β-mercaptoethanol (βME), bromophenol blue, EDTA, 
glycerol, SDS, and Tris HCL (pH 6.8). The samples were heated at 100°C in order to 
denature the proteins. 
 
Total cell extracts (10-20μg) were separated on 12% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gels that were made with 30% 
acrylamide, 10% ammonium persulphate, 10% SDS, TEMED, 1.5M Tris, and water, 
before being electro-blotted onto a nitrocellulose membrane. Ponceau S solution 
(Sigma Aldrich) was used to detect the successful transfer of proteins to the 
membrane. The membrane was then washed and blocked in overnight at 4°C in 5% 
BSA, before being probed with primary antibodies against ferroportin, SMAD5, STAT3, 
and phosphorylated SMAD and STAT proteins (Table 7.5). HRP-conjugated secondary 
antibodies (REF) were applied at room temperature and the protein products were then 
visualised using the ECL Prime System (GE Healthcare Life Sciences). 
 
Antibody Company Catalogue number 
Ferroportin Novus Biological 21502SS 
Ferroportin Santa Cruz SC-49668 
Ferroportin Abcam AB70866 
SMAD5 Cell Signalling 9517 
STAT3 Cell Signalling 4904 
Phospho-SMAD1/5 Cell Signalling 9516 
Phospho-STAT3 Cell Signalling 9134 
GAPDH Millipore MAB374 
Table 7.5 Antibodies used in immunoblotting experiments 
 
7.2.2 Clinical Study 
The aim of this study was to assess the response of hepcidin levels in patients 
receiving systemic glucocorticoid therapy, over a 4-day period. 
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7.2.2.1 Subjects 
Subjects were adult patients who were admitted to the Renal Unit at King’s College 
Hospital to receive glucocorticoid therapy in the form of methylprednisolone. We chose 
to include patients suspected of renal vasculitis or glomerulonephritis, as they were a 
group of patients who were relatively frequently encountered who were to receive 
pulsed steroid therapy as part of routine clinical care. 
 
7.2.2.2 Study Design 
This was an exploratory, prospective, longitudinal cohort study. Patients with existing 
end-stage kidney disease or presenting with an acute kidney injury requiring dialysis 
(before the baseline study sample) were excluded from the study due to the impact of 
dialysis on hepcidin levels. The inclusion criteria (Table 7.6) were extremely broad. We 
excluded anyone who had received steroid therapy within 4 weeks of admission, based 
on the case report described in Table 7.2. In effect, this excluded the vast majority of 
renal transplant patients, who were taking prednisolone as part of their transplant 
immunosuppression regimen, and who may otherwise have been considered if they 
were admitted for treatment for acute transplant rejection. Exclusion criteria included a 
history of haematological dyscrasias, defined as any disease process that necessitated 
the patient having visited the Haematology department at any time for treatment or 
follow-up (except for iron-deficiency anaemia). 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
≥18 years of age Active malignancy 
Suspected renal vasculitis or glomerulonephritis Acute kidney injury requiring dialysis 
 Blood transfusion within 4 weeks 
 Chronic inflammatory condition 
 End-stage kidney disease 
 History of haematological dyscrasia 
 History of liver disease 
 Hospital admission within 4 weeks 
 Signs of acute/occult bleeding 
 Steroid therapy within 4 weeks 
Table 7.6 Inclusion and exclusion criteria for glucocorticoid study 
 
Patients identified as having an acute kidney injury as a result of an ANCA-associated 
vasculitis or crescentic glomerulonephritis were transferred into the Renal Unit from 
other wards within King’s College Hospital, or peripheral hospitals allied to KCH, with a 
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plan to treat with steroids. Initial treatment for these conditions was 3 intravenous 
pulses of methylprednisolone (500mg). 
 
Once the patients had been identified, they were approached and given a patient 
information sheet. If they agreed to participate in the study and provided written 
informed consent, baseline blood samples were taken. 
 
Figure 7.3 Schematic representation of the blood sampling schedule in relation 
to the dosing of methylprednisolone 
(Abbreviation: MP – methylprednisolone; blood samples taken on days 0, 1, and 4) 
 
A baseline sample (Day 0) was obtained prior to the first administration of 
methylprednisolone. A second sample (Day 1) was taken after the first dose of 
methylprednisolone but before the second dose, and a final sample was taken (Day 4) 
48 hours after the third and final dose of methylprednisolone (Figure 7.3). It was felt 
that samples taken after this time would have been confounded by the likely addition of 
further immunosuppressive therapies. 
 
7.2.2.3 Demographics and Baseline Data 
A total of 6 patients who satisfied the inclusion and exclusion criteria were recruited for 
this study. Other patients were eligible (n=3) but were considered unable to provide 
consent by the investigator. All the patients were admitted with a plan to treat with 
steroids; 5 patients had a suspected ANCA-associated vasculitis and the 6th had a 
suspected crescentic glomerulonephritis. The mean age of the 6 patients was 57.5 ± 
20.0 years. Five of the subjects were male, and 4 were Caucasian. The patients 
presented with advanced kidney dysfunction; the mean presenting creatinine was 
markedly elevated at 412.3 ± 186.3 μmol/L. As would be expected in this patient 
cohort, there was laboratory evidence of inflammation (mean CRP was 79.2 ± 54.2 
mg/L, and mean albumin was 28.5 ± 5.4 g/L). The patients were also markedly 
anaemic – the mean haemoglobin was 98.9 ± 16.2 g/L – with a normocytic picture 
(Table 7.7). 
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Age (years) 57.5 ± 20.0 
Males (n (%)) 5 (83.3) 
ANCA, myeloperoxidase/proteinase-3 4/1 
Caucasian (n (%)) 4 (66.7) 
Diabetes (n (%)) 1 (16.6) 
Hypertension (n (%)) 1 (16.6) 
Creatinine (μmol/L) 412.3 ± 186.3 
Haemoglobin (g/L) 98.9 ± 16.2 
Mean cell volume (10-15/L) 89.6 ± 4.8 
CRP (mg/L) 79.2 ± 54.2 
WBC/neutrophils/lymphocytes (109/L) 11.5 ± 1.5 / 9.0 ± 1.5 / 1.4 ± 0.4 
Albumim (g/L) 28.5 ± 5.4 
Table 7.7 Demographics and baseline laboratory data 
 
The patients had biochemical features that would be expected to induce an increase in 
hepcidin levels up (inflammation, renal impairment), with anaemia as the only factor 
expected to lower hepcidin. 
 
7.2.2.4 Methods 
The methods of hepcidin measurement by mass spectrometry have been discussed in 
detail previously (1.4.1). Routine patient blood samples were processed in the King’s 
College Hospital central laboratory. The method for HAMP mRNA measurement will be 
briefly revisited but is covered comprehensively on page 80. 
 
HAMP mRNA measurement 
• 10mL blood drawn (and divided into two) and separated by Ficoll-Hypaque Plus 
(GE Healthcare) centrifugation 
• Plasma was obtained post-centrifugation and immediately stored in 500µL 
aliquots 
• Two sets of 5x106 peripheral blood mononuclear cells were isolated for each 
participant 
• Total cellular RNA was subsequently extracted (RNeasy, Qiagen) and 
immediately stored at -80°C 
• 500ng RNA was reverse transcribed (High Capacity RNA-to-cDNA Kit, Applied 
Biosystems) 
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• All cDNA samples were processed in a single run to eliminate inter-
experimental variability 
• Amplification reactions were performed using Taqman HAMP and GAPDH 
primer-probes in triplicate 
• Quantitative RT-PCR was performed using the 7900 HAT Fast Real-Time 
system (Applied Biosystems) 
 
7.2.2.5 Statistical Analyses 
Differences were determined with the independent Student’s t test. Relationships 
between various parameters under study were also examined; simple linear 
coefficients (r) were calculated using the Pearson’s product formula. P-values <0.05 
(two-tailed) were considered statistically significant. ImageJ (NIH, version May 2018) 
was used for the optical density evaluation of the immunoblots, and the statistical 
analyses incorporated the Tukey’s method in conjunction with ANOVA to correct for 
multiple comparisons. Analyses were performed using GraphPad Prism version 6.0 for 
Macintosh, GraphPad Software, La Jolla California USA. 
 
7.2.2.6 Ethics and Regulatory Approvals 
The London Research Ethics Committee 1 (LREC 09/H0718/034) granted ethical 
approval. Local R&D approval was obtained to undertake this study, which was 
conducted in accordance with the principles outlined in the Declaration of Helsinki. 
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7.3 Results 
Results are expressed at means ± standard deviations, unless otherwise specified. 
 
7.3.1 Dexamethasone Dose-Response 
HepG2 cells were incubated in increasing doses of dexamethasone, ranging from 1.2 
ng/mL to 78.1 ng/mL for 18 hours. The control dishes contained vehicle (0.5% ethanol). 
 
 
Figure 7.4 Dose-response curve: dexamethasone concentrations 1.2 to 78.1 
ng/mL 
(Comparisons were between varying doses of dexamethasone and vehicle) 
 
There was a sustained decrease in HAMP mRNA levels with doses of dexamethasone 
that were greater than 2.4 ng/mL, although the results did not appear consistent. At a 
concentration of 4.8 ng/mL, there was a significant decrease in HAMP mRNA 
(p=0.009) compared with vehicle, and this trend was maintained at all higher doses 
with significantly reduced levels at 19.5, 39.1, and 78.1 ng/mL (all p<0.05) (Figure 7.4). 
 
The experiment was repeated with fewer serial dilutions (7 versus 14) of the initial 
stock solution of dexamethasone. There was a sustained decrease in HAMP mRNA 
seen with doses of dexamethasone as small as 0.3 ng/mL (p=0.0043), which was 
sustained through to 20 ng/mL, with no apparent dose dependent response above 0.3 
ng/mL (Figure 7.5). 
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Figure 7.5 Dose-response curve: dexamethasone concentrations 0.3 to 20 ng/mL 
(Comparison between vehicle and 0.3 ng/mL, p=0.0043) 
 
7.3.2 Effect of Dexamethasone on HepG2 Viability 
The solvent concentration of ethanol 2% did not reduce cell viability. A dose of 
20ng/mL of dexamethasone was selected to test HepG2 cell viability, and no effect on 
cell viability was observed (Figure 7.6). 
 
 
Figure 7.6 – Effect of 20ng/mL dexamethasone upon HepG2 cells 
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7.3.3 Effect of IL-6 Stimulation on Dexamethasone Treated Cells 
Dexamethasone treated HepG2 cells showed a reduction in HAMP mRNA with 
increasing concentrations of corticosteroid. Dexamethasone doses of 10ng/mL and 
above diminished the IL-6-induced upregulation of HAMP mRNA, which was clearly 
witnessed in vehicle treated cells, and in cells treated with 0.01, 0.1, and 1.0 ng/mL of 
dexamethasone (Figure 7.7). 
 
 
Figure 7.7 Effect of IL-6 stimulation (12.5ng/mL for 1 hour) upon dexamethasone 
pre-treated HepG2 cells (20ng/mL for 18 hours) 
(Black bars represent IL-6 treated cells; white bars (a-f) are vehicle (IL-6) treated cells; asterisks represent 
comparisons between IL-6 and vehicle treated cells at increasing concentrations of dexamethasone; *** 
p<0.0001, **p<0.01, *p<0.05) 
  
All differences between the vehicle treated control sample (labelled ‘a’ in Figure 7.7) 
and the other samples (labelled b-f) were significant, except sample c (Table 7.8).  
 






Table 7.8 Comparison of reference sample (a) with other non-IL-6 treated 
samples (b-f) in Figure 7.7 
 
Even when HepG2 cells were exposed to a higher dose of IL-6 (25ng/mL) for a longer 
period of time (2 hours), a similar dose dependent relationship was observed. At 
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1ng/mL and 6.25ng/mL of dexamethasone, the effect of IL-6 appeared to be 
diminished, which varied slightly from the previous experiment (Figure 7.8). 
 
Figure 7.8 Effect of IL-6 stimulation (25ng/mL for 2 hours) upon dexamethasone 
pre-treated HepG2 cells (16 hours) 
(Comparisons: the vehicle treated cells act as the reference experiment) 
 
However, the abolition of the robust IL-6 upregulation on HAMP mRNA in HepG2 cells 
occurred at dexamethasone concentrations greater than 10ng/mL in both experiments. 
 
7.3.4 Effect of BMP-6 Stimulation on Dexamethasone Treated Cells 
In contrast to IL-6, dexamethasone had no evident ability to reduce BMP-6 induced 
upregulation of HAMP.  
 
 
Figure 7.9 Effect of BMP-6 stimulation (applied for 2 hours) upon dexamethasone 
pre-treated HepG2 cells (18 hours) 
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HepG2 cells were incubated with 20ng/mL of dexamethasone for 18 hours and 
stimulated with BMP-6 at two separate concentrations for 2 hours. HAMP was nearly 
30-fold higher (p=0.0008) following the addition of 10ng/mL BMP-6, and nearly 45 to 
50-fold higher following a 20ng/mL treatment (p<0.00001) (Figure 7.9). These results 
were in keeping with previous results (5.3.4). 
 
7.3.5 Ferroportin and Dexamethasone 
HepG2 cells were treated with 20ng/mL dexamethasone for 18 hours, and 
subsequently treated with IL-6 (25ng/ml), BMP-6 (20ng/mL), or vehicle for 2 hours. 
Immunoblotting was undertaken to assess the potential in vitro effect of 
dexamethasone upon ferroportin. Two ferroportin antibodies demonstrated marked 
non-specific binding (Santa Cruz and Novus Biological). A third antibody was employed 




Figure 7.10 Western blots of GAPDH, ferroportin, STAT3, and pSTAT3 
(Dexamethasone 20ng/mL treatment applied for 18 hours; IL-6 25ng/mL, and BMP-6 20ng/mL applied for 
2 hours; blots representative of 2 independent experiments) 
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The BMP-6 control (blue line) reduced ferroportin expression, as was expected. The IL-
6 control (lane 1) did not produce meaningful data and was thus excluded from further 
analyses. Dexamethasone-treated cells had higher ferroportin expression (lane 7) than 
untreated cells (lane 6) (p=0.092), although statistical significance was lost once 
Tukey’s correction was employed to correct for multiple analyses. Dexamethasone-
treated cells that were then stimulated with cytokines (IL-6 or BMP-6, lanes 3 and 4, 
respectively) had lower FPN expression that cells treated with dexamethasone alone 
(lane 7). Cells that were stimulated with BMP-6, regardless of whether they had been 
pre-treated with dexamethasone, had lower ferroportin expression than the reference 
cells. The IL-6 stimulated cells that were treated with dexamethasone (lane 3) and the 
reference cells had similar levels of ferroportin expression (Figure 7.11).  
 
 
Figure 7.11 Optical density of FPN normalised to GAPDH 
Reference protein (ref) in lane 6; control in lane 1 (IL-6 stimulated) was not used in the analyses. BMP-6 
negative control (blue line). 
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7.3.6 Immunoblotting For STAT and SMAD Proteins 
There was no difference in STAT3 expression across any of the experimental 
conditions. Lanes 4 (dexamethasone and BMP-6) and 7 (dexamethasone alone) 
appeared to have levels of STAT3 expression that appeared lower than the others, but 
this was not borne out in the statistical analyses (Figure 7.12). 
 
Figure 7.12 Optical density of STAT3 normalised to GAPDH 
 
Blotting for phosphorylated proteins proved very difficult and the optical density 
analysis was such that it did not allow for meaningful interpretation (Figure 7.13). 
 
 
Figure 7.13 Optical density of phosphoSTAT3 normalised to GAPDH 
 
 





























































































Chapter 7. Glucocorticoids and Hepcidin 
194 
Multiple blots were also undertaken for SMAD proteins to analyse the effects of BMP-6 
stimulation in their role as a control (Figure 7.14). Despite multiple attempts to run the 
experiments in their entirety, and immunoblotting undertaken by 2 operators in different 
laboratories, the blots were not analysed due to their appearance. 
 
 
Figure 7.14 Western blots of SMAD5 and pSMAD 1/5 
(Dexamethasone 20ng/mL treatment applied for 18 hours; IL-6 25ng/mL, and BMP-6 20ng/mL 
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7.3.7 Does Glucocorticoid Steroid Therapy Reduce Hepcidin In Vivo? 
Hepcidin levels were markedly increased at baseline in 5 of the 6 patients recruited to 
this study. There was a significant decrease in hepcidin levels following the first dose of 




Figure 7.15 Hepcidin levels in AKI patients before and after receiving 3 pulses of 
methylprednisolone 
(Individual patient data plots labelled A-F; blue arrows denote timing of methylprednisolone administration; 
normal range for hepcidin-25 shown by dashed box; hepcidin levels were lower on day 1 post-
methylprednisolone compared to baseline (p=0.0486)) 
 
The decrease in hepcidin levels from day 1 to day 4 was seen in 4 out of the 6 
subjects, with 3 of the subjects having hepcidin levels within the normal range by the 
final time point. Two of the subjects (patients A and D) experienced a rise in hepcidin 
levels from day 1 to day 4. These two patients had blood transfusions after day 2 and 
3, respectively. Patient D had plasma exchange due to a presenting creatinine of 
737μmol/L and a session of haemodialysis after day 2. Patient F had a session of 
haemodialysis on day 3, but this did not appear to have an influence on their hepcidin 
levels (Figure 7.16). 
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Figure 7.16 – Individual patient data outlining haemoglobin, CRP, creatinine and 
hepcidin levels 
(Red arrows denote transfusion of pack red cells; green arrows denote commencement of haemodialysis) 
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7.3.8 Does Glucocorticoid Steroid Therapy Impact Upon PBMC HAMP? 
In contrast to the protein levels, there was no significant difference between PBMC 
HAMP levels before and after the administration of methylprednisolone. HAMP levels 
at both the day 1 and day 4 time points were numerically greater than at baseline 
(Figure 7.17). 
 
Figure 7.17 HAMP mRNA at baseline, and at days 1 and 4 after initiation of 
methylprednisolone therapy 
 
There were 5 samples (instead of 6) analysed at each of the three time points. This 
was due to the poor quality of the RNA extracted from patient A at baseline, and at day 
4, and from patient E, at day 1. The variability in results obtained in this small number 
of patients precluded any meaningful conclusion to be made. 
 
7.3.9 Hepcidin and Inflammation 
The CRP levels in all the participants were lower at the end of the study period than 
their corresponding baseline levels (p=0.0142) (Figure 7.18). Patient D experienced an 
upturn in CRP between day 3 and day 4, whilst all the other study subjects had CRP 
trends that were progressively falling. Patient C had near-normal baseline CRP levels 
and further measurements were not deemed clinically necessary. 
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Figure 7.18 CRP levels in AKI patients before and after receiving 3 pulses of 
methylprednisolone 
(Individual patient data plots labelled A-F; comparison between day 0 and day 4: p=0.0142) 
 
There were 17 (of a possible 18) available data points that allowed a comparison 
between CRP and hepcidin. There was a positive correlation (R2=0.2557, p=0.038) 
noted between the two variables (Figure 7.19).  
 
 
Figure 7.19  Correlation between CRP and hepcidin 
 
 
7.3.10 The Impact of Renal Clearance and Anaemia on Hepcidin 
There was a positive correlation between hepcidin and creatinine that was approaching 
statistical significance when the data were analysed in their entirety (Figure 7.20a). 
After a creatinine data point was removed from two patients (patients D and F) that 
were confounded by the use of haemodialysis, the correlation was significantly 
stronger (R2 0.3360, p=0.0186) (Figure 7.20b). 
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Figure 7.20 Correlation between hepcidin and creatinine (a) with all data points, 
and (b) with data excluded confounded by haemodialysis 
 
No such correlation, however, was noted between hepcidin and haemoglobin levels, 




Figure 7.21 Correlation between hepcidin and haemoglobin (a) with all data 
points, and (b) with data excluded confounded by blood transfusion 
 
  
Chapter 7. Glucocorticoids and Hepcidin 
200 
7.4 Conclusions and Discussion 
The main findings from the work undertaken in this chapter were as follows; 
 
1. Methylprednisolone reduced hepcidin levels in a highly inflamed patient group 
with severe kidney dysfunction. 
2. A similar effect was also seen in dexamethasone-treated HepG2 cells, where 
there was a significant reduction in HAMP gene expression consistent at 
concentrations of 20ng/mL and above 
3. Hepcidin levels were correlated to levels of renal function and inflammation, but 
not to the degree of anaemia. 
4. Ferroportin expression was increased in dexamethasone-treated cells. 
5. Dexamethasone-induced HAMP downregulation was IL-6 dependent. 
6. PMBC HAMP mRNA was not affected in patients given methylprednisolone 
despite a significant reduction in hepcidin levels. 
 
To the best of my knowledge, this is the first clinical study examining the effect of 
glucocorticoids in the regulation of hepcidin. In a prospective study involving a small 
clinical cohort, there was a striking reduction in hepcidin levels within 24 hours of the 
administration of a large dose of intravenous methylprednisolone. There is a high 
degree of certainty that the observed effect was due to steroid therapy, as it was 
witnessed in all of the patients, and the effect occurred relatively rapidly, without the aid 
of any other therapeutic interventions, and with little change in the patients’ clinical or 
biochemical status. 
 
Four of the 6 patients experienced a steady fall in their hepcidin levels, with 3 having 
normal hepcidin levels by day 4. Two patients saw a rise in their day 4 hepcidin levels 
(cf day 1) but they had both received transfusions of packed red cells. By virtue of 
having systemic kidney disease, the patients were, of course, highly inflamed (baseline 
CRP 79.2 ± 54.2 mg/L). Both CRP and creatinine were correlated with hepcidin levels 
and were highly likely to be responsible for the high hepcidin levels witnessed in this 
patient group. The effect of steroids in dampening inflammation provides a logical 
explanation for the witnessed effect. 
 
The ability of a blood transfusion to abrogate the hepcidin-lowering effect of 
methylprednisolone in this patient cohort is in accordance with current scientific 
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knowledge. The effect of packed red cells and administration of iron upon hepcidin are 
governed by a separate intracellular signalling pathway (BMP-SMAD), whereas 
inflammation is mediated via the JAK-STAT pathway. It also lends weight to the 
hypothesis that iron has a greater ability to induce hepcidin than inflammation and can 
overcome potent anti-inflammatories. 
 
A similar effect was seen with HepG2 cells - HAMP mRNA was suppressed to 
approximately 50% of basal levels when incubating the cells with dexamethasone 
concentrations of 20ng/mL and greater, without affecting cell viability. In separate 
experiments, increasing concentrations of dexamethasone abolished the effect of IL-6 
at concentrations of 10ng/mL and greater. However, dexamethasone did not have a 
similar effect on BMP-6. There was a reasonable degree of consistency among the 
results in the mRNA experiments. 
 
Dexamethasone is over 5 times as potent as methylprednisolone for the equivalent 
dose (British National Formulary 2018). It has been reported that following a single 
40mg IV bolus injection, peak methylprednisolone levels reached 42-47µg/100ml in 6 
adult male volunteers, which corresponds to a dexamethasone concentration of 
approximately 80ng/mL (Electronic Medicines Compendium (eMC)). This is 4-times 
higher than the dose of dexamethasone that was used in the protein extraction 
experiments and may be one of the factors that led to the inconsistent results seen in 
the Western blots. The effect of decreased HAMP mRNA expression is the increase in 
ferroportin expression, and there was partial confirmation of this in the in vitro work in 
section 7.3.5. Ferroportin expression was higher in dexamethasone-treated cells than 
in any of the other treatment groups, but confidence in this effect would have been 
higher if there was a consistency of results across the entirety of the experimental 
protein work in this chapter. The failure of the IL-6 positive control (Figure 7.11) 
remains difficult to explain. 
 
Unlike plasma hepcidin, which decreased after 1 day following steroid therapy, ex vivo 
PBMCs probed for mean HAMP mRNA levels showed highly variable results 
precluding meaningful conclusions. The effect of ANCA-associated vasculitis upon 
macrophages and monocytes perhaps confounds their use as a surrogate marker for 
hepcidin production. Thus, the composition and activation of the white cells is markedly 
different in a group of ANCA-associated vasculitis patients, compared to healthy 
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individuals (O'Brien et al. 2015), or possibly a group of relatively uninflamed 
haemodialysis patients (see 4.3.1). 
 
Finally, the small number of samples analysed exacerbated our inability to draw 
meaningful conclusions, particularly since there were additional confounders, such as 
blood transfusions and dialysis. The major limitation of the work in this chapter was due 
to an inability to produce meaningful Western blots. The method of Western blotting 
required cell culture, protein extraction, followed by electroblotting on gels that were 
made from base ingredients. The cell culture techniques were identical for both the 
mRNA and protein extraction work, and there is confidence that there were no issues 
with the cell work per se. A possible explanation for the inconsistent results likely lies 
with the techniques employed in the other areas such as gel making and protein 
analysis, which perhaps could have been overcome by using commercial gels and 
seeking expert help earlier. 
 
The major strength of this study is the consistency of both the in vitro cellular work and 
the in vivo clinical study showing suppression of HAMP expression and a reduction in 
hepcidin levels. The in vitro work suggests that this is IL-6 mediated. The clinical data 
show a highly consistent reduction in serum hepcidin levels within 24 hours of 
administering IV methylprednisolone to patients with an acute insult caused by ANCA-
associated vasculitis or a crescentic glomerulonephritis. 
 
Having shown that corticosteroids reduce hepcidin levels in an IL-6 dependent manner, 
the exact mechanism by which this occurs is yet to be determined and may either be 
driven by genomic or non-genomic mechanisms. Direct inhibition of the JAK/STAT 
signalling pathway mediated by IL-6 is one potential non-genomic mechanism at the 
intracellular protein level. Direct inhibition of transcription factors involved in HAMP 
expression may be an alternative mechanism at the genomic level. Bacchetta and 
colleagues examined the mechanism by which vitamin D caused reduced HAMP 
transcription using chromatin immunoprecipitation precipitation (in PBMCs, THP-1 
monocytes and HepG2 cells) and a similar method could be employed to investigate 
the same with corticosteroids given that both are steroid hormones. 
 
A potential experiment to investigate this further could involve a comparative analysis 
between HAMP gene expression pre- and post-corticosteroid treatment in patients 
Chapter 7. Glucocorticoids and Hepcidin 
203 
using RNA sequencing of PBMCs. This would also enable an assessment of altered 
expression of transcription factors involved in regulating HAMP expression. In order to 
navigate the potential issue of activated white cells in a pro-inflammatory state, flow 
cytometry with markers selective for PBMCs on manually derived PBMCs from whole 
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8 Discussion and Conclusion 
The novel data presented in this thesis (chapter 7) demonstrate that glucocorticoids 
possess the ability to reduce hepcidin levels in patients presenting with ANCA-
associated vasculitis or crescentic glomerulonephritis and do so by dampening the 
inflammatory response. This was corroborated by in vitro work that studied the effect of 
dexamethasone on HepG2 cells, resulting in the marked downregulation of HAMP 
transcription. It was striking that hepcidin levels decreased in all 6 patients within 24 
hours of administration of methylprednisolone, despite the presence of advanced 
kidney dysfunction. There was approximately a 50% reduction in the mean hepcidin 
level, falling from 81.8 ± 64.9 mg/L (pre-treatment), to 39.2 ± 27.6 mg/L 24 hours after 
IV methylprednisolone therapy (p=0.0486). There were no changes in any of the other 
parameters, including renal function. The mean pre-treatment creatinine was 412 ± 186 
μmol/L, compared to 412 ± 179 μmol/L, 24 hours later (p=0.44), suggesting that in this 
clinical context, inflammation is a more important factor than renal clearance in 
modulating hepcidin levels.  
 
Clearly, the major limitation of the glucocorticoid study was the small sample size of the 
clinical cohort. However, the consistency of the results in all patients along with the 
concordance seen between the in vitro cellular work (reduction in HAMP gene 
expression) and the in vivo clinical data (reduction in hepcidin levels) suggest that this 
was a real effect, hitherto not previously reported. The in vitro results suggest that the 
effect is IL-6 mediated. Taken as a whole, our data suggest that glucocorticoids 
suppress hepcidin production, which has important implications for the anaemia 
associated with inflammation/CKD. Ideas for future clinical work include the 
investigation of a greater number of patients prospectively for 12-24 months, with the 
intention of examining whether a fall in hepcidin levels is a prelude to the recovery of 
anaemia in this patient group, which would perhaps provide some insight into the 
pathogenesis of anaemia in ANCA-associated vasculitis. Although HAMP transcription 
was demonstrably lowered in HepG2 cells by dexamethasone, further work examining 
whether ferroportin levels are affected is an important line of inquiry, with additional 
work looking at other mediators in the IL-6/inflammatory pathway, and also whether 
genomic or non-genomic factors are responsible for the corticosteroid reduction in 
hepcidin. 
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Glucocorticoids are very useful anti-inflammatory treatments and are the mainstay of 
treatment in conditions such as ANCA-associated vasculitis and crescentic 
glomerulonephritis. However, they have many side effects, and studies are currently 
being undertaken to investigate the possibility of limiting their use in these conditions 
(Walsh et al. 2018); as such, it is not a feasible treatment for hyperhepcidinaemia.  
Heparin is also a potent suppressor of hepcidin and used in the anticoagulation of 
haemodialysis circuits. As discussed earlier (chapter 6), it is unlikely that the doses of 
heparin that are currently administered across haemodialysis have a significant effect 
on hepcidin or iron regulation. 
 
The case-control study (chapter 3) confirmed that hepcidin levels were markedly higher 
in haemodialysis patients than in other CKD patients, with no evidence of higher levels 
of inflammation. However, the major confounder in the haemodialysis patients was the 
weekly administration of IV iron, which undoubtedly stimulates hepcidin production. 
Therefore, the unique finding of reduced HAMP PBMC (chapter 4) in the haemodialysis 
cohort was unexpected, and tentatively points to the possibility that a feedback 
mechanism exists to downregulate HAMP in the face of hyperhepcidinaemia. Pre-
clinical evidence to support this theory has been provided by Laftah and colleagues, 
who injected mice with synthetic hepcidin and observed a subsequent reduction in 
hepatic HAMP mRNA (Laftah et al. 2004). There are few animal models investigating 
hepcidin regulation in renal failure; one such study was of a rat model using 5/6th 
nephrectomies that was undertaken by Srai and colleagues; they found that there was 
no difference in hepatic hepcidin expression between sham and nephrectomised 
animals. However, there did not appear to be any measurement of protein levels or 
inflammation in this study, which was principally designed to investigate the effect of 
erythropoietin on intestinal iron absorption, and thus could have been confounded (Srai 
et al. 2010). Further pre-clinical work could include the use of an animal model of renal 
failure designed to see whether reduced glomerular clearance leads to a reduction in 
HAMP expression and whether there is concordance between PBMC HAMP, and 
hepatic HAMP expression. If a feedback mechanism were established, elucidating the 
underlying mechanism would be an interesting line of enquiry.  
 
In my view, the data with the most impact regarding the regulation of hepcidin in 
chronic kidney disease was gleaned from the haemodialysis patients presenting with 
acute bacterial sepsis (chapter 4) Despite a very substantial increase in CRP levels, 
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they had no apparent change in hepcidin levels, suggesting an inability of hepcidin 
upregulation in this group, possibly due to HAMP downregulation. As this was an 
exploratory study, a more detailed clinical study should be undertaken with larger 
numbers and an increased blood-sampling plan in order to properly identify the kinetics 
of CRP (and other inflammatory cytokines) and hepcidin.  
 
Conclusion 
Hepcidin regulation in chronic kidney disease is highly complex and subject to a 
number of competing factors, including clearance (via the glomerulus or dialysis 
membrane), inflammation, and administration of drug treatments (erythropoietin, iron, 
red cell transfusions, and possibly heparin). 
 
Figure 8.1 Proposed schema of factors impacting on hepcidin levels in 
haemodialysis 
(dashed line indicates possible mechanism; full lines indicate known mechanism) 
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Hepcidin levels are undoubtedly highest in haemodialysis patients but HAMP levels are 
low, suggesting a negative feedback mechanism. The use of IV iron plus the chronic 
inflammatory milieu and the lack of renal clearance all play a role in elevating hepcidin, 
but when stable, chronic haemodialysis patients suffer a superadded bacterial 
infection, hepcidin levels do not appear to be further able to increase, suggesting that 
hepcidin is already at its maximal level. 
 
The use of the potent hepcidin inhibitor, heparin, in dialysis patients may play a role in 
dampening HAMP expression but it is likely that this is not the case due to the doses 
that are used. The steroid hormones oestradiol, testosterone and vitamin D are known 
to inhibit HAMP and we now know that methylprednisolone reduces hepcidin in vivo 
and dexamethasone does the same in vitro in an IL-6 dependent manner. The 
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THE REGULATION OF HEPCIDIN IN CHRONIC KIDNEY DISEASE 
 
Patient Information Sheet 
 
We would like to invite you to take part in our research study. Before you decide, we would like you 
to understand why the research is being done and what it would involve for you. One of our team will 
go through the information sheet with you and answer any questions you have. Please take time 
to read the information carefully and discuss it with friends/relatives if you wish. You may also ask us 
if there is anything that is not clear. 
 
What is the purpose of the Study? 
 
Hepcidin is a recently discovered substance that is produced by the liver, and which circulates in the 
bloodstream. Some of our previous research has shown that levels of hepcidin in patients with kidney 
disease are extremely high, and we believe that this is a major contributor to the development of 
anaemia in such patients. What is not known, however, is why and how having kidney disease leads to 
these high levels. 
 
The purpose of this preliminary study is to understand what is happening regarding production of 
hepcidin in patients who suffer from chronic kidney disease, and the factors that influence it. Of 
particular interest are those patients who do not respond to the usual treatments for anaemia. 
 
Why have I been invited?  
 
You are being invited to take part because you have chronic kidney disease, but it is up to you to 
decide whether to join the study. Participation is entirely voluntary. If you agree to take part, we will 
then ask you to sign a consent form and give you a copy of this information sheet and the consent form 
to keep.   
 
What will I be asked to do if I take part? 
 
We are asking if you would be prepared to donate one or more blood samples (up to a maximum of 
five) for this study. The volume of blood will be a maximum of 50 ml (5 tablespoons) at any one time, 
and you will be asked for no more than 50 ml of blood over a period of one month.  These blood 
samples will be performed at the same time as your routine blood tests either in the dialysis 
unit/clinic/ward. The blood samples will be processed immediately, and separated into serum, white 
and red blood cells (the red cells will be discarded). RNA will immediately be extracted from the 
white cells, and will be stored in a secure location along with the serum for analysis at a later date. The 
samples will be completely anonymised (you can not be identified). All material will be destroyed at 
the end of the study (01/04/ 2018). 
 
What are the possible side effects of taking part? 
 
The research study consists of taking blood samples. Minor bruising/pain at the site of blood taking 
would be the main side-effect, unless you are a haemodialysis, in which case, we will take the sample 
as you are being put on the dialysis machine. 
 
What are the possible benefits in taking part? 
 
The information we get from this study may help us evaluate better the treatment of anaemia in 







Research Project: REC  Page 2 of 2 
Patient Information Sheet Version No.1.0 dated 26th June, 2013 
  
you had helped us with research. Otherwise, we do not expect there to be any benefits for you in 
taking part.   
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will be kept strictly 
confidential, and any information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised. 
 
What will happen if I don’t want to carry on? 
 
You are free to withdraw at any time, without giving a reason. This would not affect the standard of 
care you receive. Information collected up till that point will still be used. 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to the researchers who 
will do their best to answer your questions [Tel No: 0207 848 0431]. If you remain unhappy and wish 
to complain formally, you can do this by calling the Patient Advice and Liaison Service on telephone 
number 0203 299 3601 or write to PALS, Ground Floor, Hambledon Wing, King’s College Hospital, 
Denmark Hill, London, SE5 9RS. 
 
Who has reviewed this study? 
 
This study has been reviewed by the Renal Research Governance Board, and has been given a 
favourable opinion by the ___________Research Ethics Committee. 
 
What will happen to the results of the research study? 
 
The results may be reported in professional publications or meetings but you will not be identified by 
name.   
 
Who is funding this study? 
 
This study is funded by the King’s College Hospital Charity. 
 
What do I do now? 
 
Thank you for considering taking part in this research. One of our team members will contact you in a 




Prof Iain Macdougall, Consultant Nephrologist 
Dr Adam Rumjon, Clinical Research Fellow 
Ms Leela Goldstein, Clinical Research Manager (Renal) 
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1. I confirm that I have read and understand the information sheet dated 22nd of March, 2010 
(version No.2.0) for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary. 
 
3. I understand that data collected (age, gender and ethnicity) during the study may be looked at 
by individuals from regulatory authorities or from the NHS Trust, where it is relevant to my taking 
part in this research. I give permission for these individuals to have access this information. 
 





_________________________  ________________ _____________________ 




_________________________  ________________ _____________________ 
Name of Person taking consent  Date   Signature  




_________________________  ________________ _____________________ 
Investigator    Date  Signature 
 
[Completed forms: 1 for participant; 1 for Investigator] 
THE RENAL UNIT 
Iain C Macdougall BSc, MD, FRCP 
Consultant Nephrologist 
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MEASUREMENT OF BLOOD HEPCIDIN LEVELS IN PATIENTS WITH 
CHRONIC KIDNEY DISEASE 
 
 
Participant Information Sheet 
 
We would like to invite you to take part in our research study. Before you decide we would like you 
to understand why the research is being done and what it would involve for you. One of our team 
will go through the information sheet with you and answer any questions you have. Please take 
time to read the information carefully. You may also ask us if there is anything that is not clear. 
 
What is the purpose of the Study? 
 
Hepcidin is a newly-discovered substance which is produced by the liver, and which circulates in the 
bloodstream. It is critical in controlling how iron is absorbed from the gut and how the body stores 
and uses it. Iron is important in the production of red blood cells and lack of it, results in anaemia. 
Scientists at King’s College, London have developed a reliable and sophisticated way to measure 
hepcidin in the blood. We expect that hepcidin will be a useful marker to help us interpret better iron 
levels in blood in patients suffering from chronic kidney disease.  
 
Why have I been invited?  
 
You are being invited to take part as a healthy volunteer. This would allow us to compare serum 
hepcidin levels in normal individuals with those obtained from patients suffering from chronic kidney 
disease. 
 
Do I have to take part? 
 
It is up to you to decide to join the study. Participation is entirely voluntary. If you agree to take part, 
we will then ask you to sign a consent form and give you a copy of this information sheet and the 
consent form to keep.   
 
What will I be asked to do if I take part? 
 
We are asking you if you would be prepared to donate one blood sample for this study. The blood 
sample provided by you will be taken to the laboratory and analysed for hepcidin levels. The volume 
of blood will be only 5ml of blood (1 teaspoonful). After analysis, your blood sample will be disposed 
of.  
 
How many blood tests will I have? 
 
Only one sample is required. 
 
What are the possible side effects of taking part? 
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What are the possible benefits in taking part? 
 
You would hopefully gain some satisfaction from knowing you had helped us with our research. 
Otherwise, we do not expect there to be any benefits for you in taking part. 
 
Will my taking part in this study be kept confidential? 
 
All information (age, gender and ethnicity) which is collected about you during the course of the 
research will be kept strictly confidential, and any information about you which leaves the hospital 
will be encoded so that you cannot be recognised.  
 
What will happen if I don’t want to carry on? 
 
You are free to withdraw at any time, without giving a reason. Information collected up until that 
point will still be used. We will NOT be storing any blood samples of our participants.  
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to the researchers who 
will do their best to answer your questions [Tel No: 0207 848 0431]. If you remain unhappy and wish 
to complain formally, you can do this by calling the Patient Advice and Liaison Service on telephone 
number 0203 299 3601 or write to PALS, Ground Floor, Hambledon Wing, King’s College Hospital, 
Denmark Hill, London, SE5 9RS. 
 
Who has reviewed this study? 
 
This study has been reviewed and has been given a favourable opinion by the London Research Ethics 
Committee. 
 
 What will happen to the results of the research study? 
 
The results may be reported in professional publications or meetings but you will not be identified by 
name.   
 
Who is funding this study? 
 
This study is funded by a grant from King’s College Hospital NHS Foundation Trust, London. 
 
What do I do now? 
 
Thank you for considering taking part in this research. One of our team members will contact you in a 




Dr Iain Macdougall, Consultant Nephrologist 
Dr Stephan Brincat, Clinical Research Fellow 
Dr Beatriz Tucker, Associate Specialist 
Ms Leela Goldstein, Anaemia Research Sister 
Department of Nephrology, King’s College Hospital 
 
Tel No: 0207 848 0431   
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